![]() | Stephen V Faraone∗Department of Psychiatry and Behavioral Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210 | Departments of Psychiatry and Neuroscience and ... |
के लिए फिर से शुरू Stephen V Faraone∗
Year | |
---|---|
2022 | Department of Psychiatry and Behavioral Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210 |
2021 | Department of Neuroscience and Physiology, State University of New York Upstate Medical University, Syracuse, New York Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, Massachusetts, USA |
2020 | K.G. Jebsen Centre for Psychiatric Disorders, Department of Biomedicine, University of Bergen, Bergen, Norway Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical Center, Syracuse, NY, USA Department of Psychiatry and of Neuroscience and Physiology, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, United States The full list of authors in the ENIGMA working groups, author affiliations, author disclosures, and acknowledgments are provided in online supplements. |
2019 | Departments of Psychiatry and Neuroscience and Physiology, SUNY Upstate Medical University, New York, USA The Department of Human Genetics, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands (Klein, Bralten, Roth Mota, Arias-Vasquez, Franke); University Medical Center Utrecht, UMC Utrecht Brain Center, Department of Psychiatry, Utrecht, the Netherlands (Klein); the Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Walters, Neale); Program in Medical and Population Genetics (Walters) and Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Mass (Walters, Neale); the Department of Biomedicine and the Center for Integrative Sequencing, Aarhus University, Aarhus, Denmark (Demontis, Mattheisen, Børglum); the Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Denmark (Demontis, Børglum); the Department of Genetics and the Neuroscience Center, University of North Carolina, Chapel Hill (Stein); the Imaging Genetics Center, USC Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles (Hibar, Thompson); the Department of Epidemiology and the Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands (Adams); the Department of Psychiatry and the Research Institute, Hospital for Sick Children, University of Toronto, Toronto (Schachar); the Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (Sonuga-Barke); the Department of Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany (Mattheisen); the Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institute, Stockholm (Mattheisen); Stockholm Health Care Services, Stockholm County Council, Stockholm (Mattheisen); the Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles (Thompson); the Quantitative Genetics Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Medland); the Department of Psychiatry and the Department of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, N.Y. (Faraone); the K.G. Jebsen Center for Neuropsychiatric Disorders, University of Bergen, Bergen, Norway (Faraone); and the Department of Psychiatry, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands (Roth Mota, Arias-Vasquez, Franke). Department of Psychiatry, Upstate Medical University, Syracuse, New York; Department of Neuroscience and Physiology, Upstate Medical University, Syracuse, New York. SUNY Upstate Medical University, Syracuse, NY |
Stephen V Faraone∗: आँकड़ों को प्रभावित करें
Concept | World rank |
---|---|
impulsive subtype | #1 |
daodisc1 | #1 |
african children adhd | #1 |
unfamiliar challenges | #1 |
desipraminestimulants | #1 |
qms adhd | #1 |
maf⩾1 | #1 |
acting medications | #1 |
adhddbds adhd | #1 |
142 combined subtype | #1 |
relatives children | #1 |
mwq inattention items | #1 |
snpssnpsa | #1 |
adhdtd siblings | #1 |
nmu oral | #1 |
pain tolerance fm | #1 |
bpd anx bpd | #1 |
rs2469758–rs2461489 | #1 |
disorders comorbid mania | #1 |
ldx sizes children | #1 |
familial vulnerability schizophrenia | #1 |
adhd prs rtv | #1 |
odd disorders follow | #1 |
2 familial factors | #1 |
reproducibility adolescent | #1 |
disorders parents | #1 |
assess adult adhd | #1 |
c2orf82 | #1 |
adhd neuropsychological functioning | #1 |
adhd female individuals | #1 |
qms adult adhd | #1 |
ctcata | #1 |
iiv hyperactivity behavior | #1 |
pediatric bipolar spectrum | #1 |
adhd highly | #1 |
140 adhd probands | #1 |
learning disorders adhd | #1 |
rs1482337–rs2252471 | #1 |
adult persistence adhd | #1 |
adhd siblings | #1 |
population screen | #1 |
adhd conduct disorder | #1 |
standardized manner | #1 |
levels dysfunction | #1 |
antisocial disorder relatives | #1 |
persistent adhd symptoms | #1 |
asrs scores | #1 |
disability asthma | #1 |
evidence stimulant treatment | #1 |
unique impairments | #1 |
p44e05 | #1 |
schizophrenia rs1076560t | #1 |
inflation personal satisfaction | #1 |
type adhd | #1 |
sexes bpi disorder | #1 |
anxiety disorders siblings | #1 |
hyperactivity cross | #1 |
relszs | #1 |
prsanalyses | #1 |
rs3792452 | #1 |
bmi ldx | #1 |
adhd personality traits | #1 |
sud adolescence | #1 |
conduct bipolar disorders | #1 |
dbds adhddbds | #1 |
stimulant treatment | #1 |
disorder report | #1 |
youth adhd | #1 |
family‐based association test | #1 |
18 items impairment | #1 |
risk factor psud | #1 |
behavioral disinhibition offspring | #1 |
adolescent response inhibition | #1 |
transmission parents | #1 |
d10s195 | #1 |
htf9c | #1 |
hamshere | #1 |
adhd adverse impact | #1 |
adhd genetic variants | #1 |
normal sexual dimorphisms | #1 |
p0499 | #1 |
scqscore | #1 |
late‐onset adhd | #1 |
adhd depressed children | #1 |
adhd familial disorder | #1 |
cbclbp profile children | #1 |
adolescent patients adhd | #1 |
23 candidate genes | #1 |
adhd adolescent patients | #1 |
age1542 | #1 |
orosmph adult adhd | #1 |
adhd france | #1 |
childhood adhd adulthood | #1 |
asrs | #1 |
motor preference adhd | #1 |
female humans inhibition | #1 |
paternal over‐transmission | #1 |
emotional problems pmee | #1 |
major depression youth | #1 |
adhd neuropsychological impairments | #1 |
drd2 risk gene | #1 |
convergent functional genomic | #1 |
aklt01 tova api | #1 |
hyperactivity pdi | #1 |
expression adhd | #1 |
week treatment response | #1 |
adhd asm snps | #1 |
familial underpinnings | #1 |
adhdrs5 | #1 |
pediatric bipolari disorder | #1 |
studies method | #1 |
bpd hypothesis | #1 |
genetic frontal schizophrenia | #1 |
rs9610449 | #1 |
40basepairrepeat | #1 |
mdd pdag mdd | #1 |
etiology disorder | #1 |
predictors adhd | #1 |
familial evidence | #1 |
non‐random error | #1 |
rates relatives | #1 |
diagnoses valid | #1 |
genetic correlations schizophrenia | #1 |
predicted clinical response | #1 |
asds clinical scales | #1 |
depression symptoms aggregation | #1 |
parental probands | #1 |
genotype calling procedures | #1 |
depression adhd child | #1 |
rs3746544 rs1051312 | #1 |
motor preference asthma | #1 |
criteria mania | #1 |
consensus statement combination | #1 |
bipolar disorder parents | #1 |
adhd risk factors | #1 |
gene attention | #1 |
nmu nasal nmu | #1 |
adhd ads | #1 |
2276ct | #1 |
idir proteins siblings | #1 |
fhraff | #1 |
adolescent follow youth | #1 |
parental children | #1 |
desr adhd | #1 |
placebo ldx treatment | #1 |
n55374 | #1 |
downward extension adolescents | #1 |
treatment stimulant | #1 |
braingenie | #1 |
pepple | #1 |
greater risk adhd | #1 |
mothers fam | #1 |
subthreshold adhd subjects | #1 |
teacher combined | #1 |
onset adult subjects | #1 |
treatment moderated | #1 |
bpd girls | #1 |
aspd youth | #1 |
nonreferred subjects | #1 |
git1 association adhd | #1 |
ldx size children | #1 |
genes adhd | #1 |
schizophrenia families smoking | #1 |
ldx bmi | #1 |
adhd sex | #1 |
adhd oppositional | #1 |
healthy cortical development | #1 |
dat1 adhd | #1 |
ermph placebo groups | #1 |
–rs2272080 | #1 |
daily parent rating | #1 |
p81e06 | #1 |
2327t | #1 |
male adolescents adhdct | #1 |
prescription stimulant adults | #1 |
slc9a9 | #1 |
pdi impulsiveness | #1 |
placebo cgsq | #1 |
17year | #1 |
association maoa | #1 |
childhood predictors adhd | #1 |
validity diagnosis | #1 |
adhd neuropsychological | #1 |
haplotypes adhd | #1 |
addictive drugs dust | #1 |
adult adhd treatment | #1 |
youth bpi disorder | #1 |
referred juveniles | #1 |
schizotaxia schizophrenia | #1 |
persistence childhood adhd | #1 |
drugplacebo response curve | #1 |
ainslbl | #1 |
83097 | #1 |
children motor competence | #1 |
subjects ldx | #1 |
co‐expression modules | #1 |
sexdifferentiated effects traits | #1 |
odd affective symptoms | #1 |
relatives conduct disorder | #1 |
adhdmethodcurves | #1 |
nonreferred adult | #1 |
children mania diagnosis | #1 |
mgh studies | #1 |
substantial genetic component | #1 |
vcfs manic symptoms | #1 |
fm pain tolerance | #1 |
familial subtype | #1 |
switches bipolar disorder | #1 |
offspring behavioral disinhibition | #1 |
dust addictive drug | #1 |
learning disabilities girls | #1 |
neuropsychological probes | #1 |
drugplacebo | #1 |
odd relatives | #1 |
psychopathology reward dysfunction | #1 |
context adhd | #1 |
d15s1012 | #1 |
hyperactivity databases | #1 |
children behavioral inhibition | #1 |
time qualitative review | #1 |
maoa adhd | #1 |
familybased studies association | #1 |
relatives diagnoses | #1 |
postmortem brain identifies | #1 |
adhd bpi disorder | #1 |
relatives risk adhd | #1 |
comt odd | #1 |
rs550818 | #1 |
distribution child | #1 |
dbds adhd | #1 |
comt fsiq | #1 |
familiar disease | #1 |
adhd child comorbidity | #1 |
age onset criterion | #1 |
rs1633445 | #1 |
intelligence additive effects | #1 |
treatment mts | #1 |
sud phenotypes | #1 |
youth adhd prss | #1 |
dsmiiir dsmiv adhd | #1 |
neuropsychological testing individuals | #1 |
familial transmission adhd | #1 |
stimulants childhood | #1 |
families adhd | #1 |
adhd income loss | #1 |
distinct subtype | #1 |
child psychiatry referrals | #1 |
motorendophenotypes | #1 |
probands comorbidity | #1 |
sodasmph | #1 |
motor preference | #1 |
adhd girls adhd | #1 |
symptom burden adults | #1 |
10repeats | #1 |
add parent report | #1 |
adhd social class | #1 |
adults life | #1 |
adolescents genetic risk | #1 |
adhd clinical | #1 |
idir aversion | #1 |
bpprss | #1 |
apol1 schizophrenia | #1 |
120 normal controls | #1 |
rs1040399 | #1 |
rs6000200 | #1 |
overweight obesity males | #1 |
adhd clinical characteristics | #1 |
alcohol dependence relatives | #1 |
p446e08 | #1 |
cortical surface adhd | #1 |
stimulant treatment alcohol | #1 |
1 relatives | #1 |
cbclbp profile | #1 |
smoking wm microstructure | #1 |
regions lgi | #1 |
taf9bp2 | #1 |
adhd gwas | #1 |
anxiety disorders twins | #1 |
familial risk analyses | #1 |
adhd hyperactivity automobile | #1 |
2064 trios | #1 |
locus adhd | #1 |
female gender boys | #1 |
comorbid psychopathology childhood | #1 |
subtype adhd | #1 |
teacher report | #1 |
add 73 probands | #1 |
drd2 disrupts | #1 |
palau early | #1 |
parental md | #1 |
parental adhd sud | #1 |
bpd probands | #1 |
adhd methods | #1 |
adhd probands | #1 |
adolescent sud | #1 |
disorder adhd | #1 |
bpi disorder | #1 |
a409p | #1 |
adhd subjects controls | #1 |
lifetime adhd | #1 |
dsmiv subtypes adhd | #1 |
onset criterion adhd | #1 |
deficits time | #1 |
adhd sample model | #1 |
clinical features adhd | #1 |
diagnosis bpi disorder | #1 |
rs11133767 | #1 |
association adhd | #1 |
nonverbal social–emotional cues | #1 |
desr probands siblings | #1 |
studies depressed children | #1 |
adherence xr | #1 |
expected growth children | #1 |
bpi disorder efds | #1 |
psud relatives | #1 |
affective symptoms children | #1 |
adhd maternal | #1 |
adhd module | #1 |
galantamine hydrogen bromide | #1 |
adhd 11 years | #1 |
nonreferred sample | #1 |
diagnoses probands | #1 |
tdt analysis | #1 |
adhd single nucleotide | #1 |
adhd girls | #1 |
adhd african children | #1 |
schizotaxia negative symptoms | #1 |
gene aggressive behavior | #1 |
affs add | #1 |
oral nmu nmu | #1 |
rs7124601 | #1 |
rs12843268 | #1 |
hyperactivity body | #1 |
repeat allele | #1 |
valid psychiatric disorder | #1 |
diagnostic efficiency analysis | #1 |
p902e−07 | #1 |
p758e08 | #1 |
adhd vntr | #1 |
lod213 | #1 |
rorb bipolar disorder | #1 |
oih fm | #1 |
offspring sud parents | #1 |
adhd iiv | #1 |
51 genes | #1 |
risk tourette spectrum | #1 |
elaborative verbal encoding | #1 |
dat110 6 | #1 |
method authors | #1 |
onset distributions | #1 |
p20e04 | #1 |
anxious depressed subscales | #1 |
bpi sza | #1 |
probands add | #1 |
discipline problem | #1 |
familial association adhd | #1 |
neural network correlates | #1 |
risk childhood onset | #1 |
distal genomic region | #1 |
adhd children | #1 |
adhd 5 | #1 |
selfreport adhd | #1 |
4q28 | #1 |
adhd control probands | #1 |
dsm5 adult adhd | #1 |
manic symptoms disorder | #1 |
unaffected siblings volumes | #1 |
adhd adult adhd | #1 |
adhd mp | #1 |
schizophrenia hrscz | #1 |
adhd psychoactive substance | #1 |
stimulants comorbidity | #1 |
adhd candidate genes | #1 |
prescription stimulant nmu | #1 |
weaknesses comorbidity | #1 |
increased methylation genes | #1 |
adhd pdics | #1 |
stress exposure connectivity | #1 |
aud adhd | #1 |
quantitative phenotype snp | #1 |
adhd comorbid odd | #1 |
years adhd | #1 |
rs2272080 | #1 |
concurrent adhd | #1 |
anxiety disorders findings | #1 |
symptoms adult | #1 |
adhd bipolar comorbidity | #1 |
risk factors opd | #1 |
structural differences children | #1 |
adhd cigarette smoking | #1 |
disorder | #1 |
autistic traits youth | #1 |
executive functioning adults | #1 |
school reliability | #1 |
marijuana cocaine crack | #1 |
adhd outcome | #1 |
adhd linkage | #1 |
onset chronological age | #1 |
criteria 14 children | #1 |
pdd mania | #1 |
motor skills attention | #1 |
association evidence | #1 |
euphoria cardinal symptom | #1 |
adhd genetic studies | #1 |
hyperactivity comorbidity | #1 |
disorder attention | #1 |
childhoodonset mania | #1 |
neuroleptic nonresponse | #1 |
adhd children bpd | #1 |
combination scientific data | #1 |
asd youth adhd | #1 |
disorder schizotaxia | #1 |
gsprss | #1 |
severe emotional dysregulation | #1 |
biological schizophrenia stress | #1 |
relatives adhd girls | #1 |
or133 | #1 |
pharmacological treatment adolescents | #1 |
fhrscz | #1 |
probands rates | #1 |
paediatric patients adhd | #1 |
adult adhd | #1 |
adhd cognition | #1 |
bpi relatives | #1 |
adolescents concurrent adhd | #1 |
consensus combination | #1 |
childhood genetic background | #1 |
druggable genome disorder | #1 |
relatives adhd status | #1 |
comt intelligence | #1 |
pair health | #1 |
genetic overlap adhd | #1 |
endosomal genes asds | #1 |
cognitive endophenotypes adhd | #1 |
competitivep | #1 |
efds functional outcomes | #1 |
disorder meta | #1 |
temperamental risk factor | #1 |
sud parents | #1 |
mr006 | #1 |
adolescent attention | #1 |
akt1 snp markers | #1 |
hyperactivity | #1 |
attention deficit | #1 |
genetic risk severity | #1 |
adhd maternal smoking | #1 |
genes hallucinations states | #1 |
comorbidity major depression | #1 |
risk opioid dependence | #1 |
relatives greater activation | #1 |
13052159 | #1 |
2327ct | #1 |
parental polygenic risk | #1 |
bpdsud bpd | #1 |
h2053 | #1 |
robust familiality | #1 |
adult persistence | #1 |
parental suds | #1 |
new phenotype definition | #1 |
relatives control | #1 |
suds genetic studies | #1 |
timely renewal | #1 |
referred parents | #1 |
impulsive drive | #1 |
putamen volume alterations | #1 |
stress adhd severity | #1 |
adhd structural abnormalities | #1 |
adults neurodevelopmental disorder | #1 |
probands clinical status | #1 |
cbcldesr | #1 |
adhd african | #1 |
juvenile antisocial traits | #1 |
ld addh children | #1 |
abnormalities adhd | #1 |
twin adoption studies | #1 |
adhd children mania | #1 |
stimulant nonmedical | #1 |
adhd stimulant treatment | #1 |
stimulants abuse potential | #1 |
adhd comorbid disorders | #1 |
sample adhd | #1 |
smaller total brain | #1 |
vcfsadhd adhd | #1 |
asd weaknesses | #1 |
smd greater severity | #1 |
large controlled study | #1 |
concurrent adhd sud | #1 |
hyperactivity child child | #1 |
rs916455 | #1 |
schizotypal relatives | #1 |
masir ldx | #1 |
behavioral inhibition parents | #1 |
mania criteria | #1 |
children pdag parents | #1 |
ptsd bpi disorder | #1 |
highiq youths | #1 |
cacng2 genes schizophrenia | #1 |
diagnostic continuity adhd | #1 |
scales risk | #1 |
educational failure | #1 |
snp quantitative phenotype | #1 |
dependence controls | #1 |
pharmacogenetics predictors | #1 |
neuropsychological impairments relatives | #1 |
individuals adhd | #1 |
association slc6a3 | #1 |
neurocognitive traits | #1 |
illness adolescent | #1 |
dsm bipolar disorder | #1 |
increased adhd symptoms | #1 |
moderating effects patterns | #1 |
motheronly | #1 |
quantitative analyses treatment | #1 |
endophenotypic construct | #1 |
age groups cohorts | #1 |
rf041 | #1 |
comorbid problems adhd | #1 |
odd familial disorders | #1 |
suds nicotine dependence | #1 |
autism‐associated brain regions | #1 |
adhd smoking | #1 |
cyp2d6 hypothesis | #1 |
suds neurocognitive functions | #1 |
adhd valid | #1 |
experts abstinence | #1 |
p647e07 | #1 |
adhd genetic exome | #1 |
add antisocial disorders | #1 |
behaviors substances | #1 |
model adult samples | #1 |
nasal nmu nmu | #1 |
children idiopathic adhd | #1 |
adhd screening | #1 |
molecular psychiatric genetics | #1 |
hyperactivity biomarkers | #1 |
druggable genome adhd | #1 |
psychiatric comorbidity girls | #1 |
proband youth bpd | #1 |
daorasd2 | #1 |
variance oppositional symptoms | #1 |
adhd degree relatives | #1 |
oros methylphenidate orosmph | #1 |
morbidity bipolar disorder | #1 |
95 hrr | #1 |
motor preference disability | #1 |
add opd | #1 |
adhd psychiatric | #1 |
hyperactivity cognition | #1 |
subcortical volumes adhd | #1 |
gene interaction comt | #1 |
14 children pdd | #1 |
gender adhd | #1 |
adhd antisocial | #1 |
teachers cbt intervention | #1 |
innovative sms intervention | #1 |
impulsive symptoms | #1 |
adhd higher | #1 |
zmynd17 genes | #1 |
git1 adhd | #1 |
adhd community | #1 |
chi25762 | #1 |
drd4 association | #1 |
life adult adhd | #1 |
controls adhd children | #1 |
ldx growth | #1 |
highiq adults adhd | #1 |
latrophilin 3 gene | #1 |
rs2498799 | #1 |
relatives bpi probands | #1 |
relatives drug dependence | #1 |
comorbid adult adhd | #1 |
31item | #1 |
clinical controls | #1 |
valid diagnosis | #1 |
volumes participants | #1 |
onset mania | #1 |
suds crosssectional studies | #1 |
rs9325032 | #1 |
bpd anx | #1 |
subthreshold diagnoses valid | #1 |
individuals attention | #1 |
sud bpdsud | #1 |
diagnoses relatives | #1 |
dat1 untranslated regions | #1 |
drd4 7repeat allele | #1 |
bpi disorder relatives | #1 |
neuropsychological functioning boys | #1 |
siblings adhd | #1 |
genetic correlation adhd | #1 |
administration marijuana | #1 |
diagnosis adhd | #1 |
gene comt | #1 |
relatives adhd probands | #1 |
nonreferred siblings probands | #1 |
psychiatric comorbidities adhd | #1 |
dopamine receptor polymorphism | #1 |
adhd genetic receptors | #1 |
subjects adhd | #1 |
disorder familial | #1 |
offspring parental adhd | #1 |
adhd susceptibility genes | #1 |
anxiety disorders families | #1 |
psud adhd probands | #1 |
variants aggressive behavior | #1 |
adhd social disability | #1 |
familial risk gender | #1 |
adults diagnosis | #1 |
based association study | #1 |
inattentive hyperactive | #1 |
preschool comorbidity | #1 |
adhd symptom counts | #1 |
adhd gene | #1 |
adult adhd differences | #1 |
bpi disorder children | #1 |
adhd adolescent | #1 |
prss adhd | #1 |
type attention | #1 |
hyperactive impulsive symptoms | #1 |
validity adhd | #1 |
siblings adolescent | #1 |
cbclbp | #1 |
adhd dat1 gene | #1 |
hamiltondepression | #1 |
adhd probands relatives | #1 |
volume alterations | #1 |
impulsive behavioral aggression | #1 |
chi28783 | #1 |
comorbidity conduct | #1 |
sob sob association | #1 |
proband youth bpdsud | #1 |
racial heterogeneity | #1 |
stimulant misuse | #1 |
adhd clinical trial | #1 |
psud controls | #1 |
adhd adoption studies | #1 |
growth delays weight | #1 |
chinese outpatient sample | #1 |
drug dependence relatives | #1 |
memory adults | #1 |
model ermph | #1 |
cigarette smoking siblings | #1 |
laboratory driving simulation | #1 |
5‐generation | #1 |
falconer3 | #1 |
methylphenidate efficacy | #1 |
cgsq ermph | #1 |
children growth delays | #1 |
lifetime impairment survey | #1 |
persons rels | #1 |
bipolar disorder bpprss | #1 |
4‐year follow‐up study | #1 |
adhd phenotypes | #1 |
nplz | #1 |
mph controls | #1 |
vall66 | #1 |
odd disruptive behavior | #1 |
asrs‐v11 | #1 |
followup assessment | #1 |
schizotaxia negative schizotypy | #1 |
report adhd | #1 |
adhdrsivinv | #1 |
masir | #1 |
dao gene schizophrenia | #1 |
prss psychiatric disorders | #1 |
rs2279805 | #1 |
dyscalculia adhd | #1 |
adhd genetic | #1 |
teenage parents individuals | #1 |
multi‐stage study | #1 |
pediatric panic disorder | #1 |
antisocial disorders risk | #1 |
clinically diagnosed obesity | #1 |
masxr treatment | #1 |
subsets linkage | #1 |
adhd predictors | #1 |
offspring parental md | #1 |
children bpi disorder | #1 |
bpd parents | #1 |
tass adhd | #1 |
rs3916970 | #1 |
thermenos | #1 |
serotonin genetic | #1 |
peer environmental factors | #1 |
interviews disease humans | #1 |
effects lisdexamfetamine dimesylate | #1 |
rs9627183 | #1 |
aadhd hyperactivity biomarkers | #1 |
parental panic depression | #1 |
covariates dopamine receptors | #1 |
cohorts age groups | #1 |
features adhd | #1 |
bipolar disorders psud | #1 |
nfspds | #1 |
trypotphan | #1 |
adhd antisocial disorders | #1 |
nonmental diseases adhd | #1 |
“forgetfulness | #1 |
siblings control probands | #1 |
adhd somatosensory functioning | #1 |
prs58502974 | #1 |
schizophrenia nonpsychotic relatives | #1 |
iiv shr | #1 |
bmi mts | #1 |
adults ldx sizes | #1 |
structured interview mania | #1 |
comorbid oppositional | #1 |
subthreshold pediatric | #1 |
896 cases | #1 |
bpi disorder sexes | #1 |
shlod | #1 |
maoa neuropsychological functioning | #1 |
highiq youths adhd | #1 |
nr3c1 stress exposure | #1 |
notch4 polymorphisms | #1 |
clinical interview mania | #1 |
mtbi adhd | #1 |
children general psychopathology | #1 |
relatives add probands | #1 |
valid disorder | #1 |
genes etiology | #1 |
pdd subjects mania | #1 |
rs1051312 | #1 |
relatives bipolar | #1 |
palauans maps loci | #1 |
135–526 | #1 |
controls adhd probands | #1 |
sud adolescent | #1 |
daonrg1 | #1 |
linkage wave | #1 |
mania clinical interview | #1 |
molecular genetics network | #1 |
depression offspring variables | #1 |
1350t | #1 |
adhd pattern | #1 |
specific psychopathology children | #1 |
adhdi prenatal exposure | #1 |
sbrv adhd | #1 |
stimulant treatment adhd | #1 |
adhd efficacy outcome | #1 |
antisocial families | #1 |
prodromal overt psychosis | #1 |
adhd studies | #1 |
major depression share | #1 |
tass internal consistency | #1 |
stimulant nmu | #1 |
children antisocial disorders | #1 |
paternal overtransmission | #1 |
stimulant treatment youth | #1 |
high‐risk adolescent offspring | #1 |
autism symptoms adhd | #1 |
psychiatric comorbidity md | #1 |
adverse impact adhd | #1 |
adhd probands adhd | #1 |
hyperactive impulsive | #1 |
adult samples model | #1 |
adult samples adhd | #1 |
unexplored void | #1 |
sud risk offspring | #1 |
adhd treatment treatment | #1 |
mitigates stimulant | #1 |
pdics | #1 |
growth outcomes adhd | #1 |
sex bpi disorder | #1 |
aud alcohol disorders | #1 |
nonpsychotic relatives controls | #1 |
bpd relatives | #1 |
mania conduct disorder | #1 |
findings adhd | #1 |
adhd youth ld | #1 |
asrs aisrs | #1 |
analysis adhd | #1 |
adults stimulant sizes | #1 |
hyperactivity child | #1 |
amses amrs | #1 |
nimh genetics initiative | #1 |
aggressive symptoms risk | #1 |
european treatment guidelines | #1 |
sp067 | #1 |
deficits expected growth | #1 |
adhde | #1 |
trait educational attainment | #1 |
adhd proband | #1 |
non‐adhd children | #1 |
fbxo33 | #1 |
exposure parental adhd | #1 |
age 7repeat allele | #1 |
adhd haplotype block | #1 |
symptoms aggregation | #1 |
anxiousdepressed | #1 |
adhd reliability | #1 |
oral methylphenidate treatment | #1 |
nonreferred adults | #1 |
adhd children exposure | #1 |
desr subjects | #1 |
aff add | #1 |
gsprs adhd | #1 |
pediatric bpi disorder | #1 |
onset attention | #1 |
stimulant treatment risk | #1 |
bipolar adhd | #1 |
interaction adhd | #1 |
trypotphan hydroxylase | #1 |
adhd comorbid | #1 |
parental sud sud | #1 |
pain tolerance oih | #1 |
psychopharmacologic | #1 |
stimulant treatment profiles | #1 |
adhd oxidative stress | #1 |
adhd module mwq | #1 |
psychiatric risk vcfs | #1 |
manic symptoms vcfs | #1 |
ldx amses | #1 |
adhd brain alterations | #1 |
adhd functional | #1 |
adhd antisocial comorbidity | #1 |
anx bpd | #1 |
ats siblings | #1 |
17yearold boys | #1 |
subcortical structure volume | #1 |
siblings adhd probands | #1 |
probands adhd | #1 |
studies adhd | #1 |
fidgety philipp | #1 |
youth informant source | #1 |
disorders hypothesis | #1 |
adhd efds | #1 |
ldx expected height | #1 |
genetic heterogeneity adhd | #1 |
girls disorder | #1 |
intron8 | #1 |
rs1076560t | #1 |
adhd highiq youths | #1 |
77e08 | #1 |
pdag mdd mdd | #1 |
21 circadian genes | #1 |
bpi disorder adhd | #1 |
smoking schizophrenia families | #1 |
adhd sample | #1 |
familially | #1 |
adhd teenage parents | #1 |
schizophrenia code | #1 |
ldx masir | #1 |
adhd clinical obesity | #1 |
affective symptoms dbds | #1 |
inattentive subtype adhd | #1 |
mania pdd subjects | #1 |
efficacy medications | #1 |
clinical correlates ocd | #1 |
loci adhd | #1 |
vntr haplotype | #1 |
ptsd siblings | #1 |
regions age | #1 |
diagnoses adhd | #1 |
dopamine d4 gene | #1 |
re‐review | #1 |
sbrv | #1 |
rationaleadhd | #1 |
aadhd cadhd | #1 |
common genetic risk | #1 |
deletioncarrier | #1 |
deficit hyperactivity | #1 |
conduct disorder probands | #1 |
notch4 polymorphisms schizophrenia | #1 |
pdd pdd subjects | #1 |
association evidence schizophrenia | #1 |
chronological age age | #1 |
nhe inhibitors adhd | #1 |
adhd maoa | #1 |
adhd gsprs | #1 |
suds relatives | #1 |
adoption studies | #1 |
adhd desr | #1 |
motorendophenotype | #1 |
adults cadhd | #1 |
disorder follow | #1 |
candidate genes adhd | #1 |
adhd population | #1 |
efds bpi disorder | #1 |
adherence stimulant medication | #1 |
potential endophenotypes adhd | #1 |
qelbree | #1 |
shr iiv | #1 |
adhd stronger connectivity | #1 |
adhd baseline | #1 |
adult probands siblings | #1 |
syp female adhd | #1 |
risk female relatives | #1 |
social adjustment inventory | #1 |
self‐reported adhd | #1 |
risk psud | #1 |
rutters | #1 |
symptoms versus impairment | #1 |
stimulants height | #1 |
genetics adhd | #1 |
sensitive adhd | #1 |
kiaa1292 | #1 |
anachronisms | #1 |
rf025 | #1 |
adolescence longitudinal analysis | #1 |
neuroanatomic predictors | #1 |
interobserver agreement measures | #1 |
nfspd | #1 |
hyperactivity disorder | #1 |
smoking cessation controls | #1 |
desr adults | #1 |
hyperactivity disorder adults | #1 |
items 99item cbs | #1 |
2455 controls | #1 |
treatment bsd | #1 |
adhd asd youth | #1 |
selfreport adhd symptoms | #1 |
parental bpd | #1 |
74±77 | #1 |
adhd symptoms crf | #1 |
nonmental diseases | #1 |
p97e−03 | #1 |
adulthood genetic architecture | #1 |
comparison subjects participants | #1 |
criteria age | #1 |
psychopathology implications | #1 |
rtv adhd prs | #1 |
scz palau | #1 |
9 nhe9 | #1 |
medications adhd | #1 |
bpd firstdegree relatives | #1 |
lifetime impairment | #1 |
relation stress exposure | #1 |
ermph cgsq | #1 |
brain activity flow | #1 |
bipolar disorder girls | #1 |
rs2449340 | #1 |
48basepairrepeat | #1 |
anterior insular lobule | #1 |
efs girls | #1 |
nonreferred siblings | #1 |
subthreshold adhd | #1 |
adhd drd4 | #1 |
fsiq comt | #1 |
visual memory deficit | #1 |
efficacy adderall | #1 |
relatives alcohol dependence | #1 |
s034 | #1 |
cortical thickness adhd | #1 |
siblings antisocial families | #1 |
adult adhd diagnosis | #1 |
adhd obesity overweight | #1 |
add pdics | #1 |
parents sud | #1 |
oih cpt | #1 |
stimulant treatment adults | #1 |
mania manic features | #1 |
network‐level assessment | #1 |
addh dmi | #1 |
ldx growth delays | #1 |
adhd disorder | #1 |
aggregate cutoff score | #1 |
fiveminutespeechsample | #1 |
smd higher rates | #1 |
adhddbds | #1 |
tomoxetine adult adhd | #1 |
adhd dbds | #1 |
bpd bpd anx | #1 |
inattentive symptoms adults | #1 |
schizophrenia notch4 | #1 |
relatives girls | #1 |
growth deficits deficits | #1 |
genetic variants adhd | #1 |
stimulant therapy youths | #1 |
exposure maternal smoking | #1 |
ptsd adhd probands | #1 |
siblings adhd children | #1 |
ldx adult adhd | #1 |
hyperactivity female | #1 |
12allele | #1 |
schizotaxia subjects | #1 |
treatment stimulants | #1 |
schizophrenia fhrs | #1 |
inattention items | #1 |
cdh13 memory performance | #1 |
adhd desr probands | #1 |
adhd dsm | #1 |
infas | #1 |
association syp | #1 |
antisocial disorders bpd | #1 |
emotional symptoms adhd | #1 |
patients adhdpi | #1 |
relatives wm performance | #1 |
girls learning disabilities | #1 |
adhd children depression | #1 |
adhd community sample | #1 |
treatment effects values | #1 |
risk anxiety disorders | #1 |
firstdegree relatives children | #1 |
slc9a9 adhd | #1 |
2276tc | #1 |
lateonset adhd | #1 |
tourettes syndrome adhd | #1 |
adolescent outcome adhd | #1 |
c759t | #1 |
comt maoa interaction | #1 |
persistent adhd adults | #1 |
norepinephrine transporter gene | #1 |
bpi disorder aspd | #1 |
onset distribution | #1 |
groups girls | #1 |
severe dysregulation | #1 |
sob association adhd | #1 |
alcohol disorders offspring | #1 |
cases adhd | #1 |
etiology adhd | #1 |
aisrs asrs | #1 |
disorder versus disability | #1 |
adhd baseline assessment | #1 |
callingalgorithms | #1 |
european treatment guideline | #1 |
pooleddata | #1 |
paliperidone monotherapy | #1 |
versus disability | #1 |
adhd neuroimage study | #1 |
tidqam | #1 |
adhd serotonin | #1 |
prospective datasets | #1 |
criteria pdd | #1 |
adhd switches | #1 |
impulsiveness inattention | #1 |
disorder hyperactivity | #1 |
manic children pdd | #1 |
overlapping symptoms | #1 |
rs1799835 | #1 |
neurocognitive functions suds | #1 |
osa genetic heterogeneity | #1 |
transient financial stress | #1 |
time reproduction children | #1 |
add aff | #1 |
pilot study adhd | #1 |
adhd | #1 |
adhd asthma | #1 |
greater risk add | #1 |
anxiety disorders relatives | #1 |
benefit‐risk ratio | #1 |
desr adult probands | #1 |
schizophrenia bipolar psychoses | #1 |
maternal inattention anxiety | #1 |
relatives bpi | #1 |
shared endophenotypes | #1 |
maoa impulsivity | #1 |
asthma motor preference | #1 |
bpi disorder youth | #1 |
disorders aa | #1 |
persistence adhd | #1 |
hyperactivity biomarkers aadhd | #1 |
pdd criteria | #1 |
risk disorder | #1 |
interaction adhd severity | #1 |
rs7118422 | #1 |
efficacy outcome week | #1 |
pippi longstocking | #1 |
expressed emotion children | #1 |
adhd follow | #1 |
conduct disorder aspd | #1 |
differences medications | #1 |
genomesignificance | #1 |
lateandmoderate | #1 |
neuropsychologic function schizophrenia | #1 |
parents proband youth | #1 |
fspds | #1 |
inattention shr | #1 |
adhd druggable genes | #1 |
adhd rat | #1 |
anxiety disorders baseline | #1 |
24 gm day | #1 |
association behavioral inhibition | #1 |
boys social disability | #1 |
adhdassociated alleles | #1 |
mwq adhd module | #1 |
personality traits adults | #1 |
adolescent psychiatric cohort | #1 |
rs11568324 | #1 |
oral nmu | #1 |
higher prevalence girls | #1 |
relatives default network | #1 |
prescription stimulant nonmedical | #1 |
schizophrenia familybased studies | #1 |
larger samples | #1 |
bipolars unipolar relatives | #1 |
smoking adhd | #1 |
adhd context | #1 |
meaningful anxiety phenotype | #1 |
rs6077690 | #1 |
female adhd | #1 |
association dopamine receptors | #1 |
affective psychosis hraff | #1 |
age stimulant treatment | #1 |
adhd specific | #1 |
inattention adhd | #1 |
parents behavioral disinhibition | #1 |
anx relatives | #1 |
children ermph | #1 |
children disorder | #1 |
“3 | #1 |
vivo neuroreceptor imaging | #1 |
efds youth | #1 |
187 children | #1 |
increasing resource demand | #1 |
children teaes | #1 |
persistence pediatric disorder | #1 |
pathways adhd | #1 |
pdi hyperactivity | #1 |
odd control | #1 |
criteria☆ | #1 |
twin adoption | #1 |
neuropsychological performance adhd | #1 |
predictors persistence | #1 |
ldx sizes adults | #1 |
siblings males | #1 |
aklt01 adhd | #1 |
genes disorder | #1 |
connectivity executive control | #1 |
association psychiatric comorbidity | #1 |
expected height weight | #1 |
higher pdi | #1 |
female individuals adhd | #1 |
marijuana smoking metaanalysis | #1 |
adhd long term | #1 |
faraone | #1 |
risk suds | #1 |
desr siblings | #1 |
exposure clinical features | #1 |
risk comt gene | #1 |
35191 | #1 |
transmission adhd | #1 |
slc6a4 gene risk | #1 |
regulation desr | #1 |
chronic emotional dysregulation | #1 |
depressed children depression | #1 |
p27e05 | #1 |
adhd conclusions | #1 |
oih pain tolerance | #1 |
adhdtd | #1 |
future dsm | #1 |
genetic association rorb | #1 |
persistence disorder | #1 |
trait impulsivity adhdct | #1 |
adhd psychiatric conditions | #1 |
genes association studies | #1 |
autistic traits presence | #1 |
adhd gender | #1 |
adhd children ld | #1 |
comt maoa | #1 |
n122 | #1 |
height ldx | #1 |
sud adolescent patients | #1 |
familial disorders adhd | #1 |
metaanalysis controlled study | #1 |
adhd responders | #1 |
elevated risk adhd | #1 |
stimulant treatment differences | #1 |
adhd familial risk | #1 |
hyperactivity comorbidity humans | #1 |
diagnostic criteria adhd | #1 |
np functioning chr | #1 |
bpd bpdsud | #1 |
highiq adults | #1 |
psychiatric disorders adhd | #1 |
adhd slc6a3 genotype | #1 |
psychiatric conditions adults | #1 |
adhd genetic correlation | #1 |
relatives multiplex families | #1 |
rs3776512 | #1 |
productivity adhd | #1 |
adhd alcohol dependence | #1 |
adhd cbcl | #1 |
relatives 3 probands | #1 |
relatives pediatric probands | #1 |
genetic variation nr3c1 | #1 |
nonreferred samples | #1 |
cacng2 gene | #1 |
rs41084 | #1 |
children adolescents cohorts | #1 |
control probands | #1 |
children motor domain | #1 |
adhd concurrent sud | #1 |
measurement invariance study | #1 |
vulnerability indicators schizophrenia | #1 |
loci asd symptoms | #1 |
parental panic disorder | #1 |
biased maternal reporting | #1 |
adhd adult disorder | #1 |
patients adhdct | #1 |
adhd scores | #1 |
bipolar mdd | #1 |
metabias | #1 |
familial links | #1 |
adhd learning | #1 |
adhd bipolar studies | #1 |
p179e06 | #1 |
adhd familial | #1 |
rare protective allele | #1 |
clock genes rorb | #1 |
adhd adhdtd | #1 |
rs552655 | #1 |
authors adhd | #1 |
impairments adults | #1 |
parents md | #1 |
hypothesized precursors | #1 |
risk adhd | #1 |
cbt intervention adolescents | #1 |
adhd diagnosed | #1 |
adhd prss | #1 |
tass adhdrs | #1 |
adhdoddcd | #1 |
pdd mania mania | #1 |
hyperactivity case | #1 |
noninhibited children | #1 |
adhd aud | #1 |
matter volumes volumes | #1 |
adhd background | #1 |
adhd educational deficits | #1 |
abstinence pharmacological treatment | #1 |
mspi allele | #1 |
tova api aklt01 | #1 |
stable behavioral inhibition | #1 |
5ht1b receptor gene | #1 |
bipolar disorder switches | #1 |
drug frequency variables | #1 |
1236a | #1 |
medications adult adhd | #1 |
familial moderators | #1 |
99item cbs | #1 |
bpd anx relatives | #1 |
biomarkers adhd | #1 |
dat1 vntr | #1 |
higher adhd | #1 |
palau scz | #1 |
relatives control probands | #1 |
snps drd4 gene | #1 |
drd5 vntr | #1 |
disorder boys | #1 |
studies attention | #1 |
genes sexdifferentiated effects | #1 |
hartsough | #1 |
schizophrenia current knowledge | #1 |
cdbpd | #1 |
mr005 | #1 |
hyperactivity child humans | #1 |
dna methylation adhd | #1 |
shifting sands | #1 |
key conceptual issues | #1 |
relbps | #1 |
referred samples | #1 |
late onset adhd | #1 |
140 adhd | #1 |
disorganized symptom dimensions | #1 |
adhd sexes | #1 |
risk substance disorders | #1 |
snps quantitative phenotypes | #1 |
structured interview pdd | #1 |
prs rtv | #1 |
5q23q31 | #1 |
mania referred children | #1 |
lobe mri measures | #1 |
adhd followup | #1 |
mp adhd | #1 |
impactnl | #1 |
parental sud adhd | #1 |
alphaglx | #1 |
htf9c gene | #1 |
molecular genetic studies | #1 |
matching fallacy | #1 |
genetic sexual dimorphism | #1 |
illness child comorbidity | #1 |
adhd total score | #1 |
outcome adhd | #1 |
substance disorders relatives | #1 |
increased expression methylation | #1 |
arch ger psychiatry | #1 |
adhd snps | #1 |
opd add opd | #1 |
229 families | #1 |
adhd alleles | #1 |
treatment masxr | #1 |
“schizotypes | #1 |
cardinal symptom mania | #1 |
disorder relatives | #1 |
md parents | #1 |
boys female gender | #1 |
hypothesis disorders | #1 |
adhd disorders comorbidity | #1 |
pregnancy adhd | #1 |
african‐american pedigrees | #1 |
mddprss | #1 |
earlyandmoderate | #1 |
rs3027400 | #1 |
adults adhd subjects | #1 |
hyperactivity child genome | #1 |
remission definition | #1 |
caregiver strain cgsq | #1 |
neurocognitive marker | #1 |
male individuals adhd | #1 |
adhd attention | #1 |
studies adhd children | #1 |
sud nicotine dependence | #1 |
9r allele | #1 |
adhd smoking risk | #1 |
slc9a9 disease associations | #1 |
rs2469770 | #1 |
adhd females | #1 |
dysfunctional gene | #1 |
longitudinal outcome boys | #1 |
adhd aes | #1 |
unipolar relatives bipolars | #1 |
adhd medications placebo | #1 |
15q13 deletions | #1 |
elevated rates adhd | #1 |
cbcl clinical scales | #1 |
discordant twin study | #1 |
efficacy outcome adhd | #1 |
adhd dyscalculia | #1 |
adhd risk alleles | #1 |
starsadhd | #1 |
adhd candidate | #1 |
allele adhd | #1 |
adhd findings | #1 |
adhd increased | #1 |
groundskeeper | #1 |
4q3121 | #1 |
association attention | #1 |
subjects lateonset adhd | #1 |
positive peer affiliation | #1 |
genetic studies sud | #1 |
insular lobule | #1 |
comorbid problems | #1 |
adhd prs gwas | #1 |
schizophrenic probands1portions | #1 |
adhd volumetric reductions | #1 |
suggestive linkage signals | #1 |
deficit | #1 |
adhd fam | #1 |
training raters | #1 |
multiplex sample | #1 |
confusability analyses | #1 |
rate symptoms | #1 |
opd add | #1 |
disorder molecular | #1 |
df39 | #1 |
tic persistence | #1 |
112 80 | #1 |
d10s2327 | #1 |
foursnp | #1 |
adhd seconddegree relatives | #1 |
adhd comorbid dbds | #1 |
mania rates | #1 |
patients attentional disorders | #1 |
nonreferred | #1 |
cigarette smoking metaanalysis | #1 |
35191 controls | #1 |
risk subsequent substance | #1 |
adhd adhd cases | #1 |
ptsd familial disorders | #1 |
relatives multiplex | #1 |
new psychometric definition | #1 |
ermph clinical response | #1 |
cadhd aadhd | #1 |
association tph2 | #1 |
association snap25 | #1 |
adhdfamilies | #1 |
controls rels | #1 |
paediatric adhd | #1 |
pinslbl | #1 |
suggestive linkage | #1 |
intellectual delays | #1 |
diagnostic continuity | #1 |
longitudinal analysis childhood | #1 |
suds adhd | #1 |
relatives 1 probands | #1 |
neurocognitive dysfunctions | #1 |
bpi probands | #1 |
adhd euphoria | #1 |
n6979 | #1 |
prevalence attention | #1 |
morbidity adhd | #1 |
nonaffected siblings children | #1 |
new diagnoses age | #1 |
schizophrenia european samples | #1 |
actual motor performance | #1 |
copy organization | #1 |
comorbid odd adhd | #1 |
genetic studies adhd | #1 |
20183 | #1 |
adhd mdd prss | #1 |
paternal smoking conception | #1 |
gene studies | #1 |
sud remittent adhd | #1 |
adhd adhd probands | #1 |
compared adhd | #1 |
fam mothers | #1 |
motor problems adhd | #1 |
risk aggressive symptoms | #1 |
rels persons | #1 |
adhd drug dependence | #1 |
20183 cases | #1 |
adhd chinese population | #1 |
sob adhd | #1 |
low attention | #1 |
evidence sud phenotypes | #1 |
males overweight obesity | #1 |
cortical networks attention | #1 |
adhd prss adhd | #1 |
longacting medications | #1 |
gender familial risk | #1 |
proband child | #1 |
patterns psychiatric comorbidity | #1 |
mph adult adhd | #1 |
phenotype adhd | #1 |
hyperactivity disorder scores | #1 |
ldx sizes | #1 |
adolescents sud treatment | #1 |
adherence stimulant treatment | #1 |
adhd mini | #1 |
add relatives | #1 |
impaired sensorimotor timing | #1 |
depressed children adhd | #1 |
mania pdd | #1 |
children behavioral | #1 |
impact tic disorders | #1 |
clinical response orosmph | #1 |
treating adhd | #1 |
executive function outcome | #2 |
adhd method | #2 |
masxr | #2 |
ncrl wky | #2 |
schizophrenia calcineurin | #2 |
adhd outcomes | #2 |
youth selfreports | #2 |
adhd genetics | #2 |
chromosomes 6 14 | #2 |
millennium consortium | #2 |
deficit hyperactivity disorder | #2 |
association mtbi | #2 |
d0·18 | #2 |
stress adhd | #2 |
disorder impact | #2 |
6 17 | #2 |
spectrum phenotypes | #2 |
subjects adults | #2 |
concurrent attention | #2 |
bpd sud | #2 |
disorders similarities | #2 |
youth meaningful | #2 |
mood disorders adhd | #2 |
subjects conduct disorder | #2 |
asrs health organization | #2 |
anx bipolar disorder | #2 |
deficits executive | #2 |
youth rates | #2 |
child comorbidity illness | #2 |
adhd neuropsychological deficits | #2 |
addicted | #2 |
deficits efds | #2 |
major depression findings | #2 |
adhdprss | #2 |
scales sex | #2 |
elusive indicators | #2 |
comorbidity disorder | #2 |
adhd bpd | #2 |
separation attention deficit | #2 |
adolescents substance disorder | #2 |
families schizophrenia patients | #2 |
mirsky | #2 |
bidirectional overlap | #2 |
10092 | #2 |
juvenile antisocial | #2 |
disorder inattentive | #2 |
tourette spectrum | #2 |
dimesylate treatment | #2 |
regions studies | #2 |
actively reducing severity | #2 |
case subjects adhd | #2 |
schizophrenia genetic studies | #2 |
hyperactivity impulsiveness | #2 |
morning behavior | #2 |
factors attention | #2 |
rates adhd | #2 |
rs6938431 | #2 |
schizotypy handedness | #2 |
617 years | #2 |
2q143 | #2 |
treatment sud patients | #2 |
parental anxiety disorders | #2 |
cacng2 genes | #2 |
large controlled | #2 |
deficit sustained attention | #2 |
sex differences adhd | #2 |
rates odd | #2 |
expanded versions | #2 |
systematized delusions | #2 |
subjects desr | #2 |
personal satisfaction | #2 |
schizotaxia discussion | #2 |
work needed | #2 |
pediatrically | #2 |
rs1801028 | #2 |
preventing schizophrenia | #2 |
antisocial disorders | #2 |
background attention | #2 |
psychiatric comorbidity | #2 |
female probands | #2 |
n‐acetylcysteine treatment | #2 |
familial adhd | #2 |
small literature | #2 |
disorder girls | #2 |
wwwhapmaporg | #2 |
dsmiiir adhd | #2 |
underlying bipolarity | #2 |
6p243 | #2 |
adhd objective | #2 |
ppv hyperactivity diagnostic | #2 |
quetiapine monotherapy treatment | #2 |
symptoms neuropsychological | #2 |
relatives add | #2 |
status rating scales | #2 |
adhd icv | #2 |
hyperactivity attention deficit | #2 |
subjects criteria | #2 |
comorbidity disorders comorbidity | #2 |
expanded symptom criteria | #2 |
heterogeneity schizophrenia | #2 |
adhd assessed | #2 |
adhd families | #2 |
hyperactivity diagnostic | #2 |
deficits adults | #2 |
adra2a polymorphism | #2 |
molecular genetics schizophrenia | #2 |
pilot adult | #2 |
galantamine hbr placebo | #2 |
methylphenidate attention | #2 |
methodological complexities | #2 |
age onset distribution | #2 |
dsm subtypes | #2 |
adhd choice | #2 |
adhd risk factor | #2 |
iii attention | #2 |
cbcl desr | #2 |
disorder studies | #2 |
dsm adhd | #2 |
comorbidity attention | #2 |
association data | #2 |
referred youth | #2 |
boys maoa | #2 |
rs40184 | #2 |
juvenile bipolar phenotype | #2 |
idiopathic adhd | #2 |
neuropsychoanalytic treatment | #2 |
conners adult adhd | #2 |
rs3746544 | #2 |
chromosomes inclusion | #2 |
adhd control subjects | #2 |
suggestive linkage loci | #2 |
performancemeasures | #2 |
immune disorder | #2 |
relatives adhd | #2 |
familial association | #2 |
consecutively referred children | #2 |
adhd major depression | #2 |
bpd adhd | #2 |
schizophrenia interactions | #2 |
treatment childhood adhd | #2 |
eye vergence responses | #2 |
risk female cases | #2 |
actively reducing | #2 |
bipolar disorder sud | #2 |
ldsc genetic correlations | #2 |
dysfunction offspring | #2 |
girls adhd | #2 |
adhd conduct | #2 |
comorbidity probands | #2 |
adherence stimulants | #2 |
variance adult | #2 |
neuroleptic dose reduction | #2 |
bias child child | #2 |
proinflammatory expansion | #2 |
6‐year longitudinal study | #2 |
conjfdr005 | #2 |
familial risk analysis | #2 |
ldsc heritability | #2 |
structured diagnostic interviews | #2 |
adhd autism symptoms | #2 |
consecutively referred | #2 |
young adult years | #2 |
postcleavage | #2 |
disorders suds | #2 |
n2455 | #2 |
dsmjbd | #2 |
combinedtype | #2 |
emf impairments | #2 |
adhd comparison | #2 |
pdd overlap | #2 |
assessed structured | #2 |
cbcl clinical | #2 |
default network schizophrenia | #2 |
serum neuroleptic activity | #2 |
screening diagnosis treatment | #2 |
ratio081 | #2 |
morbidity dysfunction | #2 |
persistent attention | #2 |
hrscz | #2 |
disorder oppositional | #2 |
wky nhsd | #2 |
adhdonly | #2 |
adults attention | #2 |
comorbid aggression | #2 |
nicotine substance | #2 |
comparison probands | #2 |
adhd combined subtype | #2 |
antisocial disorders relatives | #2 |
activation trigger | #2 |
clinically referred children | #2 |
stin2vntr | #2 |
lgi regions | #2 |
adhd adhd children | #2 |
galantamine hbr | #2 |
relatives schizophrenic | #2 |
disorder children | #2 |
findings children | #2 |
consortium neuroscience | #2 |
twin studies adhd | #2 |
clinically referred | #2 |
risk factor adhd | #2 |
internal distractibility | #2 |
investigator ratings | #2 |
subthreshold diagnoses | #2 |
adhd risk icv | #2 |
association meta analysis | #2 |
adhd height | #2 |
adhd mph response | #2 |
cigarette smoking suds | #2 |
add probands | #2 |
adhd disability | #2 |
6 17 years | #2 |
somatosensory functioning | #2 |
shared genetic background | #2 |
modest evidence | #2 |
d10s1432 | #2 |
ncrl | #2 |
scz data | #2 |
eye vergence | #2 |
stimulants | #2 |
health organization asrs | #2 |
reward‐related activation | #2 |
risk panic disorder | #2 |
disorder adults | #2 |
p161e05 | #2 |
comorbid oppositional defiant | #2 |
adhd surface area | #2 |
g72 daao | #2 |
child behavioral inhibition | #2 |
testretest reliability screener | #2 |
adhd risk gene | #2 |
adhd emotional symptoms | #2 |
bsfq | #2 |
developmental subtype | #2 |
key cognitive phenotypes | #2 |
disorder background | #2 |
checklist clinical | #2 |
models adhd | #2 |
lallele homozygotes | #2 |
adhd subjects | #2 |
adverse effects subjects | #2 |
euphorigenic effects | #2 |
probands relatives | #2 |
adhd genes | #2 |
oral prescription | #2 |
qualitative literature review | #2 |
manic children | #2 |
n17666 | #2 |
adhd acc | #2 |
n11221 | #2 |
disorders findings | #2 |
amses | #2 |
checklist scales | #2 |
expert clinician | #2 |
hantac | #2 |
naltrexone adults | #2 |
selfmedicating | #2 |
adhd odd | #2 |
adhd combined | #2 |
parents disorder | #2 |
scales adolescent | #2 |
adhd relatives | #2 |
male psychiatric | #2 |
iii adhd | #2 |
risk add | #2 |
function deficits | #2 |
sud bpd | #2 |
aklt01 | #2 |
disease humans inhibition | #2 |
efds | #2 |
factors adhd | #2 |
infancy complications | #2 |
adhd report | #2 |
adhd adults | #2 |
attentional control effects | #2 |
wiatii | #2 |
subsyndromal manifestations | #2 |
s038 | #2 |
5 loci adhd | #2 |
disease humans receptors | #2 |
diagnosis attention | #2 |
efficacy stimulants | #2 |
odd girls | #2 |
parent rating | #2 |
hypothesis adhd | #2 |
140 girls | #2 |
qualitative review | #2 |
structure adult adhd | #2 |
n2246 | #2 |
aggressive symptoms | #2 |
psychotic relatives | #2 |
n328917 | #2 |
structured diagnostic | #2 |
subsequent substance | #2 |
scale asrs | #2 |
disorder adolescent | #2 |
candidate genetic pathways | #2 |
relatives simplex families | #2 |
disorder add | #2 |
derived diagnosis | #2 |
informant source | #2 |
schizophrenia parahippocampal gyrus | #2 |
bipolar disorder relatives | #2 |
probands | #2 |
role adhd | #2 |
strong heritability | #2 |
18 dsm | #2 |
control subjects adhd | #2 |
unweighted screener asrs | #2 |
adhd comparison subjects | #2 |
adhd african americans | #2 |
hypothalamic abnormalities | #2 |
allele schizophrenia | #2 |
neuropsychological function girls | #2 |
cognition youth | #2 |
attention‐deficit hyperactivity | #2 |
familybased studies | #2 |
cpt oih | #2 |
wm deficits | #2 |
initial stimulant | #2 |
cbcl profile | #2 |
affective probands | #2 |
d2s410 | #2 |
disorder findings | #2 |
blind raters | #2 |
adhd bipolar | #2 |
adults adhd | #2 |
evidence adhd | #2 |
versus controls | #2 |
adhdliability | #2 |
child comorbidity | #2 |
wky ncrl | #2 |
current adult adhd | #2 |
psychiatrically | #2 |
familial trait | #2 |
qtl linkage adhd | #2 |
dsmiv adhd | #2 |
adhd birth | #2 |
comorbid conduct | #2 |
adhd comorbid problems | #2 |
comorbid conduct problems | #2 |
cbcljbd children | #2 |
jackknife procedure | #2 |
siblings youth | #2 |
hyperactivity female humans | #2 |
bipolar disorder symptomatology | #2 |
enigma adhd | #2 |
method subjects | #2 |
adhd case subjects | #2 |
adhd impact | #2 |
adhd lower | #2 |
adhd psychiatric disorders | #2 |
maternal smoking mothers | #2 |
acpts | #2 |
≥210 | #2 |
childhoodonset adhd | #2 |
adhd neuropsychological tests | #2 |
viloxazine extendedrelease | #2 |
n1934 | #2 |
hypothetical task | #2 |
comorbidity adhd | #2 |
adhd major | #2 |
comorbid conduct disorder | #2 |
multigenic inheritance | #2 |
dsmiv subtypes | #2 |
disorders adhd | #2 |
youth attention | #2 |
alleles attention | #2 |
drug abuse dependence | #2 |
variants adhd | #2 |
schizophrenia twin studies | #2 |
items screener | #2 |
life social adjustment | #2 |
stimulants adhd | #2 |
parents major depression | #2 |
enigma adventure | #2 |
bmi adhd symptoms | #2 |
maoa comt | #2 |
overlap mania | #2 |
polygenic resilience score | #2 |
cbsk | #2 |
multicenter adhd | #2 |
unipolar relatives | #2 |
rates bpd | #2 |
manic switches | #2 |
prior reports | #2 |
problems adhd | #2 |
ermph children | #2 |
comparative profile analysis | #2 |
psychoactive substance disorders | #2 |
levels comorbidity | #2 |
psychotic mood disorder | #2 |
nonpsychotic relatives | #2 |
cnvs copy variants | #2 |
correlates adhd | #2 |
disorder conclusions | #2 |
stimulant therapy | #2 |
age onset distributions | #2 |
specific haplotype | #2 |
opioid induced hyperalgesia | #2 |
adhd physical conditions | #2 |
derived phenotypes | #2 |
genome‐wide association scan | #2 |
genetic transmission | #2 |
diabetes disorders | #2 |
trauma adhd | #2 |
adhd suds | #2 |
relatives | #2 |
adhd ldx | #2 |
genome‐wide association data | #2 |
schizophrenia pedigrees | #2 |
studies adderall | #2 |
desr children | #2 |
deficits sustained attention | #2 |
stimulants adults | #2 |
childhood adolescent adhd | #2 |
snp12snp2ctgn | #2 |
adhd growth | #2 |
weaknesses youth | #2 |
support genetic factors | #2 |
target features | #2 |
rs1800955 | #2 |
n3199 | #2 |
adult samples | #2 |
adhd lifespan | #2 |
patterns comorbidity | #2 |
effects paternal smoking | #2 |
adhd adhd patients | #2 |
efds adults | #2 |
7point | #2 |
comt adhd | #3 |
adhd metaanalysis | #3 |
adhdpi | #3 |
“negativity | #3 |
evidence genetic association | #3 |
67e07 | #3 |
rs6565113 | #3 |
chromosome 10q22 | #3 |
morning school | #3 |
sibling trait | #3 |
bipolar disease | #3 |
international adhd | #3 |
caarsss | #3 |
dose response effects | #3 |
bipolar psychoses | #3 |
impairment adhd | #3 |
familial nature | #3 |
variance severity | #3 |
disorder conduct | #3 |
familial risk factors | #3 |
adolescent adhd | #3 |
growth deficits | #3 |
asthma adhd | #3 |
risk factors sud | #3 |
risk panic | #3 |
checklist cbcl | #3 |
non500 | #3 |
vcfsadhd | #3 |
ldx amphetamine | #3 |
petronis | #3 |
teacher reports | #3 |
adhd mtbi | #3 |
subjects sud | #3 |
dsmiiir diagnosis | #3 |
parental substance disorders | #3 |
defined adhd | #3 |
excess transmission | #3 |
weight effects | #3 |
clinically referred adults | #3 |
psychopathologic conditions | #3 |
adhd systematic review | #3 |
notch4 schizophrenia | #3 |
adhd combined type | #3 |
adhd mdd | #3 |
temperamental correlates | #3 |
disorders conclusions | #3 |
comorbidity diagnosis | #3 |
impulsivity errors | #3 |
structural imaging findings | #3 |
observed age | #3 |
controls 6 disorders | #3 |
schizotaxia | #3 |
relatives persons | #3 |
adhd common | #3 |
7repeat allele | #3 |
adhd psychiatric comorbidity | #3 |
longitudinal follow | #3 |
neuropsychiatric disorders similarities | #3 |
brain methylation | #3 |
cognition comorbidity | #3 |
nervous stimulants | #3 |
z280 | #3 |
enuresis adhd | #3 |
adhd psud | #3 |
manic symptoms youth | #3 |
anxiety behavioral inhibition | #3 |
zakzanis | #3 |
response methylphenidate | #3 |
intron13 | #3 |
md adhd | #3 |
sexdifferentiated effects | #3 |
psychotic behaviour | #3 |
atomoxetine response | #3 |
n1777 | #3 |
parents panic | #3 |
hyperactivity central | #3 |
n5827 | #3 |
hyperactivity bipolar | #3 |
learning disabilities adhd | #3 |
predisposition schizophrenia | #3 |
cigarette smoking children | #3 |
morbidity risk | #3 |
adhd control | #3 |
drug nicotine | #3 |
nmu prescription stimulants | #3 |
mania disorders | #3 |
vulnerability indicators | #3 |
relatives proband groups | #3 |
deficient emotional | #3 |
tic disorders adhd | #3 |
conduct disorder adhd | #3 |
anxiety disorders parents | #3 |
pairwise correlations disorders | #3 |
sud youths | #3 |
model adhd | #3 |
508e7 | #3 |
ptsd adhd | #3 |
genetic receptors serotonin | #3 |
highly heritable disorder | #3 |
gsprs | #3 |
enigma neuroimaging genetics | #3 |
reln promoter | #3 |
htr1e | #3 |
npl scores | #3 |
n2271 | #3 |
youths ocd | #3 |
educational deficits | #3 |
children adhd | #3 |
prenatal adversities | #3 |
desr | #3 |
comorbidities adhd | #3 |
persistence psychiatric disorders | #3 |
studies square | #3 |
parents panic disorder | #3 |
schizophrenia allele | #3 |
sirolimus 12 months | #3 |
genetics initiative | #3 |
interactions schizophrenia | #3 |
smds scz | #3 |
hyperactivity attention | #3 |
impact adhd | #3 |
cbcl scales | #3 |
adhd data | #3 |
association confounders | #3 |
control probands relatives | #3 |
disproportionate impairment | #3 |
snps haplotype | #3 |
european‐american | #3 |
adhd emotional | #3 |
enigma global neuroscience | #3 |
relationship adhd | #3 |
metadoxine extended release | #3 |
adhd polygenic | #3 |
pdd adhd | #3 |
children vcfsadhd | #3 |
adhd bipolar disorder | #3 |
siblings young | #3 |
adhd comorbid conditions | #3 |
dat1 | #3 |
stimulants treatment | #3 |
qtl linkage | #3 |
adult psychiatric outcomes | #3 |
similarities genetic etiology | #3 |
27 risk loci | #3 |
schizophrenia neurocognitive performance | #3 |
substances symptoms | #3 |
adhd implications | #3 |
adhd ptsd | #3 |
resilience score | #3 |
7 repeat | #3 |
probands parental | #3 |
wonderlic personnel test | #3 |
emotional dysregulation adhd | #3 |
tsuang | #3 |
sud offspring | #3 |
nonpsychotic relatives persons | #3 |
md females | #3 |
9rcarriers | #3 |
social perception skills | #3 |
firstdegree relatives | #3 |
manic symptoms children | #3 |
adhd stimulant medication | #3 |
enigma wgs wgs | #3 |
oprm1 variants | #3 |
networks adhd | #3 |
adhd mental disorders | #3 |
smoking probands | #3 |
drd5 marker | #3 |
children mania | #3 |
experienced pain | #3 |
inattentive subtype | #3 |
intra‐individual variability | #3 |
disorder comorbid | #3 |
adhd presence | #3 |
syndromatic | #3 |
abstraction verbal memory | #3 |
13q222 | #3 |
nicotine disorders | #3 |
disease humans interviews | #3 |
bpd rates | #3 |
drd4 7 | #3 |
sud children | #3 |
ocd groups asd | #3 |
candidate gene studies | #3 |
children adhd diagnosis | #3 |
asrs v11 | #3 |
adhd mania | #3 |
simulated workplace laboratory | #3 |
substance disorders adhd | #3 |
alcohol adhd | #3 |
cgsq | #3 |
adhd pairwise correlations | #3 |
schizophrenic outpatients | #3 |
remittent | #3 |
neurological polymorphism | #3 |
asd ocd groups | #3 |
comorbidity panic disorder | #3 |
potential gene | #3 |
schizoaffective bipolar disorder | #3 |
common disorders brain | #3 |
lambdasib | #3 |
topic adolescent | #3 |
adhd wm deficits | #3 |
girls attention | #3 |
anxiety disorders authors | #3 |
schizophrenia schizotaxia | #3 |
lbw adhd | #3 |
amphetamines attention | #3 |
cpt deficits | #3 |
major depression comorbidity | #3 |
ermph | #3 |
deficits height | #3 |
large battery | #3 |
psychiatric comorbidity adhd | #3 |
childhood attention‐deficit | #3 |
disabilities male | #3 |
relatives bipolar disorder | #3 |
adhd rare cnvs | #3 |
mania children | #3 |
mtbi studies | #3 |
adhd risk | #3 |
faraone reply | #3 |
schizophrenia genotype | #3 |
adolescents mania | #3 |
methylphenidate studies | #3 |
dmi addh | #3 |
global neuroscience decade | #3 |
comt promoter | #3 |
naltrexone methylphenidate | #3 |
n2323 | #3 |
cortical thickness cases | #3 |
comorbid attention | #4 |
roh risk | #4 |
relatives controls | #4 |
subsequent substance disorders | #4 |
controls basal ganglia | #4 |
onset adhd | #4 |
lifetime dimensions | #4 |
homogeneous subtypes | #4 |
reward dysfunction | #4 |
findings risk | #4 |
secondary psychotic symptoms | #4 |
notch4 locus | #4 |
addictive drug | #4 |
chinese sample | #4 |
nonoral routes administration | #4 |
remittent adhd | #4 |
enrichment adhd | #4 |
17q111q12 | #4 |
reported adhd | #4 |
gxr adhd | #4 |
adhd pharmacotherapy | #4 |
rutter | #4 |
md individuals | #4 |
quantitative models | #4 |
adhd subgroups | #4 |
metaanalyzes | #4 |
mts growth | #4 |
hemmings | #4 |
treatment adhd | #4 |
functioning adhd | #4 |
adhd pharmacogenetic studies | #4 |
parental panic | #4 |
relatives normal controls | #4 |
adhd brain regions | #4 |
familial vulnerability | #4 |
adhd individuals | #4 |
psud | #4 |
female probands relatives | #4 |
risk factors adhd | #4 |
growing literature | #4 |
4year followup | #4 |
risk factors bpd | #4 |
adhd impairments | #4 |
adhd pdd | #4 |
jbd | #4 |
d4s2361 | #4 |
neuropsychological performance schizophrenia | #4 |
pavgrnk000417 | #4 |
time reproduction | #4 |
disorders comorbidity | #4 |
presence adhd | #4 |
developmental improvement | #4 |
metadoxine placebo | #4 |
anxiety disorders mdd | #4 |
families girls | #4 |
sd133 | #4 |
inhibition anxiety | #4 |
attention adhd | #4 |
scores adhd | #4 |
bpd sud patients | #4 |
primary substance abuse | #4 |
factors substance | #4 |
adhd controls | #4 |
expected height | #4 |
health female | #4 |
receiver operator characteristic | #4 |
hypescheme | #4 |
differences adults | #4 |
comorbid aggression adhd | #4 |
vcfs sample | #4 |
adhd substance abuse | #4 |
maternal smoking alcohol | #4 |
adhd reported | #4 |
treatment adult adhd | #4 |
rs3916968 | #4 |
preterm sample | #4 |
shr ncrl | #4 |
rs1079727 | #4 |
adhd adulthood | #4 |
intelligence snps | #4 |
handedness schizotypy | #4 |
mhlod | #4 |
pord05 | #4 |
comorbidity humans | #4 |
choice adhd | #4 |
phenotypes adhd | #4 |
snps intelligence | #4 |
psychiatrically referred | #4 |
adhd association | #4 |
subthreshold | #4 |
adhd etiology | #4 |
poor motor performance | #4 |
suds adolescents | #4 |
rates psychiatric | #4 |
anxiety disorders offspring | #4 |
openlabel studies | #4 |
adhd children mph | #4 |
stimulantnaïve | #4 |
adhd participants | #4 |
adhd md | #4 |
executive function deficits | #4 |
adhd status | #4 |
disorder objective | #4 |
reported findings | #4 |
rels | #4 |
comorbid psychiatric | #4 |
coordination problems | #4 |
46222 | #4 |
motor coordination problems | #4 |
aggregation adhd | #4 |
risk gene schizophrenia | #4 |
adhd symptom | #4 |
bpd sud bpd | #4 |
rs3785143 | #4 |
4th international meeting | #4 |
vulnerability schizophrenia | #4 |
d4s1644 | #4 |
disorders panic | #4 |
adolescent outcome | #4 |
maoa | #4 |
humans lisdexamfetamine | #4 |
objective studies | #4 |
neuropsychoanalytic | #4 |
adults | #4 |
independent transmission | #4 |
adolescent years | #4 |
achievement goal orientation | #4 |
odd adhd | #4 |
safren | #4 |
gender children | #4 |
strattera | #4 |
rutters indicators | #4 |
depression parental depression | #4 |
offspring sud | #4 |
cbcljbd phenotype | #4 |
panic disorder pregnancy | #4 |
distinct disorder | #4 |
adhd neuropsychological performance | #4 |
adhd youth | #4 |
child behavior checklist | #4 |
adhd based | #4 |
psychiatric comorbidity risk | #4 |
boys higher prevalence | #4 |
enigmaadhd | #4 |
asd mood disorders | #4 |
psc35 | #4 |
inattentive adhd | #4 |
adderall methylphenidate | #4 |
pediatric mania | #4 |
genetic heterogeneity schizophrenia | #4 |
global neuroscience | #4 |
vcfs adhd | #4 |
tests psychiatric | #4 |
schizophrenia genetic factors | #4 |
treatment stimulant medication | #4 |
angerirritability | #4 |
disorders attention | #4 |
parents bpd | #4 |
impaired intellect | #4 |
height deficits | #4 |
risk variants adhd | #4 |
quantitative phenotype | #4 |
disease genome humans | #4 |
acting formulations | #4 |
lgi age | #4 |
subjects schizotaxia | #4 |
disorders neuropsychological | #4 |
support mechanism | #4 |
rs3916971 | #4 |
cbcl | #4 |
psychiatric gene discoveries | #4 |
children comorbid adhd | #4 |
deficits executive functioning | #4 |
total score week | #4 |
snpbased | #4 |
adhd control children | #4 |
behavior checklist | #4 |
psychiatrically referred youth | #4 |
report scale | #4 |
sud bpd sud | #4 |
fmri replication | #4 |
transporter genotypes | #4 |
increased neural responses | #4 |
substance disorders suds | #4 |
treatment seeking patients | #4 |
rs140700 | #4 |
selenbp1 schizophrenia | #4 |
cbclaps | #4 |
rate switching | #4 |
bipolar disorder linkage | #4 |
image sample | #4 |
desistent | #5 |
d22s683 | #5 |
ncrl rats | #5 |
referred children | #5 |
panic disorder parents | #5 |
height weight | #5 |
ppp3cc schizophrenia | #5 |
symptoms hyperactivity | #5 |
referred sample | #5 |
adhd bupropion | #5 |
adhd inattentive type | #5 |
study genetic factors | #5 |
effects adhd | #5 |
screener | #5 |
initial responsiveness | #5 |
serum neuroleptic | #5 |
palauan | #5 |
psychosis scale | #5 |
pdmd | #5 |
hyperactivity clinical trials | #5 |
nt5dc1 | #5 |
adults adult | #5 |
children dbds | #5 |
adhd nonaffected siblings | #5 |
nonmedical nmu | #5 |
unipolar mdd | #5 |
proband risk | #5 |
resilience project | #5 |
wcst scores | #5 |
depression panic disorder | #5 |
neuropsychological risk | #5 |
familial subtypes | #5 |
zmynd17 | #5 |
large collaborative study | #5 |
children ldx | #5 |
risk relatives | #5 |
neuropsychiatric comorbidity | #5 |
xr adults | #5 |
2nd cohort | #5 |
dsm age | #5 |
nonaffected siblings | #5 |
shared haplotypes | #5 |
adhd adult | #5 |
comorbid disorders | #5 |
puwma | #5 |
tass | #5 |
onset criterion | #5 |
rs1799836 | #5 |
torture review | #5 |
impairment survey | #5 |
function adhd | #5 |
sms intervention | #5 |
psychosis velocardiofacial syndrome | #5 |
disorders psychiatric | #5 |
oosterlaan | #5 |
3q13 | #5 |
combined subtype | #5 |
kuntsi | #5 |
parents psychiatric | #5 |
severe scores | #5 |
multivariate endophenotypes | #5 |
report screening | #5 |
ascertainment source | #5 |
adult attention | #5 |
disorders follow | #5 |
lifetime impact | #5 |
checklist child | #5 |
adult probands | #5 |
hyperactivity caregivers | #5 |
disorder rating | #5 |
diagnosis mania | #5 |
intellectually capable adults | #5 |
adhd ld | #5 |
psychiatric disorders study | #5 |
inhibited children | #5 |
etiopathologies | #5 |
asrs screener | #5 |
behavioral inhibition children | #5 |
referred youths | #5 |
pathways association | #5 |
year prospective | #5 |
social disability | #5 |
adhd tic disorders | #5 |
parental adhd | #5 |
organization adult | #5 |
grubb | #5 |
sud | #5 |
iiv adhd | #5 |
major depression parents | #5 |
desipramine placebo | #5 |
boys attention | #5 |
relatives female probands | #5 |
memantine hydrochloride | #5 |
adhd youths | #5 |
dopamine risk | #5 |
adhd cases | #5 |
conventional medications | #5 |
risk anxiety | #5 |
auditory vigilance | #5 |
interview psychological | #5 |
prembr | #5 |
female individuals | #5 |
highly heritable | #5 |
growth dysregulation | #5 |
cbcl data | #5 |
aagc | #5 |
impaired parents humans | #5 |
elevated rates | #5 |
adhd comorbid anxiety | #5 |
maternal reports | #5 |
disorder anxiety | #5 |
child child behavior | #5 |
adolescent alleles | #5 |
schizophrenia palau | #5 |
psychiatric correlates | #5 |
3 probands | #5 |
oppositional defiant disorder | #5 |
pdd subjects | #5 |
adhdlike symptoms | #5 |
pleiotropic effects disorders | #5 |
bipolar disorder pedigrees | #5 |
genetic linkage schizophrenia | #5 |
youth vcfs | #5 |
humans interview | #5 |
adhd response | #5 |
disorder parents | #5 |
methylphenidate adults | #5 |
bipolar disorder bpd | #5 |
impairment baseline | #5 |
cardinal symptom | #5 |
familial distribution | #5 |
kiddieschedule | #5 |
mood disorders asd | #5 |
adolescence adhd | #5 |
inattentive symptoms | #5 |
risk factors schizophrenia | #5 |
adhd treated | #5 |
disorder sud | #5 |
anxiety disorders anx | #5 |
mothers anxiety disorders | #5 |
hechtman | #5 |
sex adhd | #5 |
clinical obesity | #5 |
disorder genetic | #5 |
criteria schizotaxia | #5 |
familial risk adhd | #5 |
parental sud | #5 |
mania adhd | #5 |
scale adhd | #5 |
schizophrenia deficit | #6 |
adhd compared | #6 |
ppp3cb | #6 |
premorbid cognitive ability | #6 |
nhe inhibitors | #6 |
total gray matter | #6 |
large heterogeneous | #6 |
seidman | #6 |
loci autism | #6 |
males adhd | #6 |
liability schizophrenia | #6 |
disorders relatives | #6 |
adults disorder | #6 |
schizophrenic probands | #6 |
children relatives | #6 |
bpdsud | #6 |
schizophrenia spectrum schizophrenia | #6 |
psychiatric | #6 |
placebo response response | #6 |
irmph | #6 |
140 children | #6 |
tmcq | #6 |
male odds | #6 |
altered neural connectivity | #6 |
hierarchical factor model | #6 |
cognition adults | #6 |
clinical features children | #6 |
maniclike symptoms | #6 |
benefitrisk ratio | #6 |
psychiatric disorders prss | #6 |
psychoactive substance | #6 |
genetic linkage genome | #6 |
unfamiliar situations | #6 |
child delayed | #6 |
neuropsychological functioning | #6 |
concurrent validation | #6 |
disorders adolescent | #6 |
cpg sites methylation | #6 |
enigma wgs | #6 |
risk sud | #6 |
clinical scales | #6 |
dopamine transporter gene | #6 |
oceanic palau | #6 |
risk attention | #6 |
symptoms adhd | #6 |
behavioral inhibition | #6 |
objective marker | #6 |
druggable genome | #6 |
niacin schizophrenia | #6 |
psychopathology children | #6 |
value09 | #6 |
combined subtypes | #6 |
parents major | #6 |
bpd controls | #6 |
combined condition | #6 |
paternal age schizophrenia | #6 |
stimulant prescription | #6 |
t515 | #6 |
vulnerability indicator | #6 |
pediatric bpd | #6 |
neuroleptic activity | #6 |
hyperactivity child chromosomes | #6 |
scales psychometrics | #6 |
genome‐wide | #6 |
dsm iii | #6 |
adhdia | #6 |
xp114p113 | #6 |
nmu | #6 |
wm performance patients | #6 |
criteria adhd | #6 |
dnajc9 | #6 |
4634 | #6 |
prevalence adult adhd | #6 |
cbcljbd | #6 |
individual alleles | #6 |
stimulant treatment children | #6 |
nonparanoid schizophrenia | #6 |
oppositional defiant | #6 |
p1e04 | #6 |
disorder combined | #6 |
pediatric bipolar | #6 |
taan | #6 |
referred adults | #6 |
prior stimulant treatment | #6 |
hyperactivity disease models | #6 |
year recall | #6 |
females adhd | #6 |
depression panic | #6 |
chromosome 15 locus | #6 |
genetic child | #6 |
driving simulation | #6 |
pediatric mood disorders | #6 |
anxiety disorder relatives | #6 |
adhd children adults | #6 |
referred children adolescents | #6 |
groups adults | #6 |
cognitive impairments adhd | #6 |
downward extension | #6 |
relatives probands | #6 |
association studies schizophrenia | #6 |
fspd | #6 |
schizophrenia g72 | #6 |
environmental adversity | #6 |
life adults | #6 |
pseudocontrols | #6 |
adhd variability | #6 |
schizophrenia premorbid | #6 |
facial memory | #6 |
adhd life | #6 |
adhd mood disorders | #6 |
literature efficacy | #6 |
ascertained | #6 |
adhd increased risk | #6 |
symptoms disorder | #6 |
t518 | #6 |
familial loadings | #6 |
adhd mental retardation | #6 |
specific predictor | #6 |
parental major depression | #6 |
teenage parenthood | #6 |
mixed amphetamine | #6 |
gxr efficacy | #6 |
adhd firstdegree relatives | #6 |
adhd tic | #6 |
adhd genetic factors | #6 |
bpd comorbid | #6 |
adhd women | #6 |
differences cortical thickness | #6 |
pavgrnk | #6 |
interpreting estimates | #6 |
followup studies | #6 |
normal sexual dimorphism | #6 |
parent reports | #7 |
prevention schizophrenia | #7 |
genome‐wide association | #7 |
adhd emotional dysregulation | #7 |
dimensional measures | #7 |
persistence anxiety disorders | #7 |
members schizophrenia | #7 |
methylphenidate therapy | #7 |
studies dopamine | #7 |
bipolar unipolar disorders | #7 |
child impaired | #7 |
nrp104 | #7 |
methylomics | #7 |
development adhd | #7 |
spn812 | #7 |
idir | #7 |
snap25 adhd | #7 |
qlesqsf | #7 |
parents prevalence | #7 |
tomoxetine | #7 |
measures adhd | #7 |
highrisk siblings | #7 |
haplotype schizophrenia | #7 |
long repeats | #7 |
exon15 | #7 |
statistical measure | #7 |
authors goal | #7 |
candidate gene schizophrenia | #7 |
teachers boys | #7 |
myosin5b | #7 |
neurocognitive performances | #7 |
confusability | #7 |
palauans | #7 |
nalysis | #7 |
disorders probands | #7 |
drd5 | #7 |
pediatric major depression | #7 |
hyperactivity brain | #7 |
sensorimotor timing | #7 |
locus haplotypes | #7 |
ldx treatment | #7 |
pmee | #7 |
odd | #7 |
neuroimage study | #7 |
ancestry attention | #7 |
nmu prescription | #7 |
coming years | #7 |
swedish registry data | #7 |
association cdh13 | #7 |
adhdct | #7 |
adhd improvement | #7 |
adhd criteria | #7 |
controls probands | #7 |
seeking substance | #7 |
kgas | #7 |
children bpd | #7 |
attention task | #7 |
saica | #7 |
outpatient child | #7 |
dependence rates | #7 |
relatives schizophrenic patients | #7 |
combined type adhd | #7 |
implicating | #7 |
adhd sud sud | #7 |
adhd asrs | #7 |
adhd symptoms | #7 |
adhd substance disorders | #7 |
adhd overweight obesity | #7 |
asd asd youth | #7 |
n1031 | #7 |
polygenic scores adhd | #7 |
skin flush response | #7 |
wonderlic | #7 |
childhood disorder | #7 |
conduct disorder girls | #7 |
mph adhd adults | #7 |
flush response | #7 |
hraff | #7 |
systematic chart review | #7 |
pdqr | #7 |
adhd authors | #7 |
chromosome workshop | #7 |
parents psychiatric disorders | #7 |
children learning disorders | #7 |
boys adhd | #7 |
pdag mdd | #7 |
adhd symptoms association | #7 |
children tourettes syndrome | #7 |
velo‐cardio‐facial | #7 |
markov chain analysis | #7 |
disorder substance | #7 |
mph adhd | #7 |
adhd persistence | #7 |
exome chip analyses | #7 |
asd youth | #7 |
mdd pdag | #7 |
adhdrs | #7 |
relatives risk | #7 |
adhd boys girls | #7 |
6 psychiatric disorders | #7 |
adhd adolescence | #8 |
cadhd | #8 |
adhd dat1 | #8 |
adhd rtv | #8 |
onset bpd | #8 |
probands risk | #8 |
crossover comparison | #8 |
offspring trios | #8 |
familybased association study | #8 |
aversion adhd | #8 |
10q223 | #8 |
adhd remission | #8 |
volumetric reductions | #8 |
attention | #8 |
symptoms impairment | #8 |
biederman | #8 |
pvalues005 | #8 |
treatment lead | #8 |
therapeutic dilemmas | #8 |
notch4 | #8 |
controls relatives | #8 |
adhd associations | #8 |
mwq | #8 |
human aggression | #8 |
promising directions | #8 |
disorder probands | #8 |
pempirical | #8 |
autistic traits children | #8 |
symptoms behaviors | #8 |
hemideletion | #8 |
link adhd | #8 |
affairs cooperative | #8 |
biological relatives | #8 |
disease humans polymorphism | #8 |
sample youth | #8 |
adhd boys | #8 |
bpd disorders | #8 |
schizophrenia polymorphisms | #8 |
control adhd | #8 |
euphoria | #8 |
behavior attention | #8 |
childhood mania | #8 |
shared familial effects | #8 |
n1314 | #8 |
diagnosed adhd | #8 |
adhd symptom scores | #8 |
substantial evidence | #8 |
disorders baseline | #8 |
unaffected siblings adhd | #8 |
behavioral inhibition anxiety | #8 |
impulsivity adhd | #8 |
participants adhd | #8 |
agreement measures | #8 |
adhd manic symptoms | #8 |
attention deficit adhd | #8 |
multigenerational pedigree | #8 |
differential utility | #8 |
familial aggregation adhd | #8 |
adhd stimulant | #8 |
avoidant disorder | #8 |
polygenic associations | #8 |
abbreviated questionnaire | #8 |
child diagnostic | #8 |
schizophrenia members | #8 |
psychiatric genomics | #8 |
disorders families | #8 |
negative symptoms scale | #8 |
subjects children | #8 |
studies provide | #8 |
analysis association | #8 |
adhdhi | #8 |
male multifactorial inheritance | #8 |
mph adults | #8 |
chromosome schizophrenia | #8 |
gender effects | #8 |
behavioral inhibition risk | #8 |
prescription stimulant | #8 |
nonpsychotic | #8 |
rs3916965 | #8 |
metaanalysis schizophrenia | #8 |
treatment sirolimus | #8 |
diagnosis major depression | #8 |
dimesylate ldx | #8 |
nonverbal social | #8 |
indicators schizophrenia | #8 |
stimulanttreated | #8 |
adhdcd | #8 |
ordered subsets | #8 |
impaired motor performance | #8 |
adhd unaffected | #8 |
adhd inattentive | #8 |
rs3916966 | #8 |
pliszka | #8 |
presence autistic traits | #8 |
rs685012 | #9 |
diagnostic efficiency | #9 |
netherlands twin registry | #9 |
comorbidity female | #9 |
inattentive | #9 |
adhdi | #9 |
taiwanese families | #9 |
adhd enuresis | #9 |
sustained attention schizophrenia | #9 |
rpdr | #9 |
moderate sensitivity | #9 |
dao gene | #9 |
male nuclear | #9 |
blindly | #9 |
children assessed | #9 |
subtypes adhd | #9 |
festschrift | #9 |
adhd article | #9 |
comparison girls | #9 |
pregnancy depression | #9 |
sud bipolar disorder | #9 |
disorders sex interaction | #9 |
haplotype snps | #9 |
neuropsychologic function | #9 |
proband groups | #9 |
deficit disruptive | #9 |
39 datasets | #9 |
hyperactivity automobile | #9 |
adderall | #9 |
n41 | #9 |
rasd2 | #9 |
etiologically | #9 |
genes risk factors | #9 |
mdd youth | #9 |
depression offspring | #9 |
substantial risk | #9 |
schizotaxic | #9 |
adult symptoms | #9 |
25e07 | #9 |
g×s interaction disorders | #9 |
snp7 | #9 |
hyperactivity humans | #9 |
serotonin genes | #9 |
hum genet | #9 |
aisrs | #9 |
symptoms mania | #9 |
ecpbhs | #9 |
nonparanoids | #9 |
hhrr | #9 |
stimulant medication | #9 |
endophenotypic | #9 |
schizophrenia resilience | #9 |
nuremberg code | #9 |
alzheimer disease schizophrenia | #9 |
ldps | #9 |
orosmph irmph | #9 |
lag sequential analysis | #9 |
extendedrelease methylphenidate | #9 |
childhood psychosis | #9 |
adhd healthy | #9 |
disruptive behavior disorders | #9 |
nonreplications | #9 |
adult report | #9 |
serotonin gene polymorphisms | #9 |
addh | #9 |
gwas psychiatric disorders | #9 |
adhd loci | #9 |
ads individuals | #9 |
association dat1 | #10 |
gwas adhd | #10 |
image project | #10 |
sexual dimorphisms | #10 |
conduct disorder | #10 |
genes disorders | #10 |
young adult outcome | #10 |
comorbidity depressive | #10 |
evidence genetic | #10 |
small effects | #10 |
4th | #10 |
amphetamine salts | #10 |
new specialty | #10 |
adhd sud | #10 |
rorb | #10 |
rates abuse | #10 |
stimulants child | #10 |
psychiatric genetic studies | #10 |
slod | #10 |
asd tourette syndrome | #10 |
shared neurobiology | #10 |
severity adhd | #10 |
childhood adhd symptoms | #10 |
noninhibited | #10 |
systematic qualitative review | #10 |
comorbid bpd | #10 |
panic depression | #10 |
anxiety disorders children | #10 |
stimulants humans | #10 |
kruglyak | #10 |
adhd difficulties | #10 |
adult years | #10 |
drd4 | #10 |
genetics network | #10 |
d4 receptor gene | #10 |
risk md | #10 |
disorder age | #10 |
groups boys | #10 |
parent‐of‐origin effects | #10 |
case identification | #10 |
untreated adhd | #10 |
diminished risk | #10 |
caadid | #10 |
bipolar disorder probands | #10 |
aged attention | #10 |
pthreshold | #10 |
sleep problems adhd | #10 |
deficits adhd | #10 |
irmph orosmph | #10 |
normal sexual | #10 |
nephews | #10 |
genetic vulnerability schizophrenia | #10 |
dms1 | #10 |
probands bpd | #10 |
adhd childhood | #10 |
reassessed | #10 |
association death | #10 |
preteen | #10 |
psychiatric clinic | #10 |
ascertainment methods | #10 |
adhd unaffected siblings | #10 |
adhd substance disorder | #10 |
preschool depressive | #10 |
nonpharmacologic treatments | #10 |
comorbidity | #10 |
cbclap | #10 |
linkage analyses | #10 |
comorbid odd | #10 |
adulthood association | #10 |
adhd quality | #10 |
etiology pathophysiology | #11 |
hyperactivity child cross | #11 |
female relatives | #11 |
rs1137070 | #11 |
youth bpd | #11 |
adhd psychopathology | #11 |
rora rorb | #11 |
dimesylate | #11 |
multiple domains | #11 |
cardinal symptoms | #11 |
disorders mothers | #11 |
sample adults | #11 |
informativeness | #11 |
ldx placebo | #11 |
pediatric bipolar disorder | #11 |
nosologists | #11 |
diagnosis adults | #11 |
effects genes | #11 |
lisdexamfetamine ldx | #11 |
disease humans schizophrenia | #11 |
prodromal psychosis | #11 |
maternal antenatal anxiety | #11 |
adhd onset | #11 |
vcfs | #11 |
familybased association test | #11 |
shared familial | #11 |
attention deficit disorder | #11 |
gene adhd | #11 |
comorbidity patterns | #11 |
fbatpc | #11 |
ppp3cc | #11 |
polymorphism 5 | #11 |
n136 | #11 |
adolescents adhd | #11 |
remission adhd | #11 |
serotonin genetic receptor | #11 |
defiant disorder | #11 |
release methylphenidate | #11 |
adult relatives | #11 |
children bipolar | #11 |
psychiatric disorders youth | #11 |
studies mtbi | #11 |
symptom subtype | #11 |
nonadhd controls | #11 |
juvenile mania | #11 |
differences adhd | #11 |
study perspective | #11 |
adhd intellectual disability | #11 |
hydrochloride attention | #11 |
disorder pedigrees | #11 |
paternal smoking | #11 |
differences parents | #11 |
achievement adolescent | #11 |
cutraits | #11 |
major depression adhd | #11 |
offspring bipolar parents | #11 |
shr model | #11 |
panic disorder comorbidity | #11 |
adhd substance | #11 |
growth delays | #11 |
neuropsychological test scores | #11 |
inattentive type | #11 |
agoraphobia anxiety | #11 |
preschool depressive disorder | #11 |
4372 | #11 |
children addh | #11 |
adhd time | #11 |
markers adhd | #11 |
differentiated genetic | #11 |
adhd female humans | #11 |
inhibition adhd | #11 |
dopamine d5 receptors | #11 |
disorders | #11 |
deficits schizophrenia patients | #11 |
real progress | #11 |
psychotic behavior | #12 |
pleiotropic mechanisms | #12 |
psychiatric clinics | #12 |
scales treatment | #12 |
symptom rating | #12 |
treatment attention | #12 |
convergent functional | #12 |
multiplex schizophrenia | #12 |
adult outcome | #12 |
cnvs risk | #12 |
obesity adhd | #12 |
sud adhd | #12 |
test wcst | #12 |
sample consisted | #12 |
stimulant medication children | #12 |
deficits attention | #12 |
functional impairments | #12 |
girls relationship | #12 |
epilepsy mothers | #12 |
comorbidity diagnostic | #12 |
unaffected siblings individuals | #12 |
lossavoidance | #12 |
hawi | #12 |
adhd dopamine | #12 |
digital treatment | #12 |
adhd core symptoms | #12 |
kappa coefficients | #12 |
comorbid disorder | #12 |
treatment paliperidone | #12 |
onelevel | #12 |
obesity risk alleles | #12 |
adhd age | #12 |
40–48 | #12 |
perceived motor competence | #12 |
common psychiatric | #12 |
juvenile bipolar | #12 |
cbcl children | #12 |
twins humans models | #12 |
common disorders | #12 |
impaired parents | #12 |
dat1 polymorphism | #12 |
nonoral | #12 |
rs778293 | #12 |
systematized | #12 |
nhe9 | #12 |
adhd offspring | #12 |
impulsivity children | #12 |
rs947267 | #12 |
studies relatives | #12 |
early psychosis study | #12 |
assessment adhd | #12 |
adhd symptoms adults | #12 |
thalamic activation | #12 |
impaired parents child | #12 |
ksadse | #12 |
psychiatric genetics | #12 |
genes methylation | #12 |
disorder adult | #12 |
neurocognitive measures | #12 |
covid19 restrictions children | #12 |
defiant | #12 |
adolescent adult age | #12 |
psychotic mood disorders | #12 |
sec23ip | #12 |
unaffected sibs | #12 |
disorder subjects | #12 |
n1397 | #12 |
amfetamine | #12 |
youths bpd | #12 |
sud patients adhd | #12 |
probands siblings | #12 |
response atomoxetine | #12 |
striatal sensitivity | #12 |
effects time | #12 |
salts extended | #12 |
sexually dimorphic effects | #12 |
variable age | #12 |
metan | #12 |
symptoms attention | #13 |
chi12 | #13 |
environment adolescent | #13 |
114 years | #13 |
pkcm | #13 |
adverseevents | #13 |
familial risk schizophrenia | #13 |
pair 6 chromosomes | #13 |
taiwanese sample | #13 |
diagnostic threshold | #13 |
transdermal methylphenidate | #13 |
ravg | #13 |
adhd alterations | #13 |
adhd alcohol | #13 |
iiv | #13 |
morbidity risks | #13 |
rates comorbidity | #13 |
scale studies | #13 |
bpd offspring | #13 |
weight bmi | #13 |
methods subjects | #13 |
response inhibition adolescents | #13 |
adhdodd | #13 |
psychiatric risk | #13 |
necrotic death | #13 |
diagnostic concepts | #13 |
specific hypotheses | #13 |
convergent functional genomics | #13 |
robust effects | #13 |
disorders child | #13 |
permutation testing | #13 |
disorder childhood | #13 |
risk parents | #13 |
longallele | #13 |
studies bipolar | #13 |
persistence remission | #13 |
girls | #13 |
humans methylphenidate | #13 |
disorders sud | #13 |
psychometrics reproducibility | #13 |
label studies | #13 |
risk mood | #13 |
colorado springs | #13 |
disorder youth | #13 |
genomewide significance | #13 |
nonoral routes | #13 |
adhd diagnosis | #13 |
adhd cognitive | #13 |
cognitive impulsivity | #13 |
psychotic mood | #13 |
overanxious | #13 |
psychometric measure | #13 |
late onset | #13 |
male samples | #13 |
velocardiofacial syndrome vcfs | #13 |
adderall mph | #13 |
differential heritability | #14 |
older adults adhd | #14 |
stimulant abuse | #14 |
sud patients | #14 |
disorder child | #14 |
factors schizophrenia | #14 |
mixed amphetamine salts | #14 |
ocd scz | #14 |
siblings cases | #14 |
prss mdd | #14 |
children criteria | #14 |
bipolar probands | #14 |
nimh genetics | #14 |
genes schizophrenia | #14 |
adhd brain | #14 |
attention executive | #14 |
early precursors | #14 |
disorders comorbid | #14 |
quetiapine bipolar disorder | #14 |
common disorder | #14 |
cautiously | #14 |
n643 | #14 |
geschwind | #14 |
economic psychology | #14 |
adhd phenotype | #14 |
selfcontained | #14 |
teachers reports | #14 |
siblings probands | #14 |
relatives male probands | #14 |
diagnosis mdd | #14 |
studies adults | #14 |
social school | #14 |
comorbid condition | #14 |
aadhd | #14 |
disorder odd | #14 |
subcortical brain volume | #14 |
familial disorder | #14 |
adhd symptoms adulthood | #14 |
associations adhd | #14 |
symptoms psychiatric disorders | #14 |
emotional impulsivity | #14 |
lisdexamfetamine dimesylate ldx | #14 |
suds | #14 |
worldwide prevalence | #14 |
genetic studies schizophrenia | #14 |
cnvs park2 | #14 |
children stimulants | #14 |
wraadds | #14 |
unaffected siblings controls | #14 |
children bipolar disorder | #14 |
lphn3 adhd | #14 |
hillside | #14 |
mph adderall | #14 |
substance disorder patients | #15 |
wfirsp | #15 |
mphmlr | #15 |
symptom count | #15 |
chi2 | #15 |
metabolic syndrome obesity | #15 |
zranb2 | #15 |
schizophrenia families | #15 |
bipolar schizoaffective disorder | #15 |
poor perception | #15 |
adhd functional connectivity | #15 |
tests psychomotor | #15 |
disord | #15 |
psychiatric interviews | #15 |
asd mdd | #15 |
adhd study | #15 |
adhd treatment | #15 |
agents attention | #15 |
gxr children | #15 |
adhd diagnostic | #15 |
study design features | #15 |
velocardiofacial | #15 |
d10s1423 | #15 |
executive function theory | #15 |
seconddegree relatives | #15 |
treatment xr | #15 |
adhd performance | #15 |
genderdifferences | #15 |
diagnostic interviews | #15 |
rs2652511 | #15 |
4669 | #15 |
risk substance | #15 |
pregnancy risk factor | #15 |
daily living administration | #15 |
snps methylation | #15 |
sackett | #15 |
prodromal symptoms psychosis | #15 |
adults substance disorders | #15 |
adhd disorders | #15 |
interaction genotype | #15 |
nhsd | #15 |
49 children | #15 |
card sorting | #15 |
association schizophrenia | #15 |
disorder evidence | #15 |
methylation gene expression | #15 |
symptoms adulthood | #15 |
healthy comparison subjects | #15 |
male relatives | #15 |
male mood | #15 |
behavior disorders | #15 |
ocd comorbid adhd | #15 |
cbclpbd | #15 |
persons schizophrenia | #15 |
paediatric bipolar disorder | #15 |
delayed action | #16 |
scz risk | #16 |
adhd symptom severity | #16 |
informant assessment | #16 |
dexedrine | #16 |
growth children | #16 |
onset anticipation | #16 |
familial relationship | #16 |
adhd diagnoses | #16 |
ntac | #16 |
youths adhd | #16 |
hyperkinetic disorders | #16 |
multiple test | #16 |
parents anxiety disorders | #16 |
adhd anxiety symptoms | #16 |
“difficulty | #16 |
dbds | #16 |
rdoc framework | #16 |
pervasive developmental disorder | #16 |
geneenvironment interaction | #16 |
special classes | #16 |
control participants participants | #16 |
risk psychotic disorders | #16 |
adhd obesity | #16 |
brainbody | #16 |
regional cortical thickness | #16 |
drug disorder | #16 |
cprsr | #16 |
longitudinal assessments | #16 |
n424 | #16 |
linkage findings | #16 |
factual factor analysis | #16 |
method participants | #17 |
prevalence adhd | #17 |
neuropsychiatric evaluation | #17 |
assessment positive symptoms | #17 |
response inhibition network | #17 |
factors siblings | #17 |
childhood predictors | #17 |
multiple anxiety disorders | #17 |
5071 | #17 |
a161t | #17 |
studies psychiatric | #17 |
pediatric samples | #17 |
diagnostic statistical | #17 |
ocd age | #17 |
association scan | #17 |
medication type | #17 |
mania | #17 |
ldx children | #17 |
study adhd | #17 |
driving behaviors | #17 |
prospective follow | #17 |
resultsfirst | #17 |
condfdr | #17 |
bipolar disorder subjects | #17 |
rbfox1 | #17 |
random forest regression | #17 |
disability adhd | #17 |
schizophrenia psychosis | #17 |
relation adhd | #17 |
samples children | #17 |
larger sample | #17 |
young offspring | #17 |
considerable overlap | #17 |
asd ocd | #17 |
nonparametric linkage | #17 |
accn2 | #17 |
hyperactivity attitude | #17 |
pediatric disorder | #17 |
combined type | #17 |
adulthood adhd | #17 |
association markers | #17 |
substance disorders sud | #17 |
psychology schizotypal | #17 |
parents adhd | #17 |
depression md | #17 |
persistent adhd | #17 |
relatives control subjects | #18 |
psuds | #18 |
potential contributor | #18 |
stimulant | #18 |
primary substance | #18 |
risk disorders | #18 |
childhood traumas | #18 |
adhd groups | #18 |
illness twins | #18 |
transporter gene | #18 |
kcnj4 | #18 |
anxiety mdd | #18 |
4286 | #18 |
schizophrenia patients relatives | #18 |
linkage regions | #18 |
minisatellite repeats | #18 |
marijuana age | #18 |
unemotionality | #18 |
lisdexamfetamine dimesylate | #18 |
dcdq | #18 |
unaffected siblings | #18 |
children vcfs | #18 |
adhd severity | #18 |
preschool diagnostic | #18 |
bipolar major | #18 |
hrr 95 | #18 |
depression genetic risk | #18 |
prolonged therapy | #18 |
fullsiblings | #18 |
low dose naltrexone | #18 |
behavior scale | #18 |
symptom overlap | #18 |
operationalized | #18 |
neuropsychologic | #18 |
adhd cannabis | #18 |
single nucleotide severity | #18 |
meet criteria | #18 |
bipolar choice trial | #18 |
poor tolerability | #18 |
schizophrenia dtnbp1 | #18 |
conduct disorder children | #18 |
adhd sud patients | #18 |
mcgue | #19 |
adolescent age onset | #19 |
action preparations | #19 |
psychosocial features | #19 |
adhd young adults | #19 |
lod1 | #19 |
familial transmission | #19 |
assessing outcome | #19 |
scz ocd | #19 |
adhd neurodevelopmental | #19 |
medication trials | #19 |
symptoms adolescent | #19 |
disorders adults | #19 |
mental health human | #19 |
nature nurture | #19 |
adolescent age | #19 |
addicted patients | #19 |
casecontrol sample | #19 |
substance adhd | #19 |
improvement symptoms | #19 |
euphoric effects | #19 |
hyperconnectivity | #19 |
verbal memory task | #19 |
rs3918342 | #19 |
comorbidity rates | #19 |
candidate loci | #19 |
disconfirmations | #19 |
neuropsychological function | #20 |
mflynn | #20 |
slc6a2 | #20 |
outcome attention | #20 |
adolescent | #20 |
transmission ratio distortion | #20 |
linkage scans | #20 |
nonpsychotic siblings | #20 |
controlled pilot study | #20 |
inhibition children | #20 |
depression adhd | #20 |
biological families | #20 |
disorders polymorphism | #20 |
human ortholog | #20 |
gsma | #20 |
rbfox1 gene | #20 |
dicap | #20 |
humanhap550v3 | #20 |
schizophrenia attention | #20 |
prenatal exposure nicotine | #20 |
parents risk | #20 |
parent origin | #20 |
illness female humans | #20 |
neuropsychologically | #20 |
neuroleptic dose | #20 |
sibpair | #20 |
response curve | #20 |
pedigree selection | #20 |
notch4 gene | #20 |
manual mental | #20 |
kiddie | #20 |
ratings adhd | #20 |
deficits children | #20 |
gender comparisons | #21 |
humans linkage | #21 |
life enjoyment | #21 |
children comorbid | #21 |
chronic tics | #21 |
genehunterplus | #21 |
schizophrenia united | #21 |
prenatal exposure alcohol | #21 |
comorbid adhd | #21 |
prevalent cases | #21 |
prescription stimulants | #21 |
agler | #21 |
risk offspring | #21 |
monoamine oxidase maoa | #21 |
schizotypals | #21 |
rat shr | #21 |
schizophrenia taiwan | #21 |
children pdd | #21 |
psychiatric symptoms patients | #21 |
11year followup | #21 |
palau | #21 |
motor problems | #21 |
cacng2 | #21 |
male probands | #21 |
schizophrenia disease humans | #21 |
childhood conduct disorder | #21 |
methods age | #21 |
rs778294 | #21 |
sodium hydrogen exchanger | #21 |
linkage chromosomes | #21 |
prospective longitudinal | #21 |
bipolar pedigrees | #21 |
treatment growth | #21 |
controls | #22 |
ldx | #22 |
syndrome vcfs | #22 |
stimulants children | #22 |
adhd stimulants | #22 |
disruptive | #22 |
adhd impulsivity | #22 |
adderall xr | #22 |
rg022 | #22 |
adhd rating scale | #22 |
amphetamine methylphenidate | #22 |
neuropsychological profiles | #22 |
neurocognitive performance schizophrenia | #22 |
schizophrenia pgc | #22 |
study methodology | #22 |
youth bipolar | #22 |
amygdala structure | #22 |
6 disorders | #22 |
association prs | #22 |
polygenic overlap | #22 |
overtransmission | #22 |
genetic phenotype | #22 |
disorders major | #22 |
bpd subjects | #22 |
diagnostic interview | #22 |
10p | #22 |
adhd susceptibility | #22 |
preliminary reliability | #22 |
niacin skin | #22 |
children attention | #22 |
adhd anxiety | #22 |
pre‐school | #22 |
partial replication | #22 |
depression treatment patients | #22 |
familiality | #22 |
youth mdd | #22 |
n449 | #23 |
male individuals | #23 |
wechsler scales | #23 |
intrinsic curvature | #23 |
serotonin receptor gene | #23 |
snapiv | #23 |
interacting molecules | #23 |
neuroleptic withdrawal | #23 |
syp | #23 |
executive functions efs | #23 |
adhd symptoms childhood | #23 |
scq asd | #23 |
twins genetic predisposition | #23 |
genetic investigation | #23 |
oppositional | #23 |
rs464049 | #23 |
asd scq | #23 |
mdd anxiety disorders | #23 |
disequilibrium male | #23 |
risk studies | #23 |
notch4 receptors | #23 |
wide linkage | #23 |
diagnostician | #23 |
heterogeneity genetic | #23 |
anxious mothers | #23 |
phenotype definition | #23 |
interview dsm | #23 |
siblings | #23 |
metadoxine | #23 |
handful | #23 |
comprehensively | #23 |
kotkin | #23 |
propylamines | #23 |
adolescents bpd | #23 |
guanfacine extended release | #24 |
mental control | #24 |
chromosomes 6 | #24 |
stroop task performance | #24 |
nonstimulant | #24 |
statistical manual | #24 |
amrs | #24 |
quantitative phenotypes | #24 |
dsmiiir criteria | #24 |
ocd asd | #24 |
age regions | #24 |
intelligence schizophrenia | #24 |
receptor d4 | #24 |
children meeting | #24 |
female humans illness | #24 |
deficits | #24 |
genome‐wide linkage scans | #24 |
expected growth | #24 |
nieces | #24 |
adra2a | #24 |
adhd characteristics | #24 |
snorting | #24 |
refilled | #24 |
conduct problems adhd | #24 |
15q13 | #24 |
0535 | #24 |
stress exposure | #24 |
lithium bipolar disorder | #24 |
adhd comorbidities | #24 |
symptoms psychosis | #24 |
neural activation patterns | #24 |
aggression anxiety | #24 |
child female humans | #24 |
sassr | #24 |
actigraphy studies | #24 |
psychometrically | #25 |
neurocognitive predictors | #25 |
maternal criticism | #25 |
dyscalculia | #25 |
understanding adhd | #25 |
young relatives | #25 |
dapple | #25 |
conners parent | #25 |
–environment interactions | #25 |
or194 | #25 |
vietnam twin registry | #25 |
nudt3 | #25 |
anticipation schizophrenia | #25 |
behavioral disinhibition | #25 |
major affective disorders | #25 |
d22s283 | #25 |
school failure | #25 |
efficacy atomoxetine | #25 |
slc6a3 gene | #25 |
biased transmission | #25 |
psychiatric disorders children | #25 |
psychiatric nosology | #25 |
copy variants schizophrenia | #25 |
task patients | #25 |
clinical interviews | #25 |
decreased volume | #25 |
unique profile | #25 |
exposure adhd | #25 |
splicing regulator | #25 |
liker | #25 |
symptom subtypes | #25 |
baseline assessment | #25 |
wkht | #25 |
bipolar choice | #25 |
association snps | #25 |
screening scale | #25 |
wm microstructure | #26 |
behavioral disorder | #26 |
efpc | #26 |
structured interviews | #26 |
alcohol drug abuse | #26 |
prenatal health | #26 |
controls adhd | #26 |
screening diagnosis | #26 |
inrich | #26 |
gender risk | #26 |
n81 | #26 |
neurodevelopmental genes | #26 |
twins humans | #26 |
social impairment | #26 |
rs3730358 | #26 |
major depression md | #26 |
adrenergic uptake | #26 |
add | #26 |
association allele | #26 |
adhd mothers | #26 |
voxel based morphometry | #26 |
label study | #26 |
affair | #26 |
agreement raters | #26 |
selfmonitor | #26 |
maob gene | #26 |
htr1d | #26 |
adults symptoms | #26 |
psychometric measures | #26 |
orosmethylphenidate | #26 |
bipolar phenotype | #26 |
core symptoms adhd | #26 |
nonmedical prescription stimulants | #26 |
weaker effects | #27 |
disorders executive | #27 |
osterrieth | #27 |
offspring risk | #27 |
cnvs adhd | #27 |
mdd asd | #27 |
consecutively | #27 |
greater severity | #27 |
asherson | #27 |
childreniv | #27 |
d22s278 | #27 |
t102c polymorphism | #27 |
international meeting | #27 |
aff | #27 |
ptsd adults | #27 |
schizophrenia genetic | #27 |
intelligence male | #27 |
hyperactivity disorder adhd | #27 |
treatment atomoxetine | #27 |
association signals | #27 |
based association | #27 |
genetic susceptibility schizophrenia | #27 |
bipolar disorder comorbidity | #27 |
rate remission | #27 |
potential confounds | #27 |
metaalgorithm | #28 |
slc6a3 | #28 |
clinical correlates | #28 |
adhd autism | #28 |
male methylphenidate | #28 |
families schizophrenia | #28 |
genetic etiology | #28 |
emotional dysregulation | #28 |
disorder compared | #28 |
subjects bpd | #28 |
raters | #28 |
ocd disorders | #28 |
child clinical | #28 |
assessment negative symptoms | #28 |
schizophrenia onset | #28 |
polysomnography actigraphy | #28 |
snp18 | #28 |
guze | #28 |
6179 | #28 |
symptoms inattention | #28 |
sustained attention deficits | #28 |
adults study | #28 |
vigilance performance | #28 |
adhd differences | #28 |
maternal adhd | #28 |
parent teacher | #28 |
preliminary findings | #28 |
cortical gyrification | #28 |
symptom reports | #28 |
image study | #28 |
persons bipolar disorder | #28 |
rest task | #28 |
new genetics | #28 |
dopamine receptor d4 | #28 |
dopamine transporter binding | #28 |
genomewide studies | #28 |
adhd patients controls | #29 |
kcnn3 | #29 |
etiological heterogeneity | #29 |
disorder bipolar | #29 |
comorbidity ptsd | #29 |
parents bipolar disorder | #29 |
shared genetic basis | #29 |
disorders offspring | #29 |
bipolar disorder youth | #29 |
infants weight | #29 |
african‐american | #29 |
dsmiiir | #29 |
misuse diversion | #29 |
male polymorphism | #29 |
medication usage | #29 |
childhood diagnosis | #29 |
studies genes | #29 |
medication misuse | #29 |
inattention hyperactivity impulsivity | #29 |
psychosocial dysfunction | #29 |
offspring parents | #29 |
hyperactivity impulsivity | #29 |
childhood antecedents | #29 |
attention‐deficit | #29 |
growth childhood | #30 |
nicotine pregnancy | #30 |
structural brain features | #30 |
adhd child | #30 |
caarsinv | #30 |
specific psychopathology | #30 |
relatives age | #30 |
treatment adolescents | #30 |
parental predictors | #30 |
comorbid | #30 |
nimh | #30 |
bmi growth | #30 |
association paternal age | #30 |
nonaffected | #30 |
juvenile bipolar disorder | #30 |
hyperactive symptoms | #30 |
individual studies | #30 |
problems attention | #30 |
antisocial behavior asb | #30 |
robust statistical methods | #30 |
genetic perspective | #30 |
diagnosticians | #30 |
extant literature | #31 |
neuroimage | #31 |
prs adhd | #31 |
discriminates | #31 |
reanalyzed | #31 |
potential endophenotypes | #31 |
neuropsychologic deficits | #31 |
bpd risk | #31 |
sex effects | #31 |
lodscore | #31 |
kif16b | #31 |
charles river | #31 |
genotype haplotypes | #31 |
depression genetic | #31 |
impulsivity inattention | #31 |
variable tandem | #31 |
95 adhd | #31 |
methylphenidate | #31 |
twin concordance | #31 |
nonadhd | #31 |
n305 | #31 |
smoking substance | #31 |
rgs4 schizophrenia | #31 |
slc6a4 | #32 |
aggression attention | #32 |
psychiatric disorders | #32 |
studies schizophrenia | #32 |
attentiondeficit | #32 |
anxiety disorders | #32 |
randomized crossover study | #32 |
subfields hippocampus | #32 |
10p13 | #32 |
impulsecontrol | #32 |
psychosis youth | #32 |
psdq | #32 |
kremen | #32 |
rs206936 | #32 |
gender | #32 |
studies adolescent | #32 |
psychiatric genetic | #32 |
asd symptoms children | #32 |
70–80 | #32 |
schizophrenia affective psychosis | #32 |
child psychiatric | #32 |
repeat length | #32 |
parents child | #32 |
wiscr | #32 |
adhd adolescents | #32 |
bipolar disorder bpi | #32 |
anterior insular | #32 |
association genes | #33 |
briefa | #33 |
single snps | #33 |
neuropsychiatric sle | #33 |
disorder symptom | #33 |
adhd patients | #33 |
maternal smoking pregnancy | #33 |
current adhd | #33 |
neuropsychological deficits | #33 |
autism symptoms | #33 |
psychiatric status | #33 |
pharmacotherapy trials | #33 |
prior findings | #33 |
10repeat allele | #33 |
psychiatric sample | #33 |
subcortical brain | #33 |
aspd bpd | #33 |
neural reward processing | #33 |
quetiapine monotherapy | #33 |
wfirs | #33 |
animal model adhd | #33 |
children risk | #33 |
mood anxiety | #33 |
val allele | #33 |
twins factor analysis | #33 |
adhd evidence | #33 |
frontopolar | #33 |
original study | #33 |
rhobtb3 | #33 |
youth bipolar disorder | #33 |
qsf | #33 |
ld adhd | #33 |
comorbidity cross | #33 |
rs1130214 | #33 |
grm5 | #34 |
risk psychiatric disorders | #34 |
harvard | #34 |
disorders mood | #34 |
psychological tests | #34 |
young adults adhd | #34 |
treatment memantine | #34 |
snp4 | #34 |
gxr | #34 |
pharmacotherapy adhd | #34 |
md risk | #34 |
social anxiety children | #34 |
linkage studies | #34 |
candidate gene polymorphisms | #34 |
structural brain asymmetries | #34 |
disorders diagnostic | #34 |
emerging consensus | #34 |
inattention | #34 |
treatment sud | #34 |
disorder traits | #34 |
cognition interaction | #34 |
dsm5 dsmiv | #34 |
htr1b | #35 |
bipolar disorder offspring | #35 |
complex figure | #35 |
choice impulsivity | #35 |
bipolar spectrum disorders | #35 |
lithium quetiapine | #35 |
n265 | #35 |
risk females | #35 |
adhd rating | #35 |
schizophrenia relatives | #35 |
catechol‐o‐methyltransferase | #35 |
adhd sleep problems | #35 |
recall patients | #35 |
familial risk | #35 |
hyperactive disorder | #35 |
#35 | |
schizophrenia schizotypy | #35 |
lifetime rates | #35 |
sample description | #35 |
n64 | #35 |
humans intelligence | #35 |
schizophrenia gene | #35 |
participants bpd | #35 |
plink | #35 |
disorder bpd | #36 |
neurocognitive markers | #36 |
orosmph | #36 |
nocebo response | #36 |
neurotransmissions | #36 |
retrospective recall | #36 |
adhd control groups | #36 |
stimulant medications | #36 |
schizophrenia genes | #36 |
infant gender | #36 |
suny | #36 |
young adult females | #36 |
groups adhd | #36 |
overanxious disorder | #36 |
95 siblings | #36 |
adhd drug | #36 |
siblings controls | #36 |
annett | #36 |
structure psychopathology | #36 |
d6s274 | #36 |
intracranial volume icv | #36 |
gypc | #36 |
term neuropsychological | #36 |
comorbidity children | #36 |
adult antisocial | #36 |
n185 | #36 |
predictive utility | #37 |
parents adhd children | #37 |
rs5 | #37 |
tests schizophrenia | #37 |
disorder severity | #37 |
mapping genomic loci | #37 |
delayedaction preparations | #37 |
studies comorbidity | #37 |
dat1 gene | #37 |
n278 | #37 |
genetics | #37 |
adhd asd | #37 |
combined sample | #37 |
functioning adults | #37 |
lisdexamfetamine | #37 |
slc22a16 | #37 |
odd dimensions | #37 |
symptom criteria | #37 |
offspring association | #37 |
child behavioral | #37 |
16 genes | #38 |
polymorphism gene | #38 |
pik4ca | #38 |
pediatric adhd | #38 |
adhd problems | #38 |
familial risk depression | #38 |
dsm criteria | #38 |
boys | #38 |
family‐based | #38 |
genetic risk schizophrenia | #38 |
height children | #38 |
d15s1360 | #38 |
methylphenidate treatment | #38 |
genome‐wide search | #38 |
kiddie schedule | #38 |
unfamiliar | #38 |
rs2391191 | #38 |
school age children | #38 |
onset children | #39 |
asthma systematic review | #39 |
suggestive | #39 |
mdd ocd | #39 |
test association | #39 |
git1 | #39 |
wisconsin card | #39 |
mlod | #39 |
ocd adhd | #39 |
structural brain abnormalities | #39 |
behavioral traits | #39 |
washu | #39 |
markers genetic | #39 |
nonparanoid | #39 |
manic symptoms | #39 |
pharmacologic treatment | #39 |
mood stabilization | #39 |
female cases | #39 |
dsm5 criteria | #39 |
adhd behavior | #39 |
antisocial traits | #39 |
increased risk adhd | #39 |
iii personality | #39 |
genetics schizophrenia | #40 |
diagnosis bipolar disorder | #40 |
brainspan | #40 |
rs2283265 | #40 |
gxe | #40 |
reln gene | #40 |
chromosome 10p | #40 |
dsmiv criteria | #40 |
bipolars | #40 |
familial effects | #40 |
genome scan | #40 |
heinrichs | #40 |
rare copy variants | #40 |
cardiovascular adverse effects | #40 |
genetic studies | #40 |
onset | #40 |
anx | #40 |
methodological advances | #41 |
schizophrenia severity illness | #41 |
effects growth | #41 |
parent‐of‐origin | #41 |
normal comparison subjects | #41 |
methylphenidate response | #41 |
psychosocial adversity | #41 |
fhrs | #41 |
male parents | #41 |
sirolimus patients | #41 |
pediatric subjects | #41 |
chromosomes 6q | #41 |
neuropsychiatr | #41 |
bdnf adhd | #41 |
sibpairs | #41 |
dtnbp1 schizophrenia | #42 |
male panic | #42 |
serotonergic pathway | #42 |
individual items | #42 |
disorder social | #42 |
fiveyear followup | #42 |
gwas meta | #42 |
tic disorders | #42 |
diagnostic comorbidity | #42 |
n262 | #42 |
child female | #42 |
schizophrenia disorders | #42 |
sorting test | #42 |
schizophrenia | #42 |
adhd deficits | #42 |
n242 | #43 |
massachusetts general | #43 |
digs | #43 |
p094 | #43 |
simplex families | #43 |
n232 | #43 |
neuropsychological tasks | #43 |
adhd depression | #43 |
brain scans | #43 |
mri study | #43 |
p023 | #43 |
youngadult | #43 |
children enuresis | #43 |
practitioner review | #43 |
disorder prevalence | #43 |
neuropsychological differences | #43 |
adhd prs | #43 |
snp1 | #43 |
candidate endophenotype | #43 |
n176 | #43 |
sidp | #44 |
nosologic | #44 |
n140 | #44 |
secondborns | #44 |
odds ratio association | #44 |
mental disorders diseases | #44 |
treatment adult | #44 |
asd adults | #44 |
immediaterelease | #44 |
prior studies | #44 |
adolescents attention | #44 |
dopamine d5 | #44 |
multidimensionality | #44 |
risk reduction strategies | #45 |
adhd parents | #45 |
inflation rate | #45 |
offspring adhd | #45 |
wnl | #45 |
schizophrenia genome | #45 |
prevalence psychiatric | #45 |
behavior rating | #45 |
snpbased heritability | #45 |
tcerg1l | #45 |
altered brain activation | #45 |
genetic loading | #45 |
suggestive associations | #45 |
cep85l | #45 |
risk schizophrenia | #45 |
institute mental | #45 |
illness stress | #45 |
substance disorder | #45 |
pharmacogenetic studies | #45 |
pooled size | #45 |
volume reductions | #45 |
controls subjects | #45 |
uncaring | #45 |
genetic underpinnings | #45 |
baseline adhd | #45 |
machine learning study | #46 |
sex bias | #46 |
cbt intervention | #46 |
n164 | #46 |
referral bias | #46 |
gender influences | #46 |
converging evidence | #46 |
response mph | #46 |
familial coaggregation | #46 |
neuropsychological performance | #46 |
stronger connectivity | #46 |
previous findings | #46 |
adhd effects | #46 |
lyons | #46 |
nat genet | #46 |
10year followup | #46 |
natural reward | #46 |
12 months treatment | #46 |
compromised | #47 |
velocardiofacial syndrome | #47 |
loci chromosomes | #47 |
trauma risk | #47 |
n280 | #47 |
baiap2 | #47 |
comt | #47 |
abstract objective | #47 |
shared polygenic risk | #47 |
association bipolar disorder | #47 |
parents depression | #47 |
ocd mdd | #47 |
psychiatric status rating | #47 |
or125 | #47 |
genetic study | #47 |
desipramine dmi | #47 |
pooled odds ratio | #47 |
schizophrenia alleles | #47 |
meehl | #47 |
disorders studies | #47 |
oppositional symptoms | #47 |
childhood disorders | #47 |
scientific foundation | #48 |
disorder case | #48 |
effects gender | #48 |
association test | #48 |
1711 | #48 |
shared heritability | #48 |
n27 | #48 |
mpp3 | #48 |
rtv | #48 |
adhd dyslexia | #48 |
n103 | #48 |
nullhypothesis | #48 |
adhd prevalence | #48 |
revised | #48 |
serotonin plasma | #49 |
disorder cognitive | #49 |
anxa7 | #49 |
inbred wky rats | #49 |
schizophrenia cognition | #49 |
nurture | #49 |
mental disorders children | #49 |
negative schizotypy | #49 |
hyperactivity autism | #49 |
familial loading | #49 |
drug holidays | #49 |
snap‐25 | #49 |
rs2494732 | #49 |
weak evidence | #49 |
volume differences | #49 |
geneenvironment interactions | #50 |
genomic relationships | #50 |
intergenerational effects | #50 |
life outcomes | #50 |
dsmiv dsm5 | #50 |
maoauvntr | #50 |
proteins polymorphism | #50 |
caseness | #50 |
parent teacher ratings | #50 |
impulsivity symptoms | #50 |
early onset schizophrenia | #50 |
pair 6 | #50 |
wiat | #50 |
rocf | #50 |
extended pedigrees | #50 |
vdm | #50 |
studies biomarkers | #50 |
wais | #50 |
n168 | #50 |
disorders children | #51 |
adults ocd | #51 |
common psychiatric disorders | #51 |
male personality | #51 |
1542 | #51 |
gender association | #51 |
psychology adult | #51 |
substantial role | #51 |
peer affiliation | #51 |
bpd | #51 |
adhd knowledge | #51 |
compelling | #51 |
manovas | #51 |
epilepsy adhd | #51 |
intracranial volume | #52 |
youth asd | #52 |
schizophrenia controls | #52 |
major depression | #52 |
growth height | #52 |
oros methylphenidate | #52 |
selenbp1 | #52 |
metaanalysis association | #52 |
adra1a | #52 |
combined adhd | #52 |
chronic schizophrenia patients | #52 |
gray matter alterations | #52 |
asdadhd | #52 |
a218c | #52 |
bipolar disorder children | #52 |
schizophrenia sex | #52 |
risktaking behavior | #53 |
scales schizophrenia | #53 |
schizophrenia adolescent | #53 |
smoking schizophrenia | #53 |
adhdc | #53 |
placebo children | #53 |
extended‐release | #53 |
parahippocampal gyrus | #53 |
snps candidate genes | #53 |
n138 | #53 |
adoption study | #53 |
risk analysis | #53 |
mania depression | #53 |
psychopathology | #53 |
ppm1h | #53 |
dopamine plasma | #53 |
tourettes disorder | #53 |
pregnancy time | #54 |
ablim1 | #54 |
bpd children | #54 |
dnms | #54 |
unphased | #54 |
genetic reproducibility | #54 |
alcohol drug | #54 |
onset bipolar | #54 |
schizophrenia psychotic disorders | #54 |
risk study | #54 |
psychlit | #54 |
jackknife | #54 |
chromosome 6p | #54 |
sample children | #55 |
disorders prevalence | #55 |
disorders risk | #55 |
endophenotype | #55 |
tova | #55 |
longitudinal case | #55 |
gene interaction | #55 |
childhood trauma exposure | #55 |
child behavior | #55 |
viloxazine | #55 |
children diagnosis | #55 |
neuropsychological studies | #55 |
emotional lability | #55 |
mid adolescence | #55 |
flat affect | #55 |
1252 | #55 |
degree relatives | #56 |
schizophrenia offspring | #56 |
extendedrelease | #56 |
cotwin | #56 |
entry points | #56 |
n43 | #56 |
tics children | #56 |
hyperactive | #56 |
subfield | #56 |
alcohol substance | #56 |
disorder agoraphobia | #56 |
children siblings | #56 |
pair chromosomes | #56 |
oddsratio | #57 |
rating inventory | #57 |
methylphenidate hydrochloride | #57 |
etdt | #57 |
barkley | #57 |
apol | #57 |
shared genetic etiology | #57 |
atomoxetine hydrochloride | #57 |
model attention | #57 |
zdhhc8 | #57 |
interregional profiles differences | #57 |
brain structure function | #57 |
association comt | #58 |
single snp | #58 |
100 children | #58 |
adhd atomoxetine | #58 |
controlled study | #58 |
childhood young adulthood | #58 |
repeat alleles | #58 |
controls children | #58 |
heritable receptors | #58 |
function schizophrenia | #58 |
children | #58 |
compelling evidence | #58 |
comorbid psychiatric disorders | #58 |
dbq | #58 |
analysis schizophrenia | #58 |
conners | #58 |
tests attention | #58 |
vntr polymorphisms | #58 |
rtn4r | #59 |
risk siblings | #59 |
mdd adhd | #59 |
risk psychiatric | #59 |
mdd children | #59 |
neuroleptic | #59 |
schizophrenia smoking | #59 |
comt schizophrenia | #59 |
inattention hyperactivity | #60 |
3 domains | #60 |
disorders including | #60 |
disruptive behavior disorder | #60 |
lphn3 | #60 |
functional remission | #60 |
abuse dependence | #60 |
generalize | #60 |
executive functioning | #60 |
duval | #60 |
reported associations | #60 |
13q32 | #61 |
wide scan | #61 |
disorders asd | #61 |
comparison subjects | #61 |
study adults | #61 |
uninhibited | #61 |
study adherence | #61 |
dysregulation profile | #61 |
uncles | #61 |
oih | #61 |
disruptive behavior | #61 |
unipolars | #61 |
homogeneous subgroups | #61 |
cronbachs alpha | #61 |
mph treatment | #62 |
schizophrenia human | #62 |
polygenic risk schizophrenia | #62 |
inhibition memory | #62 |
tdts | #62 |
1537 | #62 |
4 year | #62 |
symptoms | #62 |
substantial heritability | #62 |
bipolar youth | #62 |
relatives schizophrenia | #62 |
maternal psychopathology | #62 |
factors anxiety | #62 |
neurocognitive | #63 |
disorders bipolar | #63 |
accounted | #63 |
schizophrenia schizophrenic | #63 |
stability time | #63 |
risk severity | #63 |
treatments adhd | #63 |
n179 | #63 |
behavioral dysregulation | #63 |
structured interview | #63 |
ksads | #63 |
childhood onset | #64 |
40 countries | #64 |
prefrontal dysfunction | #64 |
adhd 95 | #64 |
treatment desipramine | #64 |
endosomal | #64 |
males association | #64 |
methylphenidate mph | #64 |
qlesq | #64 |
methylation cpg sites | #64 |
risk trauma | #64 |
methylphenidate adhd | #64 |
rating scales | #64 |
child | #64 |
children mph | #64 |
diagnostic utility | #64 |
europeanamerican | #64 |
phacking | #64 |
linkage | #64 |
zcchc4 | #65 |
small sample size | #65 |
male siblings | #65 |
marry | #65 |
emotional regulation | #65 |
function female | #65 |
temperamental | #65 |
emo | #65 |
adhd epilepsy | #65 |
neuropsychological impairments | #65 |
controls siblings | #65 |
schizophrenic | #65 |
occurrence adhd | #65 |
disorders genetic | #65 |
comorbid diagnosis | #65 |
etiology schizophrenia | #65 |
oxidase gene | #65 |
net gene | #65 |
prior work | #65 |
study studies | #66 |
tourettes syndrome | #66 |
cbcldp | #66 |
tic disorder | #66 |
simple phobia | #66 |
children mental retardation | #66 |
afternoons | #66 |
disorder chromosome | #66 |
neuropsychological profile | #66 |
behavioral genetic | #66 |
attention hyperactivity | #66 |
vswm | #66 |
global ratings | #66 |
extended release | #66 |
ci105 | #66 |
adhd dcd | #66 |
grade retention | #67 |
risk bipolar | #67 |
subjects | #67 |
label trial | #67 |
chronic tic disorder | #67 |
n217 | #67 |
substance disorder sud | #67 |
findings association | #67 |
mental diseases | #67 |
entire sample | #67 |
patients bipolar disorders | #67 |
variance attention | #67 |
nonrighthandedness | #67 |
questionnaires treatment | #67 |
treatment quetiapine | #67 |
parents teachers | #67 |
brain gene | #68 |
delay aversion | #68 |
conceptual issues | #68 |
offspring | #68 |
qms | #68 |
snparray | #68 |
hypofrontality | #68 |
naturalistic | #68 |
polymorphism schizophrenia | #69 |
physical anhedonia | #69 |
panic disorder | #69 |
regulatory enzymes | #69 |
chronological age | #69 |
stress response genes | #69 |
clarifying | #69 |
ctgn | #69 |
scale assessment | #69 |
impulsivity hyperactivity | #69 |
low adherence | #69 |
people adhd | #69 |
humans schizophrenia | #69 |
symptom checklist | #69 |
illicit substances | #69 |
smoking children | #70 |
linkage scan | #70 |
oros mph | #70 |
subsequent diagnosis | #70 |
neuropsychological consequences | #70 |
new diagnoses | #70 |
latrophilin | #70 |
a2bp1 | #70 |
npl | #70 |
core adhd symptoms | #70 |
nonrandom mating | #70 |
interactions genes | #70 |
adhd anxiety disorders | #71 |
mspi polymorphism | #71 |
genetic | #71 |
neuroimaging genetics | #71 |
vergence | #71 |
treated children | #71 |
objective examine | #71 |
genes role | #71 |
adhd behaviors | #71 |
boys age | #72 |
digital health intervention | #72 |
methodological issues | #72 |
digital intervention | #72 |
molecular genetic | #72 |
school functioning | #72 |
genetic receptors | #72 |
learning disorders | #72 |
ocd subjects | #72 |
cortical abnormalities | #73 |
kagan | #73 |
logodds | #73 |
patients rest | #73 |
cellular models | #73 |
disorders childhood | #73 |
anxiety adhd | #73 |
schizophrenia genetics | #73 |
3372 | #73 |
youth | #73 |
relapse depression | #73 |
adhd medications | #73 |
poison control centers | #73 |
adhd subtype | #73 |
candidate endophenotypes | #73 |
etiological | #73 |
adult | #73 |
allele association | #74 |
based diagnosis | #74 |
preferential transmission | #74 |
pfkfb2 | #74 |
desipramine | #74 |
transmission disequilibrium | #74 |
age schizophrenia | #74 |
reaction time variability | #74 |
slc1a1 | #75 |
impairment children | #75 |
onset anxiety | #75 |
akl | #75 |
mind wandering | #75 |
hyperactivity adhd | #75 |
referred | #75 |
drd4 gene | #75 |
weight body mass | #75 |
child china | #75 |
adhd traits | #75 |
efficacy outcome | #75 |
risk sample | #75 |
antisocial | #75 |
neale | #75 |
linkage schizophrenia | #75 |
yates | #76 |
nondeficit | #76 |
schizophrenia young | #76 |
chronic tic | #76 |
positive schizotypy | #76 |
child humans | #76 |
depression pregnancy | #76 |
adhd total | #76 |
disorders brain | #76 |
centers disease control | #76 |
child depressive | #76 |
childhood adhd | #77 |
performance adhd | #77 |
atomoxetine children | #77 |
performance schizophrenia | #77 |
cortex schizophrenia | #77 |
psychological male | #77 |
lod score | #77 |
wcst performance | #77 |
women antidepressants | #78 |
adhd impairment | #78 |
disorders female | #78 |
pharmacologic treatments | #78 |
rare copy | #78 |
predixcan | #78 |
local gyrification | #78 |
bipolar disorder adhd | #78 |
bpi | #78 |
disorder panic | #79 |
pregnancy mothers | #79 |
student athletes | #79 |
genetic linkage studies | #79 |
patients adhd | #79 |
age adhd | #79 |
studies relationship | #79 |
obesity metabolic syndrome | #79 |
n46 | #79 |
additive effects | #79 |
anxiety separation | #79 |
nosological | #79 |
retrospective assessment | #79 |
schizophrenic patients | #79 |
cardinal | #79 |
clinical interview | #80 |
linkage chromosome | #80 |
maternal smoking | #80 |
total brain | #80 |
siblings schizophrenia | #80 |
adhd rats | #80 |
adhd drugs | #80 |
treatment adults | #81 |
pathophysiology adhd | #81 |
bipolar disorder | #81 |
body mass diabetes | #81 |
hacking | #81 |
endophenotypes | #81 |
disliking | #81 |
children parents | #81 |
interregional profiles | #81 |
subcortical brain volumes | #81 |
differences age | #81 |
oral routes | #81 |
major diagnostic | #81 |
eyhs | #81 |
symptoms diagnosis | #82 |
behavior assessment | #82 |
gene schizophrenia | #82 |
adults asd | #82 |
auditory verbal | #82 |
association maternal smoking | #82 |
frontopolar cortex | #82 |
comorbidity survey | #82 |
genes pathways | #82 |
square distribution | #82 |
cumulative evidence | #82 |
impaired quality life | #82 |
comorbidity disorders | #82 |
paterson | #83 |
illness | #83 |
multifactorial inheritance | #83 |
unreliability | #83 |
oros | #83 |
neurocognitive functioning | #83 |
adult form | #83 |
management adhd | #83 |
tests risk | #83 |
substance disorders | #83 |
disorders anxiety | #83 |
complex disorder | #84 |
15q133 | #84 |
adhd adhd symptoms | #84 |
women adhd | #84 |
21 months | #84 |
buprenorphine maintenance | #85 |
9r | #85 |
adhd assessment | #85 |
linkage loci | #85 |
genomics consortium | #85 |
adhd subtypes | #85 |
humans risk | #85 |
recycling endosome | #85 |
brain asymmetry | #85 |
european samples | #85 |
wide significance | #85 |
atomoxetine | #85 |
monitoring response | #85 |
hyperkinetic disorder | #85 |
adhdrsiv | #85 |
pord | #86 |
child conduct | #86 |
affective psychosis | #86 |
humans inhibition | #86 |
findings implications | #86 |
parents | #86 |
siblings children | #86 |
paranoid | #86 |
bipolar spectrum disorder | #87 |
n203 | #87 |
synaptosomal protein | #87 |
3utr | #87 |
bipolar | #87 |
putamen volume | #87 |
comparison children | #87 |
risk alleles | #87 |
ptsd trauma | #87 |
drug effects | #88 |
bonferroni correction | #88 |
druggable | #88 |
hyperkinetic | #88 |
common risk | #88 |
comorbid psychopathology | #88 |
2455 | #89 |
comprehensive identification | #89 |
empirically | #89 |
machine learning analysis | #89 |
chrna2 | #89 |
22 studies | #89 |
auditory attention | #89 |
caars | #89 |
metaanalytic review | #89 |
nucleotide schizophrenia | #89 |
euphoric | #89 |
prenatal nicotine exposure | #89 |
male neuropsychological | #90 |
antidepressants pregnancy | #90 |
watt | #90 |
pervasive | #90 |
snps haplotypes | #90 |
242 | #90 |
linkage genome | #90 |
verbal ability | #90 |
attention deficit hyperactivity | #90 |
association metaanalysis | #90 |
1month | #90 |
complicates | #91 |
callousness | #91 |
adhd treatments | #91 |
assertion | #91 |
wcst | #91 |
adhd males | #91 |
parental socioeconomic status | #91 |
adhd efficacy | #91 |
identified studies | #91 |
cortical brain | #91 |
naturalistic study | #91 |
studies association | #92 |
h2snp | #92 |
candidate gene | #92 |
adults schizophrenia | #92 |
documenting | #92 |
studies sex | #92 |
treatment mania | #92 |
raise | #92 |
standardized differences | #93 |
controls participants | #93 |
rate adult | #93 |
ymrs | #93 |
narrowly | #93 |
lifetime cannabis | #93 |
referral consultation | #93 |
gottman | #94 |
aldh1l1 | #94 |
cdh13 | #94 |
hfasd | #94 |
gprc5b | #94 |
adhd measures | #94 |
sustained attention | #94 |
hyperactivity autistic | #94 |
performance variability | #94 |
social development | #94 |
growing body | #94 |
brain case | #94 |
underachievement | #94 |
executive | #95 |
minisatellite | #95 |
total brain volume | #95 |
mdd bip | #95 |
cadps2 | #95 |
asd study | #95 |
infa | #95 |
adolescents bipolar | #95 |
studies differences | #95 |
nominally | #96 |
chromosome 9q34 | #96 |
nxph1 | #96 |
phenotype polymorphism | #96 |
behavior rating inventory | #96 |
uvntr | #96 |
scq | #96 |
genome‐wide association study | #97 |
children tics | #97 |
hcadherin | #97 |
low cardiorespiratory fitness | #97 |
studies asthma | #97 |
adolescent onset | #97 |
7q36 | #97 |
oppositionality | #98 |
driving behavior | #98 |
single nucleotide receptor | #98 |
syn2 | #98 |
identically | #98 |
wdpcp | #98 |
linkage study | #98 |
concerta | #98 |
hyperactivity brazil | #98 |
bipolar disorder risk | #98 |
massachusetts general hospital | #98 |
induced hyperalgesia | #98 |
nonfamilial | #98 |
abuse potential | #99 |
neurodevelopmental processes | #99 |
psychoactive | #99 |
methodssubjects | #99 |
chd6 | #99 |
xp114 | #99 |
adhd role | #99 |
medication effects | #99 |
motor timing | #99 |
nonspecificity | #99 |
disease genetics | #99 |
metaanalysis trials | #99 |
disorder diagnosis | #99 |
substrains | #99 |
adhd methylphenidate | #100 |
pelham | #100 |
clinical effects | #100 |
terror | #100 |
hippocampal subfield volumes | #100 |
obesity abdominal obesity | #100 |
12year | #100 |
reticence | #100 |
advanced paternal age | #101 |
torture | #101 |
depression pregnant women | #101 |
addictive drugs | #101 |
empirical test | #101 |
genetic risk scores | #101 |
upsit | #101 |
schizophrenia psychotic | #101 |
roh | #101 |
neurocognitive impairments | #101 |
diagnostic boundaries | #101 |
harlan | #101 |
tsls | #101 |
slc6a4 gene | #101 |
genomewide | #101 |
cosegregation | #101 |
disorder psychiatric | #102 |
inhibition psychological | #102 |
male neuropsychological tests | #102 |
treatment seeking | #102 |
parents offspring | #102 |
sob | #102 |
functional pathways | #102 |
individuals aud | #102 |
klf13 | #102 |
genetic pedigree polymorphism | #103 |
patients 12 months | #103 |
ocd children | #103 |
clinical picture | #103 |
genome wide association | #103 |
schizophrenia mood disorders | #103 |
touchstone | #103 |
symptom profile | #103 |
pgc | #103 |
genetic mechanism | #104 |
schizophrenia metaanalysis | #104 |
1934 | #104 |
genomic region | #104 |
motor competence | #104 |
controlled studies | #104 |
tourette disorder | #104 |
individual sites | #104 |
current article | #105 |
school dropout | #105 |
adhd review | #105 |
academic problems | #105 |
drug dyskinesia | #105 |
schizophrenia probands | #105 |
neuropsychological dysfunction | #105 |
dsmiv diagnosis | #105 |
cogs | #106 |
humans lod | #106 |
children methylphenidate | #106 |
children odd | #106 |
daao | #107 |
consecutive sample | #107 |
functional correlates | #107 |
sequential analysis | #107 |
ldn | #107 |
disorder female | #107 |
λs | #107 |
adolescents bipolar disorder | #107 |
matter volumes | #107 |
oral methylphenidate | #107 |
chronic tic disorders | #107 |
lenticular | #107 |
growth outcomes | #107 |
mothers adhd | #107 |
association cigarette smoking | #108 |
pediatric psychopharmacology | #108 |
origin effects | #108 |
antimanic agents | #108 |
pervasive developmental | #108 |
site differences | #108 |
proband | #108 |
nesarc | #108 |
n197 | #108 |
maternal warmth | #108 |
afni | #108 |
aged psychiatric | #108 |
symptoms childhood | #108 |
918 | #108 |
risk bipolar disorder | #109 |
gabra6 | #109 |
longitudinal trajectories | #109 |
neuroleptic medication | #109 |
adhd medication | #109 |
worthy | #109 |
total scores | #109 |
depression bipolar | #109 |
psychosis proneness | #109 |
irrespective | #109 |
linkage association | #110 |
adhd parent | #110 |
rat models | #110 |
adult adhd symptoms | #110 |
markers genome | #110 |
enlistment | #110 |
affective symptoms | #111 |
selective reporting | #111 |
n107 | #111 |
symptom ratings | #111 |
dao | #111 |
5httlpr genotype | #111 |
dimorphisms | #111 |
affective psychoses | #111 |
independent studies | #112 |
substantial proportion | #112 |
factors social | #112 |
bipolar parents | #112 |
pediatric obsessive | #112 |
unmedicated | #112 |
childhood risk factors | #112 |
impact exposure | #112 |
dopamine d4 receptors | #112 |
brain gene expression | #112 |
neuropsychological functions | #113 |
cronbach | #113 |
xr | #113 |
male prevalence | #113 |
functional neuroanatomy | #114 |
omim | #114 |
analysis statistical | #114 |
comorbid anxiety | #114 |
liability | #115 |
–r | #115 |
schizophrenia severity | #115 |
n34 | #115 |
endorsed | #115 |
nuclear families | #115 |
genet | #115 |
neuropsychological | #116 |
formulating | #116 |
diseases twins | #116 |
wm abnormalities | #116 |
schizophrenic psychology | #116 |
prenatal smoking | #117 |
current symptoms | #117 |
trait impulsivity | #117 |
coordinated analysis | #117 |
z29 | #117 |
neurocognitive endophenotypes | #117 |
polygenic association | #117 |
unipolar | #117 |
quality life outcomes | #117 |
grandfathers | #118 |
satisfaction questionnaire | #118 |
major female | #118 |
academic functioning | #118 |
prevention science | #118 |
grandiosity | #118 |
definitively | #118 |
large study | #118 |
genetic receptor serotonin | #118 |
spm2 | #118 |
naa ratio | #119 |
efd | #119 |
midadolescence | #119 |
method data | #119 |
dopaminergic genes | #119 |
schizophrenia linkage | #119 |
t01 | #120 |
differences children | #120 |
misunderstandings | #120 |
disorder autism | #121 |
remittance | #121 |
subfield volumes | #121 |
cgibp | #121 |
neurocognitive deficits | #121 |
aunts | #121 |
new avenues | #121 |
n108 | #121 |
brain alterations | #122 |
levels adhd | #122 |
schizoaffective | #122 |
refute | #122 |
adhd comorbidity | #122 |
urvs | #122 |
pabs | #122 |
msit | #122 |
neuropsychiatric disorders | #122 |
structural brain alterations | #122 |
psychopathology symptoms | #122 |
anxious | #122 |
disregard | #122 |
male risk | #122 |
disorder depressive | #122 |
v11 | #122 |
adhd ocd | #123 |
wechsler | #123 |
age initiation | #123 |
chr psychosis | #123 |
adcy2 | #123 |
clinical status | #123 |
maximum lod score | #124 |
g×s interaction | #124 |
treatment subjects | #124 |
9q34 | #124 |
laboratory observations | #124 |
trios | #124 |
twothirds | #124 |
p097 | #124 |
wechsler intelligence scale | #124 |
drug placebo | #124 |
attention regulation | #124 |
longitudinal sample | #124 |
anxiety problems | #125 |
machine learning prediction | #125 |
caregiver strain | #125 |
disorder risk | #125 |
patients chronic schizophrenia | #125 |
psychosis individuals | #125 |
segregation analysis | #125 |
odd conduct disorder | #126 |
drug disorders | #126 |
parent version | #126 |
familial influences | #126 |
complex genetics | #126 |
biological parents | #126 |
developmental aspects | #126 |
positive negative symptoms | #126 |
memory adhd | #126 |
stevenson | #127 |
genes | #127 |
drd2 | #127 |
taiwanese population | #127 |
psychiatric diagnoses | #127 |
disinhibited | #127 |
adult alleles | #127 |
attention child | #127 |
aged 6 | #128 |
neuropsychological measures | #128 |
behavioral outcome | #129 |
opiate antagonists | #129 |
intactness | #129 |
familial | #129 |
n102 | #129 |
implicate | #129 |
personality assessment | #129 |
adhd inattention | #130 |
retrospective data analysis | #130 |
1990a | #130 |
families | #130 |
kinesthesia | #131 |
strong evidence | #131 |
moderating effects | #131 |
incapacitation | #131 |
pair 15 chromosomes | #131 |
adolescents ocd | #131 |
mood anxiety disorders | #131 |
differed | #131 |
snps | #131 |
bip mdd | #131 |
register study | #131 |
animals attention | #131 |
childhood anxiety disorders | #132 |
linkage humans | #132 |
hkd | #132 |
late adolescents | #132 |
sodas | #132 |
child cognition | #132 |
large european cohort | #132 |
learning disabilities | #132 |
male prospective | #132 |
entire brain | #132 |
n79 | #132 |
p074 | #132 |
onset bipolar disorder | #133 |
heroin dependence | #133 |
mph | #133 |
preliminary examination | #134 |
children adults | #134 |
vntr | #134 |
disorders social | #134 |
social deficits | #135 |
association analyses | #135 |
male massachusetts | #135 |
social environments | #136 |
relied | #136 |
olfactory identification | #136 |
adolescents young | #136 |
sorcs3 | #136 |
firstborns | #136 |
tspan8 | #136 |
risk factors smoking | #136 |
schizophrenia affective disorders | #137 |
gaming | #137 |
association asthma | #137 |
expressed emotion | #137 |
psychological male memory | #137 |
longitudinal evidence | #137 |
memantine treatment | #137 |
studies examined | #137 |
adolescent bipolar | #137 |
6q | #138 |
control individuals | #138 |
asds | #138 |
evidence association | #138 |
mtor activation | #138 |
biomarkers diagnosis | #138 |
meet | #139 |
fhr | #139 |
mgh | #139 |
n129 | #139 |
schizophrenia studies | #139 |
neuropsychiatric | #139 |
symptoms disorders | #139 |
n115 | #140 |
schizotypal traits | #140 |
parental anxiety | #140 |
intriguing | #140 |
prss | #141 |
genetic vulnerability | #141 |
disorder comorbidity | #141 |
emotional symptoms | #141 |
haplotype block | #141 |
neurotrophic | #142 |
22q112 deletion syndrome | #142 |
covid19 restrictions | #142 |
5ht1b receptors | #142 |
disorders psychotic | #142 |
disorders personality | #142 |
hydrogen exchangers | #143 |
molecular genetics | #143 |
peripheral biomarkers | #143 |
risk factors obesity | #143 |
conduct | #143 |
fetal movement | #143 |
blind study | #144 |
child psychopathology | #144 |
g72 | #144 |
elston | #144 |
rfg | #144 |
statistical female humans | #144 |
diagnostic procedure | #144 |
agents tricyclic | #144 |
humans linear | #144 |
diagnosed attention | #144 |
genetic heterogeneity | #145 |
n105 | #145 |
individual symptoms | #145 |
drug alcohol | #145 |
genome‐wide association studies | #145 |
p00018 | #145 |
affs | #145 |
pcb exposure | #145 |
early initiation | #145 |
studies depressive | #145 |
major psychoses | #145 |
common genetic variants | #145 |
intelligence quotient | #146 |
atypicality | #146 |
prenatal nicotine | #146 |
twin studies | #146 |
warranted | #146 |
genders | #146 |
adult psychopathology | #146 |
oppositional behavior | #146 |
lras | #147 |
intraindividual variability | #147 |
histrionic | #147 |
comprising | #147 |
abbreviated | #147 |
p0016 | #147 |
sabp | #148 |
single locus | #148 |
adolescent young | #148 |
cognitive variables | #148 |
basc | #148 |
risk mdd | #149 |
schizotypy | #149 |
cdrsr | #149 |
brain correlates | #149 |
parental substance | #149 |
adhd symptoms children | #149 |
adhd relationship | #150 |
nonmedical | #150 |
categorical | #150 |
chrnb2 | #150 |
impulsive | #150 |
highlighting | #150 |
sud treatment | #150 |
higher burden | #151 |
synaptic biology | #151 |
consisted | #151 |
schizophrenia diagnosis | #152 |
functional impairment | #152 |
copy variants cnvs | #152 |
linkage disequilibrium mapping | #152 |
httlpr | #152 |
parent report | #152 |
autistic traits | #152 |
undegraded | #152 |
large sample | #152 |
atxn1 | #152 |
xq21 | #152 |
implicates | #152 |
increases risk | #152 |
placebo subjects | #152 |
diagnostic systems | #152 |
metaanalytic | #152 |
schizophrenia bipolar disorder | #153 |
demoralization | #153 |
alcohol conditions | #153 |
caucasian children | #153 |
editions | #153 |
genomewide linkage | #153 |
marginally | #153 |
humans learning | #153 |
schizophrenia deficits | #153 |
5 httlpr | #153 |
exposure maternal | #154 |
disorder phenotype | #154 |
emphasizing | #154 |
wisc | #154 |
atomoxetine placebo | #154 |
schizophrenia magnetic resonance | #154 |
dsm | #154 |
humans polymorphism | #155 |
year follow | #155 |
clarification | #155 |
snpheritability | #155 |
genomewide scan | #155 |
ncsr | #155 |
n84 | #156 |
interpersonal functioning | #156 |
prospective controlled study | #156 |
tests male | #156 |
genetic risk | #156 |
600000 | #156 |
new knowledge | #157 |
enigma consortium | #157 |
panic disorder agoraphobia | #157 |
dopamine d4 | #157 |
genetic linkage | #158 |
cognitive tempo | #158 |
myo5b | #158 |
greatest | #158 |
htr2c | #158 |
oprm1 | #158 |
clinical diagnostic | #158 |
primary setting | #158 |
adolescents | #158 |
sledai | #158 |
ppp2r2b | #158 |
drd4 genotype | #158 |
quetiapine treatment | #159 |
dav | #159 |
adult human brain | #159 |
teachers parents | #159 |
patients substance | #159 |
nonpersistent | #159 |
selfratings | #159 |
separation anxiety disorder | #160 |
humans impulsive | #160 |
medial temporal | #160 |
smds | #160 |
age onset | #160 |
adult adhd patients | #161 |
hyperactivity disorders | #161 |
schizophrenia bipolar | #161 |
genetic component | #161 |
behavioral difficulties | #161 |
tic symptoms | #161 |
population samples | #161 |
disorder clinical | #162 |
ksadspl | #162 |
disorder depression | #162 |
cooccurring disorders | #162 |
140 | #162 |
rats wky | #162 |
empirical tests | #162 |
sample | #163 |
paternal age | #163 |
neurobiology | #163 |
dsmiv | #163 |
5htt | #163 |
dn cells | #163 |
neuropsychological tests | #163 |
anxiety attention | #164 |
familial liability | #164 |
complex phenotype | #164 |
impairments | #164 |
diagnostic status | #164 |
illness schizophrenia | #164 |
neurocognitive performance | #165 |
years children | #165 |
washington university | #165 |
boys girls | #165 |
risk subsequent | #165 |
symptom reduction | #166 |
12–14 | #166 |
domain criteria | #166 |
earlyonset schizophrenia | #166 |
receptor gene | #166 |
cotwins | #166 |
antidepressant therapy | #166 |
shared environment | #166 |
linkage genetic | #166 |
alcohol disorders aud | #166 |
genetic influence | #166 |
association obesity | #167 |
moderates | #167 |
ipsych | #167 |
polygenic architecture | #168 |
neurocognitive functions | #168 |
children 6 years | #168 |
leonard | #168 |
wisciii | #168 |
duration illness | #169 |
n111 | #169 |
genetic association analysis | #169 |
international congress | #169 |
multifactorial | #169 |
perseverations | #169 |
matter microstructure | #169 |
risk gene | #170 |
lgi | #170 |
single nucleotide schizophrenia | #170 |
disorders young | #170 |
arrb2 | #170 |
anxiety child | #170 |
conditional probability | #170 |
cfg | #170 |
pharmacodynamic properties | #170 |
traumas | #170 |
n91 | #171 |
child psychiatry | #171 |
genesets | #171 |
functional laterality humans | #171 |
inattention impulsivity | #172 |
treatment studies | #172 |
immune disorders | #172 |
disorders study | #173 |
enuresis | #173 |
interpersonal sensitivity | #173 |
male mental | #174 |
gabbr1 | #174 |
subsyndromal | #175 |
large samples | #175 |
tics | #175 |
mph placebo | #176 |
confounds | #176 |
development schizophrenia | #176 |
kraepelin | #177 |
patients opioid | #177 |
suicide death | #177 |
hyperactive children | #177 |
confounded | #177 |
independent datasets | #177 |
disorders sex | #177 |
ascertainment | #177 |
cortical surface | #178 |
strong genetic component | #178 |
n78 | #178 |
parent rated | #178 |
strongest evidence | #179 |
gene interactions | #179 |
genetic confounding | #179 |
underpinnings | #179 |
behaviorally | #179 |
atomoxetine atx | #179 |
pregnancy children | #179 |
cvlt | #180 |
copy variants | #180 |
connectivity networks | #180 |
nagelkerke | #180 |
perceptual disorders | #181 |
unemotional traits | #181 |
mothers pregnancy | #181 |
combinatory | #181 |
htr4 | #182 |
structured | #182 |
control participants | #182 |
phenocopies | #182 |
271 | #182 |
scz bip | #182 |
mechanistic target | #183 |
studies gwas | #183 |
rating | #183 |
psychometric testing | #183 |
genotype humans | #183 |
reading difficulties | #184 |
effects atomoxetine | #184 |
wei | #184 |
based morphometry | #184 |
n‐acetylcysteine | #185 |
genome human | #185 |
pdd | #185 |
reward sensitivity | #185 |
phenocopy | #185 |
allison | #185 |
long acting | #185 |
statistical female | #186 |
biomarker studies | #186 |
predominately | #186 |
218 | #186 |
hyperactivity symptoms | #186 |
stratifying | #187 |
risperidone placebo | #187 |
schizophrenia evidence | #187 |
schizophrenia major depression | #187 |
blood biomarkers | #188 |
parahippocampus | #188 |
enigma | #188 |
3 untranslated region | #188 |
depression treatment | #188 |
autocorrelation | #188 |
genetic correlations | #189 |
undertreatment | #189 |
bna | #189 |
differential association | #189 |
functioning children | #190 |
linkage evidence | #190 |
scwt | #190 |
medication adhd | #190 |
childhood | #190 |
schedule female | #191 |
implicated | #191 |
greater activation | #191 |
dopamine genes | #191 |
mph children | #191 |
fsiq | #191 |
clarify | #191 |
psychiatric phenotypes | #191 |
social dysfunction | #191 |
mood disorder | #191 |
association response | #192 |
iasp | #192 |
612 years | #192 |
freedman | #194 |
inconsistent findings | #194 |
joseph | #194 |
polymorphisms snps | #195 |
clinical global | #195 |
placebo p001 | #195 |
sza | #195 |
cognitive endophenotypes | #195 |
dependence symptoms | #197 |
neural substrates | #197 |
arhgef9 | #197 |
wm performance | #197 |
perinatal complications | #197 |
overactivity | #197 |
developmentally | #198 |
ptk2b | #198 |
lifetime diagnosis | #198 |
mdd scz | #198 |
g×s | #198 |
snps schizophrenia | #198 |
male | #199 |
raises | #199 |
bsd | #199 |
childhood symptoms | #199 |
specific genes | #199 |
male phenotype | #199 |
asic1a | #199 |
mri data | #200 |
neuropsychological battery | #200 |
asd adhd | #200 |
small samples | #200 |
disruptive disorders | #200 |
childhood attention | #200 |
disorder humans | #201 |
functional genomics | #201 |
catecholomethyltransferase | #201 |
parents schizophrenia | #201 |
pain tolerance | #202 |
cognitive flexibility | #202 |
pdq | #203 |
genetic liability | #203 |
unaffected | #203 |
childhood adulthood | #203 |
stopsignal task | #203 |
neuropsychological correlates | #203 |
control association | #203 |
microsatellite marker | #204 |
respond | #204 |
adolescent psychiatry | #204 |
extend | #204 |
concurrent validity | #204 |
attentional control | #204 |
schizophreniform | #204 |
uptodate | #206 |
nonshared | #206 |
genes risk | #206 |
selfdirectedness | #206 |
sluggish cognitive tempo | #207 |
method drug | #207 |
parental alcohol | #208 |
prolactin levels | #208 |
susceptibility schizophrenia | #208 |
prkg1 | #208 |
clinical benefits | #209 |
baseline follow | #209 |
variable expression | #209 |
correspondence | #210 |
n96 | #210 |
maudsley | #210 |
park2 | #210 |
acds | #210 |
5year followup | #210 |
60mg | #210 |
greater risk | #211 |
vntr polymorphism | #211 |
predisposition disease | #211 |
hkdc1 | #212 |
grm7 | #212 |
adult patients adhd | #212 |
apoe4 allele | #212 |
stroop task | #212 |
dimensional models | #212 |
ps005 | #212 |
sought | #213 |
trauma ptsd | #213 |
replication studies | #213 |
negative outcomes | #213 |
sampling strategy | #213 |
suggestive evidence | #214 |
schizophrenia chinese | #214 |
disorders models | #214 |
rare cnvs | #214 |
humans neuropsychological | #214 |
continuous performance test | #214 |
cvltii | #214 |
adult cognition | #215 |
male mental disorders | #215 |
bilag | #215 |
lifetime version | #215 |
functional mri study | #216 |
vivo correlation | #216 |
male schizophrenia | #217 |
antisocial personality | #217 |
chromosome 15 | #217 |
glr | #217 |
parental | #218 |
hippocampal subfield | #218 |
panic | #218 |
gene based | #218 |
trim31 | #218 |
study selection | #219 |
misunderstood | #219 |
polygenic | #219 |
normal controls | #220 |
drug double | #220 |
snpa | #220 |
telephone interview | #221 |
symptoms adults | #221 |
triangularis | #221 |
studies cognition | #221 |
parental psychopathology | #221 |
irritable mood | #221 |
diagnoses | #222 |
n76 | #222 |
methyltransferase comt | #222 |
childhoodonset | #222 |
score male | #222 |
patient engagement | #222 |
study findings | #223 |
revisited | #223 |
learning disability | #223 |
adhd sleep | #224 |
gria2 | #224 |
effective treatments | #224 |
axis disorders | #224 |
sensing ion | #224 |
abnormalities schizophrenia | #224 |
coordination disorder | #225 |
bipolar spectrum | #225 |
default network | #225 |
hk3 | #226 |
subfields | #226 |
children placebo | #226 |
inattentiveness | #226 |
subcortical regions | #227 |
dependent variables | #227 |
criteria diagnosis | #227 |
unemotional | #227 |
individual variability | #227 |
disorder study | #227 |
scales psychotic | #227 |
comorbid anxiety disorders | #228 |
atomoxetine treatment | #228 |
age subjects | #228 |
control based | #228 |
male twins | #228 |
structural abnormalities | #229 |
birth complications | #229 |
equally | #229 |
overlapped | #229 |
psychiatric outcomes | #230 |
commission errors | #231 |
risk indicators | #231 |
international multicenter | #231 |
4years | #231 |
heritable | #231 |
differences prevalence | #232 |
hyperactivity behavior | #232 |
serotonin transporter gene | #232 |
study sample | #234 |
worse performance | #234 |
candidate genes | #234 |
probabilistic forecasts | #235 |
disorder medication | #235 |
discriminating | #235 |
shr wky rats | #236 |
route administration | #238 |
fifty years | #238 |
reliably | #238 |
placebo response | #238 |
agoraphobia | #238 |
allelic heterogeneity | #239 |
acid oxidase | #240 |
nosology | #240 |
scientific data | #240 |
healthy siblings | #240 |
patients siblings | #240 |
pdag | #240 |
adolescent offspring | #241 |
symptoms quality | #241 |
adequately | #241 |
doubleblind | #241 |
disorder asd | #241 |
psychiatric comorbidities | #242 |
neurodevelopmental model | #242 |
joint analysis | #242 |
reward processing | #242 |
impulsive choice | #242 |
sodium hydrogen | #242 |
onset obsessive | #243 |
patients relatives | #243 |
female | #243 |
valid | #243 |
aggressive behaviors | #243 |
giftedness | #244 |
n74 | #244 |
adversity | #245 |
5ht2a receptor | #245 |
disorder ptsd | #245 |
interregional | #245 |
population differences | #245 |
paliperidone | #245 |
community controls | #246 |
expression genetic | #246 |
dsmivtr | #246 |
cadm2 | #246 |
812 | #247 |
motor performance | #247 |
chinese families | #248 |
epigenetic studies | #248 |
studies associations | #248 |
cigarette smoking | #248 |
developmental disorder | #249 |
childs | #251 |
behavioral characteristics | #251 |
german patients | #252 |
hypoactivation | #252 |
genomewide association | #253 |
intellect | #253 |
tourette | #253 |
iqs | #253 |
female subjects | #253 |
benzodiazepine | #254 |
cpt performance | #254 |
studies metaanalysis | #254 |
schizophrenia adult | #254 |
study schizophrenia | #254 |
kappas | #254 |
conduct problems | #255 |
biochemical studies | #256 |
cacna1c gene | #256 |
shared genetic | #256 |
larsson | #256 |
carlson | #257 |
children adhd symptoms | #257 |
parental depression | #259 |
endorsement | #259 |
year study | #259 |
n61 | #260 |
piq | #260 |
diagnosis | #261 |
pharmacotherapy | #261 |
anxiety depressive disorders | #261 |
dexamphetamine | #261 |
obsessive compulsive disorder | #263 |
sex factors | #263 |
22q11ds | #263 |
selfreports | #263 |
fluid intelligence | #263 |
genomewide linkage scan | #263 |
disorder personality | #264 |
attention problems | #264 |
confirm | #264 |
conceptualized | #264 |
adverse health | #264 |
distinct subtypes | #264 |
long term outcomes | #265 |
5090 | #266 |
ptsd risk | #266 |
schizophrenia cases | #266 |
new models | #266 |
diagnostic validity | #266 |
scz mdd | #267 |
phenotype schizophrenia | #267 |
diagnosis schizophrenia | #268 |
strong support | #268 |
genetic approaches | #268 |
neuropsychological impairment | #268 |
test scores | #269 |
years baseline | #269 |
diagnostic process | #269 |
largest | #270 |
segregate | #270 |
age effects | #270 |
phlda1 | #270 |
withdrawn | #270 |
social adversity | #271 |
sibling pairs | #271 |
adult psychiatric | #271 |
circadian genes | #271 |
genetic overlap | #271 |
symptoms assessed | #271 |
structural brain | #272 |
diagnostic issues | #272 |
statistics topic | #273 |
444 | #273 |
alcohol smoking | #273 |
rora | #273 |
szs | #273 |
age | #273 |
schizophrenia siblings | #273 |
4year | #273 |
search terms | #273 |
sleep behavior | #274 |
22 years | #274 |
underlie | #275 |
surgency | #275 |
reading disability | #275 |
maf1 | #275 |
familial schizophrenia | #276 |
2q | #276 |
t102c | #276 |
missingness | #276 |
mania symptoms | #277 |
growing evidence | #277 |
adolescent risk | #277 |
adhd healthy controls | #277 |
nicotinic schizophrenia | #277 |
synaptosomal | #278 |
nr3c1 | #278 |
manual | #278 |
clinical setting | #278 |
early psychosis | #278 |
intelligence scale | #279 |
ocd | #279 |
silico approach | #279 |
nicotine dependence | #279 |
acting | #280 |
abuser | #280 |
rating scale | #280 |
brain volumes | #280 |
cognition female | #280 |
child parent | #280 |
n47 | #280 |
polygenic risk | #280 |
remitted | #280 |
individuals | #281 |
disorders adult | #281 |
psychotic bipolar | #281 |
premature death | #281 |
phenotyped | #281 |
collaborative analysis | #282 |
response inhibition | #282 |
onset ocd | #282 |
5ht1b | #282 |
reading problems | #282 |
continue | #283 |
velo | #283 |
titrated | #283 |
antisocial behaviors | #283 |
aspd | #284 |
3untranslated region | #285 |
normal variation | #285 |
gria3 | #285 |
neoffi | #285 |
neuroanatomical | #285 |
quantitative traits | #285 |
siblings patients | #286 |
clues | #286 |
swanson | #286 |
scale children | #286 |
explication | #286 |
quantitative analyses | #286 |
effects age | #287 |
deficit schizophrenia | #288 |
schizophrenia abnormalities | #288 |
postmortem brain | #289 |
bmisds | #289 |
psychiatric traits | #290 |
disease haplotypes | #290 |
22q112 | #290 |
pediatric ocd | #290 |
publication bias | #291 |
low serum levels | #291 |
subcortical volumes | #291 |
substrain | #292 |
modest | #293 |
groups children | #293 |
cognition disorders | #294 |
hypertensive rat | #294 |
subjective responses | #294 |
salary | #294 |
adverse impact | #295 |
post‐traumatic stress disorder | #295 |
psychosis schizophrenia | #295 |
european populations | #295 |
risk factors children | #295 |
interference control | #295 |
dtnbp1 | #295 |
ldsc | #296 |
executive functions | #296 |
continuous performance | #296 |
obesity overweight | #297 |
early onset | #297 |
anxiety disorder | #297 |
asd traits | #297 |
discriminated | #298 |
reanalysis | #298 |
diagnostic approach | #298 |
negative symptom | #299 |
predisposition | #299 |
effects stress | #300 |
cortical thickness | #300 |
qvalues | #300 |
psychiatric hospitalization | #301 |
roc analysis | #301 |
cognitive measures | #301 |
emotional problems | #302 |
published literature | #302 |
intrasubject variability | #302 |
states adolescent | #302 |
prefrontal function | #302 |
permuted | #303 |
height body | #303 |
psychometrics | #303 |
795 | #304 |
psychiatric conditions | #304 |
affective disorders | #305 |
interviewers | #305 |
manifest | #305 |
case subjects | #305 |
aggressive behavior | #305 |
dsm5 | #305 |
ats | #305 |
early morning | #306 |
dopamine transporter | #306 |
learning disorder | #307 |
n62 | #307 |
general psychopathology | #308 |
documented | #309 |
spencer | #309 |
gene environment | #309 |
membrane transport | #309 |
omission errors | #309 |
perseveration | #309 |
myh9 | #309 |
adolescent aggression | #310 |
genetic schizophrenia | #310 |
life social support | #310 |
efficacy treatment | #310 |
memory wm | #310 |
motor domain | #310 |
rdoc | #311 |
gender age | #312 |
stroop test | #312 |
childhood adolescence | #312 |
mainstays | #312 |
npsr1 | #313 |
mapping female | #313 |
genetic analyses | #314 |
underscore | #314 |
bedtimes | #315 |
risk estimation | #315 |
asb | #317 |
dorsolateral prefrontal cortex | #317 |
replicated | #317 |
demonstrable | #318 |
schizophrenia review | #318 |
5ht2c | #319 |
n55 | #319 |
individual genes | #319 |
adolescent adrenergic | #320 |
intelligence tests | #321 |
gene | #321 |
shared genetic influences | #321 |
addictive disorders | #321 |
bipolar type | #322 |
humans longitudinal | #322 |
risperidone treatment | #322 |
127 | #322 |
robins | #322 |
abusers | #323 |
time variability | #323 |
guanfacine | #324 |
conceptual models | #324 |
nolan | #324 |
manic | #325 |
sex characteristics | #326 |
yielded | #326 |
neonatal abstinence syndrome | #326 |
status female | #327 |
spurious | #327 |
impaired | #327 |
xq26 | #327 |
etiologic | #328 |
comprised | #328 |
8q | #329 |
disorders pervasive | #329 |
sexdifferences | #330 |
metaanalyses | #330 |
overrepresented | #330 |
scores patients | #331 |
htr2a | #331 |
drug response | #331 |
women schizophrenia | #332 |
txndc5 | #333 |
familial factors | #333 |
expression brain | #333 |
naltrexone | #333 |
cognitive dysfunctions | #334 |
multiple comparisons | #334 |
obesity diabetes | #334 |
forthcoming | #335 |
mood disorders | #335 |
adler | #335 |
24weeks | #335 |
methylphenidate placebo | #336 |
rey | #336 |
humans mental | #336 |
persist | #336 |
inferior parietal lobule | #336 |
asd individuals | #337 |
tph2 | #337 |
mobp | #337 |
777 | #337 |
neuropsychological test | #337 |
disentangle | #338 |
patients attention | #339 |
evening | #339 |
psychopathological | #339 |
replications | #339 |
pnmt | #340 |
disorder ocd | #340 |
evidence linkage | #340 |
exclusion criteria | #340 |
consistently | #340 |
treatment bipolar | #341 |
encompassing | #341 |
intelligence | #341 |
placebo effects | #341 |
visual memory | #342 |
bipolarity | #342 |
phobic | #342 |
maoa genotype | #342 |
multicenter analysis | #342 |
neuroimaging studies | #342 |
tbv | #344 |
mood problems | #344 |
integrated analysis | #344 |
frontal pole | #344 |
schizoaffective disorder | #344 |
comorbid diagnoses | #344 |
casecontrol studies | #345 |
systematically | #345 |
catechol methyltransferase | #345 |
864 | #346 |
gifts | #346 |
study genotype | #347 |
confused | #347 |
mdd bpd | #347 |
converging | #348 |
psychotic | #348 |
tic severity | #348 |
collaborative study | #349 |
schizotypal personality disorder | #349 |
temporal processing | #349 |
methylphenidate atomoxetine | #350 |
adolescent anxiety | #350 |
aetiological | #350 |
suspiciousness | #351 |
receptor genes | #352 |
distractibility | #352 |
disequilibrium | #352 |
adults children | #352 |
impairing | #353 |
disease genome | #353 |
substantial | #354 |
maob | #354 |
reln | #354 |
disorders middle | #354 |
child attention | #354 |
executive attention | #354 |
brain atlas | #354 |
genetic environmental | #354 |
gabra1 | #354 |
prodh | #355 |
rgs4 | #355 |
dsmiii | #355 |
male adolescent | #355 |
heterogeneous disorder | #356 |
phobic disorders | #356 |
schizophrenia data | #356 |
measures attention | #357 |
chrna7 | #357 |
children anxiety disorders | #357 |
gottesman | #358 |
maternal cigarette smoking | #359 |
disorder patients | #359 |
deviant | #359 |
psychiatric symptoms | #359 |
persists | #359 |
linkage analysis | #360 |
symptom scores | #360 |
chromosomal regions | #361 |
neuroleptic treatment | #361 |
n54 | #361 |
social adjustment | #362 |
dorsolateral prefrontal | #363 |
genetic findings | #364 |
paralimbic | #365 |
tid | #365 |
confirmation | #366 |
elevated risk | #366 |
core symptoms | #366 |
771 | #367 |
memory load | #367 |
pediatric populations | #367 |
risk psychopathology | #368 |
comparison groups | #368 |
study entry | #368 |
bpd mdd | #368 |
differential involvement | #369 |
702 | #369 |
young adulthood | #369 |
hyperactivityimpulsivity | #369 |
nervousness | #370 |
differential susceptibility | #370 |
representativeness | #370 |
current concepts | #371 |
schizophrenia risk | #371 |
damphetamine | #371 |
endorse | #372 |
replicate | #372 |
comt gene | #372 |
prevention strategies | #372 |
executive function | #373 |
genomewide association studies | #373 |
5httlpr | #373 |
small sample | #374 |
driving performance | #374 |
snp heritability | #374 |
wide analysis | #375 |
scz | #375 |
dozens | #375 |
916 | #375 |
medication children | #376 |
teenage | #376 |
emphases | #376 |
child adolescent | #377 |
sas | #377 |
memory short | #377 |
children medication | #377 |
genetic architecture | #377 |
data studies | #377 |
children adolescents | #378 |
impression | #378 |
schizotypal personality | #378 |
control adults | #379 |
marriages | #379 |
youths | #380 |
ht1b | #380 |
opd | #380 |
pearson | #380 |
converged | #380 |
methylphenidate children | #381 |
general cognitive ability | #381 |
culmination | #381 |
receptors dopamine | #381 |
invaluable | #381 |
overlap | #381 |
disorder diagnostic | #381 |
relevant articles | #381 |
chisquare | #382 |
adolescent patients | #382 |
psychopharmacological treatment | #383 |
carefully | #383 |
antimanic | #383 |
psychopathologies | #383 |
researched | #384 |
summary statistics | #384 |
gad2 | #385 |
7r | #385 |
18p | #386 |
multigenerational | #386 |
treatment children | #386 |
neural activation | #387 |
chinese subjects | #387 |
contrasted | #388 |
versa | #388 |
evenings | #388 |
npas2 | #388 |
childhood depression | #389 |
adhd symptomatology | #389 |
perinatal morbidity | #390 |
disorder symptoms | #390 |
handedness | #390 |
lefthandedness | #390 |
brain circuits | #390 |
studies children | #390 |
interaction genetic | #391 |
genetic predisposition | #391 |
schizophrenia susceptibility | #392 |
comorbid substance | #392 |
lambert | #392 |
p54 | #393 |
genes expression | #394 |
substance users | #394 |
function humans | #395 |
dopamine norepinephrine | #395 |
hippocampal subfields | #395 |
adolescents adults | #396 |
3methoxy4hydroxyphenylglycol | #397 |
mental health children | #397 |
psychometric | #397 |
disorders schizophrenia | #397 |
schizophrenia disorder | #397 |
fbat | #397 |
clinical risk psychosis | #398 |
spm8 | #398 |
earlier onset | #398 |
wandering | #398 |
neuropsychological testing | #400 |
control sample | #401 |
academic outcomes | #402 |
inattention symptoms | #402 |
core symptom | #402 |
suffocation | #402 |
inconsistencies | #403 |
relations male | #403 |
implications findings | #403 |
hyperparameter | #405 |
psychostimulants | #405 |
vntrs | #406 |
n52 | #406 |
neuropsychiatric conditions | #406 |
parahippocampal | #406 |
diagnosis children | #406 |
attending | #407 |
childhood risk | #408 |
cognitive inhibition | #408 |
behavior genetics | #409 |
0038 | #409 |
communitybased | #409 |
distinct subsets | #410 |
substance | #410 |
dextroamphetamine | #411 |
reading comprehension | #411 |
twin study | #411 |
children studies | #411 |
impulsive behavior | #411 |
childhood anxiety | #412 |
consistent evidence | #412 |
psychotic disorders | #412 |
interview | #412 |
neanderthal | #412 |
tourette syndrome | #412 |
apoe4 | #412 |
systematic literature search | #413 |
anticipation | #413 |
moderated | #413 |
151 | #414 |
performance tests | #414 |
reviewing | #414 |
polymorphism snp | #415 |
volition | #415 |
schizotypal | #416 |
genetic receptor | #416 |
elucidating | #416 |
functional effects | #417 |
effects brain | #417 |
conferred | #418 |
adult intelligence | #418 |
adolescent psychiatric | #418 |
deletion syndrome | #419 |
srsa | #419 |
questionnaires adolescent | #419 |
genetic association | #419 |
daily doses | #420 |
kdm4a | #420 |
dopamine d4 receptor | #420 |
antidepressive agents | #420 |
modestly | #421 |
sexes | #421 |
adult subjects | #421 |
drug dependence | #422 |
iccs | #422 |
operating characteristic | #422 |
cdis | #422 |
medicated | #423 |
reliability validity | #423 |
tricyclic | #423 |
characteristic curve | #424 |
gcta | #424 |
subtests | #425 |
transport proteins | #425 |
discovery sample | #425 |
parent ratings | #426 |
cardiff | #426 |
hum | #427 |
attain | #427 |
spectrum disorders | #428 |
brain volume | #428 |
diversion | #428 |
persistent symptoms | #429 |
male obsessive | #430 |
personality development | #431 |
disentangling | #431 |
teacher | #432 |
operating characteristics | #432 |
uniquely | #433 |
peps | #434 |
wistarkyoto | #435 |
1433 | #436 |
cprs | #436 |
frequency genotype | #436 |
12q | #436 |
perceptual organization | #436 |
disorder brain | #437 |
lower scores | #437 |
grin2a | #437 |
relatives patients | #437 |
srs2 | #438 |
impulsiveness | #438 |
toddlerhood | #438 |
adolescent psychopathology | #438 |
correlation coefficients | #438 |
visual learning | #438 |
nominal | #439 |
genetic genetic predisposition | #439 |
22q112ds | #439 |
digit span | #439 |
risk psychosis | #439 |
method female | #440 |
aged neuropsychological | #440 |
snps association | #440 |
major risk factor | #440 |
trex | #441 |
white matter microstructure | #441 |
allelic association | #441 |
meaningful | #441 |
post hoc analysis | #441 |
corroborated | #441 |
gmo | #441 |
planum temporale | #442 |
virtual histology | #442 |
logistic regression model | #442 |
adult analysis | #442 |
female functional | #442 |
disorders autism | #442 |
n80 | #443 |
emphasize | #444 |
disorders surveys | #444 |
10 year | #444 |
differential female | #444 |
conferring | #444 |
pcdh10 | #445 |
ntrk3 | #446 |
statistic | #446 |
862 | #446 |
534 | #446 |
nucleotide receptors | #446 |
holland | #447 |
behavior child | #448 |
genome wide | #448 |
originally | #448 |
motor coordination | #448 |
expressiveness | #449 |
earlier age | #449 |
early response | #450 |
risk variants | #450 |
wistar kyoto | #450 |
exceptions | #451 |
sex | #451 |
clinical expression | #452 |
brain abnormalities | #452 |
prevalence correlates | #452 |
subsequent risk | #452 |
children adolescent | #456 |
chat | #456 |
psychiatry | #457 |
79 | #457 |
zscores | #457 |
masse | #458 |
structural magnetic | #458 |
independently | #458 |
preliminary study | #458 |
lander | #460 |
polygenic risk score | #460 |
psychotic disorders schizophrenia | #460 |
22q112 deletion | #460 |
genetic correlation | #460 |
522 | #460 |
hyperkinesis | #461 |
smoking pregnancy | #461 |
jw | #462 |
d4 | #463 |
decrements | #465 |
neuroanatomy | #465 |
life treatment | #465 |
affection | #465 |
pregnancy complications | #465 |
runs | #466 |
gene sets | #466 |
control rates | #466 |
mini | #467 |
inbred wky | #467 |
anxiety depressive | #467 |
bpad | #468 |
subjects patients | #469 |
cacna1c | #470 |
patient adherence | #470 |
genetic effects | #470 |
disorders treatment | #470 |
remission relapse | #471 |
receiver operating | #471 |
risk allele | #472 |
psychology adolescent | #472 |
chrna4 | #473 |
response remission | #473 |
environmental risk factors | #474 |
norepinephrine transporter | #474 |
plp1 | #474 |
opioid addiction | #476 |
developmental coordination | #476 |
cautious | #476 |
obesity children | #477 |
multiple measures | #477 |
broader | #478 |
dysthymia | #479 |
multiplex families | #479 |
5th | #479 |
genetic risk variants | #480 |
symptom | #480 |
adds | #480 |
humans | #480 |
diagnostic categories | #481 |
semistructured | #481 |
cortex child | #481 |
data extraction | #482 |
genotyped | #482 |
maternal anxiety | #482 |
etiology | #483 |
arithmetic | #483 |
treatment methylphenidate | #484 |
conception | #484 |
verbal learning | #484 |
sml | #484 |
nfil3 | #484 |
756 | #485 |
adulthood | #485 |
agents bipolar | #485 |
baseline age | #486 |
outcome variables | #486 |
epidemiologically | #486 |
adult anxiety | #487 |
123 | #487 |
symptom dimensions | #487 |
evaluates | #487 |
spontaneity | #488 |
female adolescents | #489 |
unpublished | #489 |
longterm effects | #489 |
genetic disorders | #489 |
administration schedule | #490 |
neuropsychiatric disorder | #490 |
shared environmental | #490 |
schizophrenia autism | #490 |
smoking prevention | #492 |
common variant | #492 |
schizophrenia age | #492 |
pnds | #493 |
overlapping | #493 |
frequency genetic | #495 |
antisocial personality disorder | #495 |
late adolescence | #495 |
pair human | #497 |
schizophrenia patients | #497 |
restlessness | #497 |
anxiety | #497 |
psychobiology | #497 |
separation anxiety | #497 |
bonferroni | #498 |
longitudinal studies | #498 |
placebos | #499 |
genetic mechanisms | #499 |
addressed | #499 |
daoa | #499 |
candidate | #499 |
comt val158met polymorphism | #500 |
case reports | #500 |
identifying | #500 |
d4 receptors | #501 |
rat strains | #501 |
nocebo | #501 |
additional evidence | #503 |
verbal memory | #503 |
865 | #503 |
child executive | #505 |
circadian clock genes | #505 |
n26 | #506 |
subscale | #506 |
fallacy | #506 |
continued | #507 |
cooperativeness | #507 |
tobacco disorder | #508 |
reflecting | #508 |
developing schizophrenia | #509 |
delay discounting | #509 |
agg | #510 |
shared | #511 |
educational status | #511 |
dichotomous | #511 |
obsessive compulsive | #512 |
identifiable | #512 |
p80 | #512 |
95 death | #512 |
risk haplotype | #513 |
lod | #513 |
coaggregation | #514 |
disproportionate | #514 |
assessments | #515 |
phis | #515 |
disorders depression | #515 |
morning | #515 |
normal control | #516 |
total sample | #516 |
n39 | #517 |
contributing | #517 |
cognitive traits | #517 |
15q | #518 |
missing link | #519 |
fn1 | #520 |
environmental influences | #520 |
pbat | #520 |
gyrus cinguli | #521 |
dichotic | #521 |
specificity ppv | #521 |
polymorphism single | #522 |
selfreport | #522 |
disorder obsessive | #522 |
social class | #522 |
dibenzothiazepines | #523 |
attention memory | #523 |
phg | #524 |
dmi | #524 |
assortative | #524 |
dedication | #524 |
adult bipolar | #524 |
sciencedirect | #525 |
clinical diagnoses | #525 |
pacific island | #525 |
disorder treatment | #525 |
covariates | #525 |
affiliations | #526 |
functioning | #527 |
persistence | #527 |
criminality | #527 |
design study | #528 |
adverse life events | #528 |
symptomatic remission | #528 |
depression anxiety disorders | #528 |
adolescent children | #528 |
compulsive disorder | #529 |
flnc | #529 |
abrupt | #529 |
community samples | #529 |
ruled | #529 |
parental reports | #529 |
control children | #530 |
tagsnps | #530 |
increased burden | #531 |
strongest | #531 |
medications | #531 |
n40 | #532 |
autism schizophrenia | #532 |
existing studies | #532 |
subjects age | #533 |
clinical sample | #533 |
analyses conducted | #534 |
temperament character | #534 |
selective review | #535 |
intercorrelations | #535 |
asd | #535 |
global impression | #537 |
parsing | #537 |
child adhd | #538 |
autistic symptoms | #538 |
models genetic | #538 |
d4 receptor | #539 |
milder | #541 |
personality factors | #541 |
lobe humans | #542 |
disease genotype | #543 |
single nucleotide | #543 |
taiwanese | #543 |
complexities | #544 |
severe symptoms | #544 |
independent samples | #544 |
ld | #545 |
population sample | #545 |
choice behavior | #546 |
cognitive impairments | #546 |
genetic influences | #547 |
computer program | #548 |
healthy control subjects | #548 |
functional variant | #548 |
behavior male | #549 |
oral route | #549 |
risk children | #549 |
nonclinical sample | #549 |
patients schizophrenia | #549 |
dichotomized | #549 |
schizophrenia study | #549 |
clash | #549 |
genetic pathways | #550 |
fam | #550 |
765 | #550 |
motor inhibition | #551 |
case control | #551 |
ideally | #551 |
define | #551 |
major diagnosis | #552 |
performance test | #552 |
n29 | #553 |
verbal | #553 |
preadolescent | #554 |
suggests | #555 |
prs schizophrenia | #555 |
release oral | #555 |
viewed | #555 |
phenotypic features | #556 |
spectrum disorder | #556 |
neuropsychiatric diseases | #557 |
child anxiety | #557 |
nogo task | #557 |
africanamerican | #558 |
neurodevelopmental | #558 |
equivocal | #558 |
justify | #559 |
response variability | #560 |
gray matter volumes | #560 |
higher rate | #561 |
profoundly | #563 |
caregivers children | #563 |
adolescents risk | #565 |
risk smoking | #565 |
intermediate phenotypes | #566 |
twins female | #566 |
patients sud | #566 |
risky behaviors | #566 |
4th edition | #566 |
haplotype | #567 |
neurocognitive impairment | #567 |
3050 | #567 |
unaffected relatives | #568 |
replication study | #569 |
environment interaction | #570 |
10−8 | #570 |
diverging | #570 |
onsets | #570 |
birthday | #571 |
keywords | #571 |
risk genes | #571 |
dose reduction | #573 |
white matter abnormalities | #574 |
irritability | #574 |
obesity body mass | #574 |
inbred shr | #575 |
questionnaires adult | #575 |
gyri | #576 |
spaced | #576 |
asd diagnosis | #576 |
chromosomes human | #577 |
individually | #577 |
parent | #577 |
schizophrenia sample | #577 |
medical genetics | #577 |
impulsivity | #578 |
82 | #578 |
finetuning | #578 |
symptoms children | #579 |
subsample | #579 |
5httlpr polymorphism | #580 |
development anxiety | #580 |
cold pressor test | #580 |
preschool age | #580 |
haplotype analysis | #581 |
apol1 | #582 |
drd1 | #582 |
rdc | #582 |
psychiatric association | #582 |
3rd | #583 |
delinquent behavior | #583 |
hk1 | #584 |
new approaches | #584 |
data children | #585 |
fine mapping | #585 |
separately | #585 |
neuroanatomical correlates | #586 |
traumatized | #587 |
nback task | #588 |
defaultmode network | #588 |
compared controls | #588 |
examine | #588 |
138 | #589 |
haplotypes humans | #590 |
patients comorbid | #591 |
40mg | #591 |
behavior adult | #591 |
estonian | #591 |
criticism | #593 |
concordant | #594 |
2005 | #594 |
brain child | #595 |
cognition schizophrenia | #596 |
overrepresentation | #596 |
snap25 | #597 |
nonpharmacologic | #597 |
generalizable | #597 |
discounted | #597 |
affymetrix | #598 |
899 | #598 |
new directions | #598 |
differences brain | #600 |
genetic factors | #601 |
specific phobia | #603 |
diagnostic specificity | #604 |
diagnosing | #604 |
clinical settings | #604 |
disorganized | #606 |
clinician | #606 |
performance children | #606 |
cognitive outcomes | #606 |
personality traits | #607 |
social environment | #607 |
4 6 | #608 |
small fraction | #608 |
sizeable | #608 |
executive dysfunctions | #609 |
antisocial behavior | #609 |
gold standard | #609 |
true | #609 |
functional outcomes | #610 |
polygenic risk scores | #610 |
informant | #611 |
pleiotropic | #612 |
complex disorders | #612 |
chromosome 6 | #613 |
schizophrenia brain | #614 |
educational achievement | #614 |
grandmothers | #614 |
snp markers | #615 |
curve analysis | #615 |
disease etiology | #615 |
behavior disorder | #615 |
genetic epidemiology | #616 |
memory deficits | #616 |
prevalence severity | #616 |
genome scans | #617 |
tscores | #617 |
differ | #618 |
genetic associations | #618 |
val158met | #618 |
african children | #618 |
correcting | #619 |
digeorge | #619 |
genetic markers | #620 |
vigilance | #620 |
antisocial behaviour | #621 |
md | #621 |
confer | #622 |
adverse health outcomes | #623 |
receptor serotonin | #624 |
juvenile delinquency | #624 |
executive control | #625 |
executive dysfunction | #625 |
misconceptions | #625 |
mood stabilizers | #626 |
seeks | #627 |
attentional deficits | #627 |
hrr | #627 |
treatment disorder | #629 |
child gender | #629 |
fibromyalgia | #629 |
schizophrenia findings | #630 |
deficits schizophrenia | #631 |
reject | #631 |
teacher ratings | #632 |
needed | #633 |
girls boys | #634 |
genetic basis | #635 |
tiny | #637 |
generalisability | #638 |
obsessivecompulsive disorder | #638 |
icv | #638 |
disease genotype humans | #639 |
longitudinal | #640 |
advertisement | #641 |
adult outcomes | #641 |
ranks | #641 |
illness duration | #642 |
gateway | #643 |
inconsistent | #643 |
expression genes | #644 |
premorbid | #645 |
twin pairs | #645 |
subjects schizophrenia | #646 |
functioning autism | #646 |
exacerbate | #647 |
methodological | #648 |
17 years | #649 |
galantamine | #650 |
treatment effects | #652 |
gene association | #652 |
avoidant | #652 |
hyperactivity inattention | #653 |
physical conditions | #653 |
128 | #653 |
federation | #654 |
stroop | #654 |
intergenerational transmission | #655 |
bipolar disorder schizophrenia | #656 |
random allocation rats | #656 |
reward anticipation | #656 |
studies evidence | #657 |
impairment | #658 |
psychosocial treatment | #658 |
groups compared | #658 |
boldness | #658 |
volumes | #659 |
hypomanic | #659 |
association exposure | #660 |
poorer performance | #661 |
core feature | #661 |
peer relations | #662 |
structural alterations | #662 |
referrals | #662 |
lowlevel | #665 |
permission | #665 |
digeorge syndrome | #665 |
dacc | #666 |
subcortical | #666 |
psychiatric illnesses | #667 |
mood | #668 |
prominent | #669 |
swedish population | #669 |
phenotypic expression | #672 |
neurobiological | #675 |
time children | #676 |
impulsive behaviors | #677 |
disorders memory | #678 |
unselected | #678 |
129 | #679 |
sleep difficulties | #679 |
psychopathological symptoms | #680 |
middle childhood | #680 |
mental disorders humans | #680 |
gene frequency | #681 |
neurotic | #681 |
soviet union | #682 |
trait | #682 |
quetiapine | #682 |
semantic fluency | #682 |
severe phenotype | #683 |
scales | #685 |
east asian | #685 |
remitting | #685 |
p0019 | #687 |
chromosomal region | #688 |
children groups | #688 |
17q | #688 |
younger children | #689 |
fibromyalgia patients | #689 |
postmortem brains | #689 |
average age | #694 |
disorder schizophrenia | #694 |
tcas | #694 |
testretest reliability | #695 |
cortical surface area | #696 |
parcellation | #696 |
participants | #696 |
pharmacokinetic profile | #697 |
4–5 | #697 |
5years | #697 |
122 | #699 |
relevant studies | #699 |
drug abuse | #699 |
effects methylphenidate | #700 |
nonrandom | #701 |
adult mental | #701 |
quota | #701 |
illness surveys | #701 |
pleiotropic effects | #704 |
treatmentnaïve | #704 |
gwa studies | #704 |
follow studies | #705 |
adaptive functioning | #706 |
preschool years | #706 |
pathogenesis schizophrenia | #706 |
autism spectrum | #708 |
school settings | #709 |
p009 | #709 |
children diagnosed | #710 |
chronic schizophrenia | #713 |
informative | #713 |
maternal report | #714 |
dysphoric | #714 |
misuse | #714 |
eric | #714 |
prs | #714 |
disorders substance | #715 |
ethanol consumption | #715 |
stress disorder | #715 |
728 | #715 |
3 weeks | #716 |
641 | #716 |
contradictory | #717 |
abstraction | #719 |
groundwork | #719 |
meta‐analysis | #720 |
multiple genes | #721 |
clinical population | #721 |
household income | #722 |
recurrence risk | #722 |
memory | #723 |
cognitive load | #724 |
cinguli | #725 |
proponents | #725 |
common snps | #726 |
lateonset | #726 |
gender dysphoria | #726 |
male adolescents | #726 |
schizophrenics | #727 |
attention deficits | #727 |
statistical | #728 |
dizygotic | #728 |
assortative mating | #729 |
structured clinical interview | #729 |
fmri study | #730 |
786 | #730 |
metabotropic glutamate | #731 |
prevention programs | #732 |
correlates | #733 |
git | #733 |
voxel based | #733 |
phenotypic heterogeneity | #734 |
finding | #734 |
wky | #735 |
health intervention | #737 |
life cycle | #737 |
gyrification | #737 |
substancerelated disorders | #738 |
opioid dependence | #738 |
polygenic score | #739 |
inflation | #739 |
validating | #740 |
rapid cycling | #741 |
boston | #742 |
refill | #742 |
caudate | #742 |
time task | #743 |
comparators | #744 |
amphetamines | #744 |
topic twins | #745 |
soviet | #745 |
bupropion | #745 |
compulsive | #746 |
neuropsychological status | #746 |
manifested | #747 |
child interaction | #748 |
duplications | #748 |
adrb1 | #749 |
934 | #750 |
examining | #750 |
twins dizygotic | #752 |
fulfilling | #752 |
molecular genetic analysis | #754 |
347 | #754 |
post hoc | #755 |
comt val158met | #755 |
recalled | #756 |
mental disorders | #756 |
neuroleptics | #756 |
bipolar depression | #756 |
nhe | #757 |
schizophrenia scz | #757 |
disease haplotypes humans | #759 |
renewal | #760 |
sads | #761 |
variation genome | #762 |
artifact | #763 |
workday | #764 |
matter abnormalities | #764 |
humans logistic | #765 |
likelihoods | #765 |
autism asd | #766 |
people schizophrenia | #767 |
substance misuse | #768 |
disinhibition | #769 |
emerged | #772 |
comt polymorphism | #772 |
performance patients | #774 |
parent reported | #776 |
birth rates | #776 |
behavioral phenotypes | #777 |
depressive | #777 |
human pair | #777 |
phenotypes | #778 |
deletion polymorphism | #779 |
euthymic | #779 |
schizophrenia relationship | #780 |
weaknesses | #780 |
risky behavior | #780 |
inheritance | #781 |
wky rats | #782 |
iowa gambling task | #782 |
fourth edition | #783 |
questioning | #783 |
combined analysis | #783 |
emerging roles | #784 |
mega | #784 |
reformulation | #785 |
teaes | #785 |
faced | #786 |
pbd | #787 |
adolescence | #787 |
963 | #787 |
niacin | #788 |
child temperament | #789 |
medial temporal lobe | #790 |
spelling | #791 |
cgi | #791 |
behavioral | #791 |
subtypes | #792 |
individuals schizophrenia | #793 |
clinical criteria | #793 |
motivations | #794 |
symptom burden | #794 |
association polymorphisms | #794 |
delinquent | #796 |
caveats | #796 |
separate | #797 |
additional studies | #800 |
363 | #800 |
genomic regions | #802 |
dopamine d1 receptors | #803 |
prenatal exposure | #803 |
randomized clinical trials | #804 |
stimulant drugs | #804 |
dysfunction | #805 |
superior frontal | #805 |
clinically | #805 |
dorsolateral | #806 |
novelty seeking | #806 |
male memory | #806 |
latent classes | #806 |
developmental perspective | #807 |
lobule | #808 |
hdrs | #809 |
ucla | #810 |
dopamine function | #810 |
adjusting | #811 |
preschool female humans | #811 |
phonemic | #811 |
dopamine serotonin | #811 |
blind | #813 |
coadministration | #815 |
mhpg | #816 |
declarative | #816 |
tryptophan hydroxylase | #817 |
breakthroughs | #817 |
quantitative measures | #817 |
lasting | #817 |
cfb | #817 |
single gene | #818 |
substance dependence | #818 |
memory attention | #818 |
epigenetic factors | #818 |
meeting | #820 |
cortical development | #820 |
rated | #821 |
patients psychotic disorders | #821 |
counties | #821 |
hme | #822 |
switches | #822 |
parental report | #824 |
prefrontal regions | #824 |
transcriptomic analysis | #824 |
rare coding variants | #825 |
common genetic | #825 |
humans models | #827 |
adolescents asd | #827 |
s100a6 | #828 |
treatment interventions | #829 |
multipoint | #830 |
timeframe | #830 |
prevalent | #831 |
multiple testing | #831 |
lifetime prevalence | #831 |
association tests | #832 |
conduct disorders | #832 |
liabilities | #833 |
college students | #834 |
n60 | #837 |
sleep disorder | #837 |
gray | #837 |
inbred shr rats | #838 |
matter humans | #838 |
aversion | #838 |
obstetric complications | #839 |
prescription | #839 |
symptom profiles | #839 |
neurocognition | #841 |
parenthood | #842 |
participants completed | #843 |
sporadic cases | #843 |
biological basis | #844 |
consensus statement | #844 |
facial emotion recognition | #845 |
n35 | #846 |
dnm | #847 |
exception | #847 |
gwas summary | #848 |
dysregulated | #848 |
dgcr8 | #848 |
factor model | #851 |
prefrontal | #855 |
putative | #857 |
nonsignificant | #857 |
estimated prevalence | #858 |
putamen | #858 |
schizophrenia healthy | #858 |
heightened risk | #858 |
6p | #859 |
nineteen | #859 |
preschool | #861 |
handbook | #862 |
heterogeneity | #863 |
delayed effects | #865 |
global assessment | #866 |
glossary | #866 |
seventy | #866 |
crosssectional studies | #867 |
nnt | #869 |
mental | #869 |
hypothesized | #869 |
neurobiological basis | #870 |
specialized | #872 |
753 | #873 |
perseverative errors | #874 |
shr rats | #874 |
pediatric | #874 |
comorbidity depression | #875 |
existing evidence | #875 |
hypotheses | #876 |
positive symptoms | #876 |
genetic counseling | #876 |
manova | #876 |
test performance | #877 |
externalizing disorders | #879 |
gender differences | #879 |
sizes | #881 |
memory functions | #882 |
association genetic | #883 |
altered | #884 |
12p | #886 |
psychedelics | #886 |
171 | #887 |
dynamism | #888 |
delayed | #890 |
cpts | #891 |
obsessive | #893 |
n95 | #893 |
n17 | #893 |
decade | #894 |
bonn | #894 |
veterans affairs | #895 |
480 | #897 |
164 | #898 |
cortical thinning | #902 |
anterior cingulate | #903 |
biological psychiatry | #903 |
aptitude | #904 |
weight body | #904 |
genetic contribution | #904 |
reinforcer | #904 |
bipolar illness | #904 |
sibling | #904 |
visit | #905 |
late childhood | #906 |
826 | #906 |
psychosocial functioning | #906 |
adult aggression | #907 |
standardized difference | #909 |
morphometric | #910 |
ggc | #911 |
symptom control | #911 |
amygdala reactivity | #912 |
psychosocial | #912 |
pedigrees | #912 |
complications pregnancy | #913 |
visuospatial memory | #913 |
underlying pathophysiology | #914 |
versions | #914 |
association age | #916 |
disorder specific | #917 |
school performance | #917 |
cousins | #918 |
sleep children | #920 |
177 | #923 |
screening tool | #924 |
pharmacogenetic | #924 |
vulnerability | #925 |
dysthymic | #925 |
wide | #926 |
developmental trajectories | #927 |
dividing | #927 |
affective disorder | #928 |
participating | #930 |
cpg sites | #930 |
nucleotide | #930 |
permutation | #933 |
194 | #933 |
heroin addiction | #933 |
20mg | #934 |
d5 | #935 |
adolescence young adulthood | #935 |
smoking risk | #936 |
environment interactions | #936 |
3040 | #937 |
study designs | #938 |
female genotype | #938 |
diagnostic | #938 |
robustly | #940 |
irrs | #940 |
severe form | #941 |
critics | #941 |
tdt | #943 |
brain regions | #946 |
gwas | #946 |
sles | #948 |
22q | #948 |
risk developing | #949 |
albeit | #950 |
fetal exposure | #950 |
subtest | #952 |
amphetamine | #954 |
personality disorder | #954 |
relapsers | #954 |
behavioral treatment | #955 |
prompted | #956 |
effects sex | #956 |
112 | #959 |
qam | #960 |
clinical disorders | #960 |
cytoarchitecture | #962 |
female frontal | #963 |
clinical assessment | #963 |
children epilepsy | #963 |
dopamine uptake | #965 |
tandem repeat | #965 |
cgis | #965 |
scores | #965 |
scarce | #966 |
body height | #966 |
heritability estimates | #967 |
cuneus | #968 |
splicing factor | #968 |
freesurfer | #969 |
examined | #970 |
mtbi | #970 |
schizophrenia association | #970 |
pharmacological treatment | #970 |
medication treatment | #971 |
risky sexual behavior | #972 |
aggression | #972 |
262 | #973 |
chromosome mapping | #974 |
diva | #975 |
autism spectrum disorder | #976 |
fluphenazine | #977 |
resolve | #978 |
vmat2 | #978 |
psychosis risk | #978 |
neurodevelopmental disorder | #980 |
2–4 | #980 |
pertaining | #982 |
459 | #982 |
educational | #982 |
seriousness | #985 |
alleles | #986 |
symptoms age | #986 |
logistic regression models | #986 |
patients sle | #987 |
difficulties | #988 |
tci | #990 |
ranked | #990 |
small proportion | #990 |
depressed mothers | #991 |
polymorphism genetic | #994 |
pathway analysis | #995 |
temporal stability | #996 |
colleagues | #996 |
internal consistency | #997 |
comorbid conditions | #998 |
keystone | #999 |
diathesis | #999 |
detoxification | #999 |
adolescent analysis | #1000 |
child child | #1001 |
stata | #1003 |
interviews | #1003 |
comparative efficacy | #1004 |
haplotypes | #1006 |
long‐term outcome | #1007 |
allele | #1007 |
daughter | #1007 |
preschool cohort | #1007 |
confounding factors | #1007 |
0016 | #1007 |
structural mri | #1008 |
norms | #1008 |
qualifications | #1009 |
risk alcohol | #1009 |
posttraumatic stress disorder | #1009 |
multiplex | #1009 |
discriminant | #1010 |
genes environment | #1012 |
7 years | #1014 |
ltc | #1014 |
maturational | #1020 |
metabotropic | #1020 |
conclusive | #1021 |
relates | #1024 |
risk prediction | #1024 |
insufficient | #1026 |
004 | #1027 |
pharmacotherapies | #1027 |
persistent | #1028 |
obsessive – | #1028 |
pharmacologic | #1029 |
weiss | #1030 |
wwwclinicaltrialsgov | #1031 |
frontostriatal | #1031 |
analytic | #1031 |
symptoms child | #1032 |
patients panic disorder | #1032 |
preface | #1034 |
– compulsive | #1034 |
predicted | #1034 |
73 | #1034 |
brain disorders | #1035 |
rodent models | #1035 |
negative symptoms | #1035 |
total score | #1035 |
eventual | #1037 |
exploratory analyses | #1037 |
major depressive episode | #1039 |
general framework | #1040 |
serotonin | #1041 |
general intelligence | #1041 |
twin | #1043 |
gaf | #1044 |
mental health treatment | #1044 |
relate | #1045 |
heightened | #1045 |
antecedents | #1046 |
inv | #1046 |
ffi | #1050 |
late gestation | #1051 |
subtle | #1052 |
onset schizophrenia | #1052 |
benzodiazepines | #1053 |
disorders post | #1054 |
school age | #1055 |
psychiatric morbidity | #1056 |
vice | #1056 |
nogo | #1058 |
major humans | #1058 |
obscure | #1060 |
youth report | #1060 |
adolescence adulthood | #1061 |
bipolar disorders | #1062 |
genes involved | #1063 |
illicit | #1063 |
199 | #1063 |
memory disorders | #1064 |
europe female | #1065 |
paediatric patients | #1065 |
awakenings | #1068 |
heritability | #1068 |
pooled | #1068 |
childhood trauma | #1068 |
paranoia | #1068 |
memantine | #1069 |
emotional | #1069 |
negative impact | #1069 |
human genetics | #1070 |
memory impairments | #1070 |
word reading | #1070 |
single nucleotide receptors | #1071 |
risk scores | #1071 |
reading ability | #1071 |
genetic model | #1071 |
social problems | #1071 |
controlled clinical | #1071 |
character inventory | #1072 |
4q | #1072 |
validity | #1073 |
associations | #1073 |
obesity risk | #1074 |
3′utr | #1075 |
studying | #1075 |
general hospital | #1076 |
mapping chromosomes | #1077 |
schizophrenia spectrum disorders | #1078 |
transdiagnostic | #1080 |
exposure delayed | #1080 |
schizophrenia social | #1082 |
adult antipsychotic | #1082 |
anxiety children | #1083 |
contiguous | #1084 |
psds | #1086 |
onset psychosis | #1086 |
autoreceptors | #1086 |
european continental | #1088 |
alcohol marijuana | #1089 |
subtype | #1090 |
distinctive | #1090 |
polygenic scores | #1092 |
development disorders | #1092 |
obsessivecompulsive disorder ocd | #1093 |
gifted | #1094 |
irritable | #1096 |
semistructured interview | #1096 |
scientific literature | #1096 |
smoking | #1099 |
metaanalysis | #1102 |
future work | #1103 |
external validity | #1103 |
daughters | #1103 |
cnvs | #1104 |
odds | #1106 |
10 weeks | #1107 |
psychosis | #1107 |
diagnostic groups | #1107 |
bip | #1108 |
emotional behavioral | #1108 |
prioritized | #1110 |
psychoses | #1110 |
experimental test | #1110 |
10−5 | #1111 |
share | #1111 |
male children | #1112 |
depressive disorder | #1113 |
new developments | #1114 |
effects children | #1116 |
discusses | #1117 |
schizophrenia subjects | #1119 |
psychotropic | #1121 |
children anxiety | #1122 |
exchangers | #1123 |
632 | #1123 |
556 | #1124 |
mts | #1125 |
coexisting | #1125 |
projects | #1127 |
similarities | #1128 |
enriched | #1128 |
quantifies | #1128 |
dysthymic disorder | #1128 |
investigator | #1129 |
weighting | #1130 |
adult alcoholism | #1130 |
n28 | #1134 |
attention performance | #1134 |
psychiatric diagnosis | #1135 |
independent sample | #1136 |
birth outcomes | #1136 |
blood pressure response | #1138 |
laterality humans | #1138 |
susceptibility loci | #1139 |
clinical samples | #1142 |
social phobia | #1142 |
signal task | #1144 |
early adolescent | #1145 |
prodromal | #1145 |
cognitive domains | #1145 |
demographic factors | #1146 |
emotionality | #1147 |
measurement invariance | #1147 |
normal volunteers | #1147 |
refine | #1149 |
children association | #1150 |
discriminability | #1150 |
discounting | #1150 |
humans intellectual | #1150 |
developmental model | #1152 |
quick | #1152 |
continents | #1152 |
generalizability | #1153 |
normals | #1153 |
refinements | #1153 |
sensory gating | #1154 |
alspac | #1154 |
clinical profiles | #1154 |
differential humans | #1160 |
ht2c | #1160 |
uncorrected | #1160 |
phenotype | #1161 |
” “ | #1163 |
review findings | #1163 |
studies data | #1164 |
phobia | #1164 |
neurocognitive function | #1165 |
deteriorated | #1166 |
clinical groups | #1166 |
affective | #1166 |
congress | #1167 |
catecholaminergic | #1168 |
medication status | #1169 |
social outcomes | #1170 |
292 | #1171 |
quality measures | #1174 |
mspi | #1175 |
cohen | #1176 |
gwas data | #1176 |
bpd patients | #1176 |
genetic risk factors | #1177 |
nicotine exposure | #1177 |
clinical validation | #1178 |
male subjects | #1178 |
study gwas | #1179 |
childhood exposure | #1182 |
reward | #1182 |
cinguli humans | #1182 |
persisting | #1182 |
nonverbal | #1183 |
addressing | #1184 |
paradox | #1184 |
triads | #1184 |
standardized | #1187 |
functional polymorphisms | #1188 |
dysbindin | #1189 |
hydrochloride | #1189 |
64 | #1190 |
child preschool | #1192 |
psychology | #1193 |
assess | #1194 |
parenting behavior | #1197 |
onequarter | #1198 |
compulsivity | #1198 |
addictions | #1198 |
placebo | #1199 |
wm | #1199 |
asian continental | #1200 |
230 | #1200 |
wisconsin | #1201 |
morbidity | #1202 |
sib | #1204 |
systematic search | #1204 |
millennium | #1207 |
externalizing symptoms | #1209 |
problems children | #1209 |
nationwide cohort study | #1209 |
neuropsychology | #1210 |
conceptualizations | #1210 |
p004 | #1211 |
term treatment | #1215 |
sample sizes | #1218 |
male mass | #1219 |
lbw | #1220 |
underlying | #1220 |
antecedent | #1221 |
child cognitive | #1222 |
prospects | #1222 |
study role | #1224 |
profile | #1226 |
partly | #1227 |
approximated | #1227 |
0011 | #1229 |
molecular alterations | #1232 |
refining | #1232 |
subgroup | #1232 |
poster | #1233 |
health organization | #1234 |
pregnancy prenatal | #1234 |
gprotein | #1235 |
children ages | #1235 |
shortcomings | #1237 |
educational attainment | #1239 |
tandem repeats | #1242 |
brain structure | #1242 |
interpersonal relations | #1244 |
short form | #1245 |
avenues | #1247 |
kf | #1247 |
risk asthma | #1247 |
enjoyment | #1247 |
cidi | #1248 |
psychosocial outcomes | #1248 |
cpg islands | #1249 |
roc | #1251 |
delineate | #1251 |
debilitating | #1252 |
alcohol disorders | #1255 |
serotonin transporter | #1256 |
summarize | #1256 |
risk ratio | #1256 |
nervous | #1257 |
dysfunctions | #1257 |
goal | #1257 |
onset depression | #1259 |
combine | #1260 |
consensus statements | #1263 |
characterize | #1266 |
onset age | #1267 |
likewise | #1270 |
logistic regression analyses | #1271 |
child mental | #1273 |
statistical methods | #1274 |
entire | #1277 |
developmental pathways | #1277 |
386 | #1277 |
n24 | #1278 |
study evidence | #1281 |
04 | #1281 |
priori | #1282 |
paternal | #1282 |
hopes | #1283 |
neuroimaging | #1283 |
increased rates | #1283 |
behavior adolescent | #1283 |
variance | #1284 |
spontaneously hypertensive | #1285 |
general cognitive | #1286 |
087 | #1286 |
male nerve | #1288 |
somatic complaints | #1288 |
orbitofrontal | #1288 |
aspect | #1289 |
warmth | #1289 |
unmyelinated | #1291 |
dual psychiatry | #1291 |
posttraumatic | #1291 |
1hmrs | #1291 |
misclassification | #1292 |
clomipramine | #1292 |
quantitative trait | #1292 |
animal conditioning | #1292 |
negative emotion | #1295 |
pvalue | #1297 |
136 | #1297 |
chromosomes | #1298 |
cures | #1301 |
atx | #1303 |
935 | #1305 |
1520 | #1305 |
cortical volume | #1306 |
sgas | #1309 |
prediction accuracy | #1309 |
extant | #1310 |
vin | #1310 |
risperidone | #1311 |
arrests | #1312 |
motor speed | #1313 |
factor analyses | #1313 |
criteria | #1314 |
76 | #1315 |
factors smoking | #1316 |
minds | #1317 |
class analysis | #1317 |
adolescents children | #1318 |
current findings | #1320 |
hypothetical | #1321 |
predictability | #1322 |
parents adolescents | #1323 |
short | #1323 |
polymorphism | #1324 |
hypothesis | #1325 |
response treatment | #1327 |
influencing | #1330 |
confusion | #1330 |
defining | #1331 |
polysubstance | #1334 |
measures | #1334 |
253 | #1335 |
psychopharmacology | #1335 |
authors | #1336 |
genetic background | #1336 |
nonuse | #1337 |
fronto | #1338 |
obsessive–compulsive disorder | #1338 |
longterm outcome | #1342 |
clinical phenotypes | #1342 |
registry data | #1344 |
542 | #1344 |
llysine | #1345 |
explaining | #1345 |
interpretation statistical | #1349 |
compared children | #1353 |
early adulthood | #1353 |
psychoticism | #1355 |
cocaine abuse | #1356 |
loci genetic | #1356 |
diagnostic tool | #1356 |
flush | #1357 |
simon | #1357 |
variabilities | #1357 |
seekers | #1358 |
gene discovery | #1359 |
antidepressive | #1359 |
broad spectrum | #1361 |
mammalian target | #1362 |
middle frontal gyrus | #1362 |
intergenerational | #1365 |
abcd | #1367 |
neuronal development | #1369 |
school teachers | #1369 |
unexplored | #1369 |
uptake inhibitors | #1369 |
reliance | #1370 |
intellectual functioning | #1371 |
observer variation | #1374 |
covert | #1377 |
larger | #1378 |
pallidum | #1380 |
inositol | #1382 |
ghr | #1385 |
highlighted | #1386 |
thought disorder | #1386 |
new onset | #1386 |
dimensional approach | #1389 |
treatment depression | #1391 |
familial aggregation | #1391 |
prodrome | #1391 |
6 years | #1391 |
illicit drugs | #1393 |
vendors | #1394 |
thalamic | #1395 |
rats shr | #1395 |
manuscripts | #1395 |
satisfying | #1395 |
racial | #1398 |
timely | #1399 |
emotional stimuli | #1399 |
suggesting | #1400 |
lability | #1400 |
17 | #1402 |
sufficient | #1403 |
blinded | #1403 |
brain region | #1404 |
hippocampal volumes | #1405 |
placebo treatment | #1407 |
hama | #1408 |
create | #1409 |
preparations | #1410 |
personality inventory | #1412 |
1998 | #1413 |
shyness | #1414 |
issue | #1414 |
independent | #1415 |
prepubertal children | #1416 |
impressions | #1416 |
332 | #1417 |
logical | #1419 |
carry | #1419 |
humans memory | #1421 |
discoveries | #1422 |
parents children | #1422 |
exploratory factor analysis | #1423 |
greater | #1426 |
dosed | #1427 |
linkage disequilibrium | #1430 |
taps | #1431 |
163 | #1431 |
interaction effects | #1432 |
cognitive profiles | #1432 |
affairs | #1434 |
social perception | #1436 |
publication adult analysis | #1438 |
bche | #1439 |
academic | #1443 |
holidays | #1444 |
personality | #1447 |
psychotic illness | #1448 |
443 | #1448 |
chp | #1449 |
hydroxylase | #1450 |
prevalence obesity | #1450 |
ratings | #1451 |
square | #1453 |
height | #1453 |
78 | #1453 |
ewas | #1453 |
hypermethylation | #1454 |
population stratification | #1454 |
switching | #1455 |
collaborations | #1457 |
dorsal striatum | #1457 |
replicability | #1457 |
generalized anxiety | #1458 |
comparisons | #1459 |
severe depression | #1462 |
stronger | #1463 |
biological pathways | #1463 |
treatment duration | #1464 |
principal | #1467 |
discordant | #1467 |
valuable | #1468 |
untranslated | #1468 |
partial remission | #1468 |
hippocampi | #1469 |
groups differences | #1469 |
contrast effects | #1472 |
cognition patients | #1474 |
openlabel | #1474 |
statistically | #1474 |
amygdala volume | #1477 |
risk relapse | #1479 |
conducted | #1480 |
medication | #1481 |
cortex dlpfc | #1487 |
prodromal symptoms | #1488 |
issues | #1489 |
apt | #1492 |
adrb2 | #1493 |
hypomethylation | #1495 |
mri studies | #1497 |
allele carriers | #1497 |
smaller | #1497 |
lifespan | #1499 |
twins monozygotic | #1499 |
small sample sizes | #1499 |
converge | #1500 |
populationbased study | #1501 |
patients bipolar | #1502 |
cpt | #1503 |
ddc | #1505 |
multisite | #1505 |
male mothers | #1505 |
examination | #1508 |
manifestation | #1510 |
salience network | #1510 |
existing literature | #1511 |
objectivity | #1511 |
emotions female | #1513 |
attained | #1513 |
reports | #1513 |
messaging | #1514 |
cognitive ability | #1515 |
pedigree | #1516 |
screening instrument | #1517 |
eicosapentaenoic acid | #1517 |
repeat | #1518 |
criminal behavior | #1519 |
165 | #1521 |
topic | #1523 |
114 | #1523 |
cna | #1523 |
bipolar patients | #1526 |
inconsistency | #1526 |
inferior frontal | #1528 |
nacetylaspartate | #1528 |
psychiatric disorder | #1528 |
symptomatology | #1530 |
512 | #1535 |
began | #1536 |
arntl | #1540 |
default | #1541 |
nucleotide risk | #1541 |
dopamine receptor | #1542 |
poses | #1542 |
adult life | #1542 |
stress disorders | #1543 |
gwass | #1544 |
treatment schizophrenia | #1545 |
yale | #1545 |
omission | #1547 |
traits | #1549 |
card | #1551 |
problem behaviors | #1554 |
influenced | #1554 |
automobile | #1556 |
857 | #1556 |
early exposure | #1559 |
failed | #1559 |
loci | #1560 |
0009 | #1561 |
0013 | #1564 |
475 | #1565 |
subscales | #1565 |
insular | #1565 |
interpersonal | #1566 |
humans interpersonal | #1569 |
wise | #1570 |
swedish | #1573 |
191 | #1573 |
consortium | #1573 |
depression children | #1574 |
neurochemistry | #1575 |
attempted | #1576 |
meta | #1579 |
life quality | #1579 |
selfreport questionnaires | #1580 |
gene networks | #1580 |
single nucleotide polymorphism | #1582 |
findings studies | #1582 |
located | #1582 |
cutoffs | #1583 |
network dmn | #1583 |
models male | #1583 |
social functioning | #1584 |
hyperactivation | #1587 |
major depressive | #1588 |
rs4680 | #1588 |
firstepisode schizophrenia | #1588 |
pain patients | #1589 |
genetic data | #1589 |
edinburgh | #1590 |
advent | #1591 |
55 | #1592 |
phobias | #1593 |
temperament | #1594 |
subcortical structures | #1596 |
162 | #1596 |
symptom presentation | #1598 |
tpv | #1599 |
moderators | #1599 |
statistics nonparametric | #1601 |
psychotropic medications | #1601 |
jan | #1602 |
managed | #1603 |
utr | #1604 |
suffer | #1604 |
spontaneously | #1605 |
heritabilities | #1606 |
classifying | #1608 |
academic achievement | #1609 |
1979 | #1610 |
proneness | #1610 |
monoamine oxidase | #1611 |
emotional faces | #1613 |
alcoholism | #1613 |
status | #1614 |
ancestry female | #1615 |
male maternal | #1616 |
drawn | #1619 |
broadly | #1620 |
risk mental | #1622 |
large body | #1622 |
distinguishing | #1622 |
hbr | #1624 |
childhood asthma | #1624 |
snp | #1626 |
paucity | #1626 |
ht2a receptor | #1627 |
spatial organization | #1627 |
louis | #1628 |
dysphoria | #1628 |
genomics humans | #1629 |
verbal behavior | #1629 |
study children | #1630 |
kyoto | #1630 |
ambiguous | #1631 |
emrs | #1631 |
memory task | #1631 |
198 | #1633 |
susceptibility gene | #1634 |
supporting | #1635 |
mental illnesses | #1637 |
positive predictive | #1638 |
lag | #1639 |
brain female | #1640 |
rack1 | #1643 |
alpha7 | #1643 |
social communication | #1643 |
tendency | #1643 |
bprs | #1644 |
potential effects | #1646 |
socially | #1647 |
interrelations | #1649 |
treating | #1650 |
rea | #1653 |
controlled | #1653 |
nucleotide polymorphisms | #1655 |
adolescents age | #1657 |
detect | #1658 |
maximize | #1658 |
require | #1659 |
psychotic disorder | #1659 |
personality disorders | #1661 |
symptom severity | #1662 |
presentations | #1663 |
comorbid depression | #1663 |
asm | #1664 |
510 | #1665 |
chronic patients | #1666 |
mood symptoms | #1666 |
dlpfc | #1666 |
association analysis | #1667 |
indexed | #1670 |
human rights | #1670 |
bipolar disorder patients | #1671 |
13 years | #1672 |
transmitted | #1673 |
asd symptoms | #1674 |
early signs | #1675 |
alcohol spectrum | #1675 |
statements | #1675 |
53 | #1677 |
introns | #1678 |
registers | #1678 |
calling | #1678 |
social anxiety | #1679 |
homogeneous | #1679 |
beagle | #1680 |
seat | #1680 |
mathematical models | #1682 |
prescribed | #1684 |
mildly | #1684 |
46 | #1684 |
ancestries | #1685 |
memory deficit | #1685 |
mdd | #1689 |
autistic disorder | #1689 |
github | #1689 |
psychotropic drugs | #1692 |
agenda | #1692 |
impulse control | #1693 |
motor skills | #1698 |
recruited | #1698 |
diagnose | #1699 |
91 | #1702 |
memory consolidation | #1704 |
item | #1704 |
conceptualization | #1705 |
middle frontal | #1710 |
reduced activation | #1711 |
personality characteristics | #1712 |
health records | #1712 |
neuroscience | #1712 |
rater | #1712 |
schizophrenia spectrum | #1713 |
net | #1716 |
perpetrators | #1725 |
nhe1 | #1728 |
autistic | #1729 |
epigenetics | #1730 |
inhibitory control | #1731 |
107 | #1731 |
cbs | #1732 |
hindered | #1733 |
highlight | #1735 |
machine | #1735 |
stand | #1736 |
identical | #1736 |
predictors | #1739 |
aimed | #1739 |
dopamine receptors | #1741 |
sex age | #1743 |
forum | #1746 |
curated | #1746 |
longitudinal analysis | #1747 |
cognitive difficulties | #1748 |
pds | #1749 |
occipital lobe | #1750 |
tremors | #1752 |
02 | #1753 |
selfreport measures | #1753 |
questionnaires young | #1755 |
sertraline | #1756 |
326 | #1756 |
5ht2a | #1758 |
120 | #1758 |
ventral striatum | #1761 |
genetic models | #1761 |
social | #1761 |
bipolar affective | #1763 |
drowsiness | #1763 |
chance | #1765 |
includes | #1765 |
adult onset | #1766 |
mystery | #1768 |
operant | #1768 |
reflects | #1769 |
sisters | #1770 |
dopamine | #1772 |
dizygotic twins | #1773 |
treatment implications | #1773 |
depressive episode | #1775 |
patients systemic | #1775 |
patients adult | #1776 |
267 | #1776 |
establishing | #1777 |
mental recall | #1777 |
utrs | #1779 |
10−7 | #1780 |
early childhood | #1781 |
higher doses | #1786 |
commonalities | #1786 |
major | #1786 |
social anxiety disorder | #1787 |
defined | #1789 |
frustration | #1791 |
male motor | #1791 |
transdermal | #1793 |
disorder mdd | #1795 |
harbor | #1796 |
causal variants | #1797 |
disabilities | #1797 |
positive association | #1797 |
autism spectrum disorders | #1800 |
reporters | #1801 |
aged models | #1801 |
members | #1801 |
genetic variance | #1802 |
chapters | #1803 |
shr | #1804 |
females | #1805 |
families children | #1806 |
covariation | #1807 |
based analysis | #1807 |
168 | #1809 |
expanded | #1812 |
nucleotide polymorphism | #1812 |
aetiology | #1813 |
european descent | #1813 |
146 | #1813 |
frequently | #1815 |
internationality | #1815 |
purchases | #1816 |
brain imaging | #1816 |
lds | #1819 |
cohens | #1819 |
hippocampal volume | #1819 |
correlate | #1823 |
suicide attempt | #1825 |
endpoint | #1827 |
followup | #1830 |
splenium | #1831 |
foundation | #1833 |
binocular | #1833 |
psychotic patients | #1837 |
suggested | #1838 |
94 | #1840 |
neural activity | #1841 |
patterns | #1841 |
trauma exposure | #1842 |
assessment tools | #1842 |
twins | #1845 |
distinctions | #1845 |
initiative | #1845 |
literacy | #1846 |
psychological | #1847 |
pertinent | #1847 |
environmental risk | #1848 |
warrant | #1848 |
polymorphisms | #1849 |
limited | #1850 |
fearful | #1851 |
individual | #1851 |
vocabulary | #1851 |
nonparametric | #1852 |
brainderived neurotrophic factor | #1853 |
differentiating | #1853 |
young | #1853 |
persons | #1855 |
auditory hallucinations | #1856 |
abuse | #1856 |
tph | #1859 |
prevalence | #1859 |
behavioral measures | #1860 |
incentives | #1860 |
affiliation | #1861 |
cnb | #1861 |
8p | #1862 |
obstacle | #1864 |
vocalization | #1865 |
multilevel | #1865 |
poison | #1865 |
switch | #1865 |
severely | #1867 |
18 | #1869 |
structural functional | #1875 |
constitute | #1876 |
manuscript | #1877 |
roc curve | #1879 |
histograms | #1879 |
animal model | #1880 |
shrs | #1880 |
delusions | #1881 |
afb | #1882 |
longer duration | #1882 |
common genetic variation | #1883 |
genome | #1885 |
differs | #1888 |
false | #1888 |
substance abuse | #1890 |
metaanalysis studies | #1890 |
heterogeneous | #1894 |
spanning | #1894 |
susceptibility genes | #1896 |
maintained | #1899 |
latent class analysis | #1899 |
correspondences | #1901 |
psychostimulant | #1902 |
chinese | #1903 |
analyses | #1903 |
illicit drug | #1904 |
actigraphy | #1905 |
increasingly | #1907 |
specific symptoms | #1907 |
emotion | #1908 |
majority | #1909 |
epidemiologic | #1909 |
ads | #1910 |
support vector machine | #1911 |
disorders mental | #1911 |
structural differences | #1912 |
generation antipsychotics | #1913 |
africanamericans | #1915 |
χ2 | #1916 |
10h | #1920 |
inform | #1921 |
association maternal | #1923 |
satisfied | #1923 |
liking | #1923 |
aggregate | #1926 |
child cross | #1926 |
overview | #1927 |
251 | #1928 |
advertising | #1928 |
sleep problems | #1928 |
empirical studies | #1929 |
ssri | #1930 |
95 cis | #1934 |
asd children | #1934 |
borderline personality disorder | #1937 |
simulation study | #1937 |
exomes | #1938 |
stratified | #1939 |
general | #1942 |
25 years | #1945 |
literature review | #1947 |
neurobehavioral | #1949 |
representing | #1950 |
traumatic brain injury | #1950 |
trait loci | #1952 |
accumbens | #1953 |
normal children | #1954 |
efficacious | #1957 |
msp | #1958 |
neurotransmitter release | #1959 |
mems | #1961 |
intolerant | #1962 |
micronesia | #1963 |
896 | #1964 |
sdq | #1967 |
brain networks | #1968 |
vital signs | #1969 |
sorting | #1971 |
clinical implications | #1972 |
depression | #1972 |
correctly | #1972 |
connectivity | #1974 |
hoc | #1975 |
factors surveys | #1976 |
child depression | #1977 |
repeats | #1977 |
conflicting | #1978 |
listing | #1978 |
ptsd | #1981 |
hippocampus humans | #1981 |
common mental disorders | #1984 |
chinese population | #1984 |
pax5 | #1986 |
phase 3 trial | #1986 |
secondary analysis | #1987 |
brain | #1989 |
school | #1990 |
predisposing | #1991 |
current paper | #1994 |
genetic differences | #1996 |
226 | #1997 |
fmr | #1998 |
pattern | #1999 |
diagnosed | #2001 |
comparable | #2002 |
spouses | #2003 |
formulations | #2005 |
asian continental ancestry | #2005 |
harm avoidance | #2007 |
functional variants | #2010 |
behavioral symptoms | #2011 |
nos1 | #2012 |
akt1 | #2014 |
muscle function | #2014 |
absence | #2014 |
sms | #2015 |
noradrenergic | #2015 |
possibility | #2016 |
cognitive deficits | #2016 |
prescribers | #2021 |
schoolage children | #2023 |
159 | #2023 |
serve | #2026 |
sleep disturbances | #2030 |
phenomenology | #2030 |
brain responses | #2031 |
memory verbal | #2031 |
regional brain | #2032 |
neurodevelopmental disorders | #2033 |
morbid | #2036 |
prenatally | #2037 |
receptors nicotinic | #2037 |
diminished | #2040 |
retest reliability | #2040 |
asperger | #2041 |
erythematosus systemic | #2041 |
nicotinic acetylcholine | #2045 |
cognitive processing | #2046 |
227 | #2046 |
informants | #2048 |
erythematosus | #2049 |
functional | #2050 |
cognition | #2050 |
juvenile | #2052 |
contribute | #2054 |
adolescent behavior | #2056 |
external control | #2057 |
chapman | #2058 |
common diseases | #2061 |
insula | #2061 |
educated | #2062 |
stabilizers | #2064 |
ongoing | #2065 |
overweight obesity | #2066 |
demography | #2066 |
val158met polymorphism | #2067 |
preschool humans | #2068 |
massachusetts | #2069 |
functional mri | #2069 |
0008 | #2071 |
phenotypic | #2072 |
parental education | #2072 |
psychotic symptoms | #2077 |
degree | #2078 |
international consensus | #2078 |
descent | #2079 |
wake disorders | #2079 |
heterogeneity studies | #2082 |
psychomotor | #2084 |
male gender | #2085 |
5 ht2a | #2087 |
latent class | #2090 |
43 | #2090 |
factors child | #2093 |
49 | #2095 |
aud | #2096 |
wky shr | #2096 |
subsets | #2099 |
dopaminergic | #2100 |
69 | #2100 |
142 | #2102 |
general factor | #2106 |
age children | #2107 |
adult population | #2108 |
ht2a | #2108 |
causation | #2109 |
nicotinic | #2112 |
child relations | #2112 |
specific genetic | #2112 |
279 | #2115 |
brain dysfunction | #2115 |
83 | #2117 |
relative age | #2119 |
monoamine | #2119 |
poorer | #2119 |
postpartum period | #2119 |
84 | #2121 |
51 | #2122 |
pgs | #2122 |
career | #2122 |
sixth | #2124 |
identifies | #2126 |
pbls | #2126 |
dysfunctional | #2128 |
biased | #2129 |
ovid | #2130 |
functional polymorphism | #2132 |
rates | #2134 |
episode schizophrenia | #2137 |
dbh | #2137 |
psychosocial factors | #2140 |
adversities | #2141 |
interpretability | #2141 |
discrepant | #2142 |
relevant literature | #2143 |
methods participants | #2145 |
pvs | #2145 |
behavioral disorders | #2146 |
intraclass | #2147 |
receptors adrenergic | #2147 |
105 | #2147 |
juveniles | #2148 |
abnormalities | #2149 |
232 | #2150 |
finemapping | #2150 |
glutamatergic | #2150 |
represents | #2150 |
assessing | #2151 |
repositioning | #2151 |
rrr | #2153 |
mao | #2153 |
psychiatric patients | #2155 |
differentiated | #2164 |
abdominal obesity | #2164 |
clinical assessments | #2166 |
shr wky | #2167 |
declarative memory | #2167 |
differing | #2168 |
differential diagnostic | #2168 |
genetic association studies | #2168 |
glx | #2169 |
major depressive disorder | #2170 |
adversely | #2171 |
prevalences | #2171 |
mb | #2171 |
severity | #2172 |
tardive dyskinesia | #2172 |
aggregated | #2177 |
irt | #2180 |
externalizing | #2181 |
moderating | #2181 |
environmental factors | #2183 |
author | #2185 |
report measures | #2186 |
teachers | #2187 |
thought | #2188 |
computerassisted imaging | #2188 |
processing speed | #2189 |
differential expression | #2189 |
generalized anxiety disorder | #2192 |
regular | #2192 |
scale | #2192 |
serotonin 5 | #2193 |
imaging fmri | #2195 |
lifecycle | #2197 |
conceptual | #2197 |
pharmacological agents | #2199 |
achievement | #2200 |
ages | #2201 |
confounding | #2201 |
double | #2205 |
brain mapping | #2206 |
developing brain | #2206 |
abstract background | #2207 |
remained | #2209 |
ottawa | #2209 |
169 | #2209 |
surveys questionnaires | #2210 |
homozygosity | #2210 |
accidents | #2210 |
illness severity | #2211 |
antenatal | #2211 |
genetic relationship | #2212 |
occurrences | #2217 |
adverse event | #2217 |
intronic | #2219 |
complex diseases | #2220 |
completed | #2220 |
hippocampal formation | #2220 |
biologically | #2220 |
autism | #2221 |
val66met | #2222 |
visuospatial | #2225 |
cognitive task | #2225 |
20th | #2226 |
replicating | #2227 |
single | #2228 |
caudate putamen | #2229 |
trail making | #2230 |
clinical profile | #2232 |
attainment | #2234 |
community sample | #2235 |
controls age | #2238 |
hexokinase | #2241 |
prototypical | #2241 |
implications | #2242 |
qualities | #2244 |
insensitivity | #2245 |
consultation | #2246 |
preliminary data | #2248 |
hamilton | #2253 |
val66met polymorphism | #2254 |
pubertal development | #2257 |
treatment guidelines | #2260 |
genomic analysis | #2260 |
novo mutations | #2263 |
cognitive deficit | #2263 |
earlier | #2264 |
cigarette | #2264 |
criterion | #2265 |
pathways | #2266 |
rewards | #2266 |
bds | #2266 |
clinical measures | #2267 |
evident | #2273 |
overdiagnosis | #2274 |
axis | #2275 |
gray matter volume | #2275 |
cognitive development | #2275 |
remain | #2275 |
tend | #2276 |
imaging male | #2277 |
mtl | #2277 |
random allocation | #2277 |
apneahypopnea | #2279 |
systemic lupus | #2279 |
lithium | #2283 |
moderation | #2283 |
psychiatric illness | #2285 |
cognitive | #2287 |
controlling | #2290 |
minority | #2292 |
update | #2293 |
physical health | #2294 |
regions | #2294 |
diverse populations | #2294 |
socialization | #2295 |
retained | #2297 |
monitored | #2298 |
11 years | #2299 |
corticotropin | #2301 |
biology | #2304 |
clinic | #2304 |
239 | #2304 |
adjunctive | #2306 |
virtue | #2307 |
consisting | #2308 |
lupus | #2310 |
difficult | #2310 |
enormous | #2311 |
brain anatomy | #2313 |
pregnancy | #2313 |
edition | #2315 |
behaviors | #2317 |
adequate | #2318 |
performance reaction | #2319 |
tests | #2321 |
brain systems | #2321 |
fmri | #2325 |
casecontrol study | #2326 |
memory performance | #2328 |
higher prevalence | #2330 |
257 | #2331 |
questionnaires | #2332 |
organ size | #2332 |
subset | #2333 |
mind | #2334 |
archives | #2335 |
disorganization | #2335 |
covariate | #2335 |
early risk | #2336 |
depression female | #2340 |
lesser extent | #2342 |
utility | #2342 |
nature | #2344 |
functional networks | #2344 |
20th century | #2345 |
cingulate | #2346 |
schedule | #2350 |
providing | #2353 |
time perception | #2353 |
mapping child | #2358 |
powered | #2362 |
adolescent brain | #2364 |
endosome | #2365 |
factor structure | #2367 |
concurrently | #2368 |
limited evidence | #2368 |
symptoms schizophrenia | #2369 |
smallest | #2369 |
efforts | #2376 |
social cognitive | #2377 |
catecholamine | #2379 |
antipsychotic agents | #2379 |
tapping | #2384 |
predicts | #2385 |
ecologically | #2386 |
gyrus | #2388 |
drugs abuse | #2391 |
unresolved | #2393 |
convergence | #2395 |
raising | #2395 |
problem solving | #2398 |
gray matter | #2401 |
essence | #2401 |
frontal | #2403 |
pubmed | #2406 |
addictive | #2407 |
sirolimus | #2407 |
adolescent alcohol | #2408 |
distinguished | #2410 |
validate | #2412 |
preserved | #2414 |
genetic factor | #2417 |
alternative | #2418 |
statistical significance | #2418 |
modules | #2419 |
illumina | #2422 |
starting | #2423 |
classified | #2425 |
disease genetic | #2426 |
salience | #2426 |
143 | #2428 |
bdnf | #2429 |
term outcome | #2429 |
confounders | #2431 |
fmri data | #2431 |
241 | #2433 |
protein interactions | #2433 |
clinical trial | #2433 |
protein interaction | #2436 |
analyzes | #2440 |
careful | #2443 |
intellectual | #2447 |
timepoints | #2448 |
dimorphism | #2448 |
items | #2449 |
multiple studies | #2450 |
deconvolution | #2452 |
mvr | #2452 |
prefrontal cortical | #2456 |
systemic lupus erythematosus | #2456 |
overweight children | #2456 |
moderately | #2458 |
myoinositol | #2459 |
genetic susceptibility | #2459 |
anxiety symptoms | #2460 |
brain maturation | #2460 |
logistic | #2461 |
concordance | #2461 |
traumatic stress | #2461 |
autosomes | #2462 |
crossover study | #2464 |
sex distribution | #2464 |
factor bdnf | #2466 |
hungary | #2469 |
unclear | #2473 |
unique | #2473 |
relatedness | #2482 |
brain activation | #2486 |
reaction time | #2488 |
prescriptions | #2489 |
higher scores | #2489 |
psychomotor performance | #2491 |
cerebrum | #2494 |
normative data | #2495 |
hoc analysis | #2496 |
180 | #2496 |
caucasian | #2497 |
israeli | #2500 |
workplace | #2502 |
original | #2504 |
establish | #2504 |
random forest | #2507 |
interactome | #2509 |
randomized placebo | #2511 |
preschool diagnosis | #2512 |
21st | #2512 |
heterosis | #2513 |
thresholds | #2515 |
quotient | #2515 |
preceded | #2516 |
tricyclic antidepressants | #2518 |
evaluate | #2521 |
perceptual | #2523 |
temporal gyrus | #2526 |
12 years | #2528 |
rel | #2531 |
october | #2532 |
alterations | #2532 |
preliminary report | #2533 |
indicators | #2534 |
thinner | #2539 |
limitations | #2541 |
categories | #2545 |
neurosecretory | #2546 |
medication adherence | #2548 |
animals anxiety | #2550 |
psychotic features | #2553 |
risky | #2553 |
depressive disorders | #2554 |
quantitative | #2555 |
neural responses | #2555 |
exploratory study | #2555 |
bipolar affective disorder | #2557 |
memory tasks | #2557 |
chronological | #2560 |
risk loci | #2560 |
income | #2560 |
assisted magnetic | #2561 |
060 | #2562 |
273 | #2563 |
447 | #2565 |
demographic characteristics | #2565 |
sensation seeking | #2569 |
174 | #2570 |
discontinued | #2571 |
document | #2572 |
numerous | #2573 |
30 years | #2573 |
19 years | #2574 |
cool | #2575 |
depressed | #2576 |
socioeconomic | #2579 |
osmosis | #2580 |
smoking alcohol | #2581 |
adolescent females | #2584 |
elucidate | #2585 |
correction | #2585 |
pvalues | #2586 |
brothers | #2586 |
problems | #2586 |
pituitary adrenal | #2587 |
baseline | #2591 |
post traumatic | #2594 |
disrupted | #2595 |
exist | #2595 |
229 | #2596 |
internalizing externalizing | #2598 |
brain response | #2598 |
temporal pole | #2600 |
encouraging | #2601 |
iowa | #2603 |
simplex | #2603 |
n10 | #2605 |
neo | #2606 |
percentile | #2607 |
literature | #2608 |
infrequent | #2610 |
increased activation | #2611 |
advances | #2611 |
occipital | #2612 |
draft | #2614 |
lateralization | #2616 |
surveys humans | #2619 |
pooling | #2620 |
genotype | #2623 |
evidence role | #2624 |
multiple levels | #2624 |
kynurenine | #2625 |
psycinfo | #2625 |
mothers | #2630 |
imaging studies | #2633 |
bdnf gene | #2633 |
preliminary | #2634 |
institute | #2636 |
odors | #2638 |
182 | #2639 |
fetal alcohol | #2642 |
global functioning | #2642 |
behavior | #2644 |
preschool female | #2644 |
genetic variants | #2644 |
medical conditions | #2645 |
inability | #2645 |
future | #2648 |
borderline personality | #2652 |
brain derived | #2655 |
tmax | #2659 |
dysregulation | #2663 |
electronic health | #2664 |
puzzle | #2665 |
periodicals | #2665 |
n14 | #2666 |
health disorders | #2669 |
089 | #2669 |
chromosome | #2670 |
88 | #2670 |
genetic evidence | #2670 |
polysomnography | #2671 |
pcps | #2675 |
spectrum | #2675 |
mediating | #2676 |
inconclusive | #2676 |
partially | #2676 |
physiotherapy | #2678 |
adolescent development | #2678 |
memory tests | #2678 |
maternal behavior | #2679 |
increased activity | #2681 |
disadvantaged | #2685 |
adrenergic | #2687 |
widespread | #2688 |
triad | #2689 |
conditional | #2689 |
age range | #2689 |
listening | #2690 |
entry | #2692 |
reading | #2692 |
promoter region | #2694 |
evaluating | #2695 |
tfs | #2696 |
evidenced | #2698 |
immaturity | #2698 |
extended | #2700 |
chr | #2701 |
neurite | #2702 |
interrogation | #2702 |
attenuate | #2702 |
flares | #2703 |
ext | #2707 |
delinquency | #2707 |
hemispheric asymmetry | #2709 |
internalizing problems | #2710 |
404 | #2713 |
occurring | #2714 |
aggressive | #2714 |
quarter | #2718 |
positively correlated | #2719 |
purposes | #2721 |
choosing | #2723 |
thinking | #2724 |
internalizing | #2726 |
hold | #2727 |
teens | #2731 |
curve | #2731 |
awakening | #2732 |
thicker | #2733 |
doubt | #2733 |
systematic literature review | #2733 |
alcohol dependence | #2736 |
potential association | #2740 |
pdi | #2752 |
cortices | #2753 |
prepubertal | #2753 |
eventually | #2755 |
patients bipolar disorder | #2760 |
naa | #2760 |
collaboration | #2760 |
gt | #2761 |
manifestations | #2762 |
unadjusted | #2765 |
4 years | #2765 |
created | #2768 |
ccs | #2769 |
psychiatric diseases | #2773 |
reproducibility | #2773 |
phencyclidine | #2775 |
depression severity | #2776 |
preventive measures | #2777 |
25 | #2777 |
mechanisms underlying | #2783 |
clinical heterogeneity | #2783 |
children symptoms | #2784 |
bivariate | #2784 |
panic attacks | #2785 |
6 12 | #2788 |
tactile | #2790 |
411 | #2791 |
dna copy | #2791 |
dyslexia | #2792 |
overt | #2794 |
neurotrophic factor | #2794 |
auditory perception | #2796 |
constellation | #2796 |
suicidality | #2799 |
explained | #2802 |
958 | #2803 |
dependence | #2804 |
references | #2806 |
clinical experience | #2808 |
recognition visual | #2808 |
monetary | #2809 |
misdiagnosis | #2809 |
397 | #2809 |
goodness | #2810 |
predefined | #2812 |
disc1 | #2815 |
gene polymorphism | #2816 |
midnight | #2816 |
primary caregivers | #2817 |
subsequent | #2819 |
indexes | #2823 |
circuitry | #2823 |
1300 | #2824 |
telephone | #2824 |
comorbidities | #2825 |
pediatric obesity | #2827 |
intervention strategies | #2828 |
and or | #2830 |
refusal | #2833 |
disorder characterized | #2835 |
tested | #2838 |
early recognition | #2839 |
discriminant validity | #2839 |
adoption | #2841 |
reelin | #2843 |
treatment study | #2843 |
prefrontal cortex | #2844 |
socioeconomic status | #2846 |
emotional intelligence | #2849 |
early identification | #2850 |
matter volume | #2852 |
parent child | #2853 |
disabled | #2856 |
restless legs syndrome | #2857 |
suicide attempted | #2858 |
depression scale | #2863 |
continental ancestry | #2863 |
parenting parents | #2865 |
addresses | #2866 |
screened | #2866 |
internal external | #2867 |
mothers children | #2867 |
cognition humans | #2868 |
discordance | #2868 |
focus | #2869 |
silico | #2870 |
psychosocial stress | #2872 |
splicing | #2875 |
diagnosis differential | #2876 |
gwa | #2878 |
sixteen | #2880 |
appeared | #2884 |
measure | #2884 |
citations | #2885 |
age differences | #2885 |
shifting | #2885 |
rare variants | #2887 |
protective effects | #2889 |
trinucleotide | #2890 |
brain size | #2900 |
asr | #2901 |
alternate | #2902 |
debate | #2903 |
duplicate | #2905 |
low birth weight | #2906 |
alcohol disorder | #2907 |
newer | #2909 |
independent component analysis | #2911 |
etiologies | #2912 |
behavior children | #2913 |
precursor | #2914 |
amph | #2916 |
cognitive control | #2916 |
biological mechanisms | #2919 |
variability | #2919 |
institutes | #2919 |
age study | #2921 |
genetic contributions | #2922 |
115 | #2924 |
attentional | #2925 |
subject | #2928 |
486 | #2931 |
behavioral outcomes | #2931 |
adherence | #2932 |
92 | #2935 |
machine learning | #2941 |
disorders sleep | #2942 |
causal relationship | #2942 |
disorders patients | #2946 |
distinct | #2946 |
motor control | #2953 |
pcb | #2956 |
smoked | #2959 |
journal | #2965 |
facilitating | #2967 |
previous | #2968 |
331 | #2970 |
overlaps | #2971 |
markers | #2971 |
models neurological | #2976 |
stratification | #2981 |
qtl | #2983 |
725 | #2983 |
weight height | #2988 |
investigators | #2989 |
attempts | #2991 |
imaging mri | #2991 |
tic | #2997 |
performance measures | #2997 |
overweight | #2998 |
variants | #2999 |
subjective | #3000 |
bold | #3002 |
referral | #3005 |
196 | #3006 |
centres | #3006 |
377 | #3007 |
19th century | #3010 |
remission | #3011 |
genetic variation | #3011 |
genetic promoter regions | #3012 |
resonance imaging | #3016 |
987 | #3017 |
chen | #3018 |
worldwide | #3020 |
response relationship | #3021 |
inferior frontal gyrus | #3022 |
disease susceptibility | #3023 |
mouse models | #3024 |
choice | #3028 |
conference | #3030 |
models psychological | #3033 |
familiarity | #3034 |
emotion dysregulation | #3036 |
difficulties questionnaire | #3039 |
symptoms patients | #3039 |
female humans life | #3040 |
thomson | #3044 |
neural correlates | #3047 |
variants genes | #3053 |
developmental | #3054 |
treatment adherence | #3054 |
protective factor | #3057 |
improvement | #3058 |
pilot | #3061 |
280 | #3061 |
fear female | #3063 |
117 | #3064 |
ultimately | #3065 |
339 | #3068 |
216 | #3072 |
stress reactivity | #3073 |
p0004 | #3074 |
frontal lobe | #3076 |
appears | #3077 |
cortical | #3078 |
driving | #3078 |
positive | #3079 |
sociodemographics | #3081 |
males | #3089 |
key findings | #3092 |
pairwise | #3093 |
allelic | #3094 |
pregnancy women | #3095 |
predictable | #3098 |
stressful life | #3098 |
modified version | #3099 |
central nervous | #3104 |
intron | #3105 |
076 | #3107 |
brain health | #3107 |
naïve | #3110 |
siemens | #3111 |
interviewed | #3114 |
symptoms study | #3116 |
articles | #3123 |
amygdala hippocampus | #3123 |
marijuana abuse | #3124 |
mass screening | #3125 |
ptsd symptoms | #3127 |
383 | #3127 |
functional laterality | #3129 |
tcc | #3132 |
psychiatrist | #3133 |
temporal cortex | #3134 |
childhood adversity | #3135 |
pharmacies | #3137 |
maternal | #3142 |
accuracies | #3144 |
nation | #3146 |
european countries | #3146 |
99 | #3150 |
exploratory | #3150 |
ancestry | #3151 |
behavior social | #3152 |
pharmacokinetic | #3157 |
oxford | #3157 |
explanations | #3165 |
spd | #3165 |
biological processes | #3166 |
functional consequences | #3166 |
aggregation | #3168 |
hippocampal | #3169 |
teenagers | #3170 |
status humans | #3171 |
caution | #3171 |
report | #3174 |
hypophyseal | #3175 |
math | #3176 |
wealth | #3178 |
contrast | #3180 |
adolescents young adults | #3187 |
methyltransferase | #3187 |
imaging study | #3187 |
receiver | #3188 |
prodrug | #3189 |
view | #3190 |
published | #3190 |
collect | #3195 |
emotion processing | #3195 |
comprehension | #3201 |
initial treatment | #3202 |
attempt | #3202 |
erythematosus sle | #3205 |
answers | #3208 |
normative | #3209 |
naming | #3212 |
snvs | #3214 |
gene polymorphisms | #3216 |
pathophysiological | #3216 |
psychotherapy | #3222 |
environment | #3223 |
angeles | #3228 |
situation | #3229 |
scanner | #3229 |
discontinuity | #3229 |
65 | #3235 |
depression study | #3236 |
mediation analysis | #3237 |
htt | #3237 |
414 | #3239 |
abstinence | #3241 |
databases genetic | #3247 |
determine | #3250 |
features | #3254 |
210 | #3255 |
211 | #3257 |
correlated | #3257 |
publicly | #3265 |
caudate nucleus | #3265 |
humans magnetic | #3266 |
17p | #3266 |
interactive effects | #3266 |
moderator | #3269 |
370 | #3270 |
symbols | #3271 |
researchers | #3272 |
prefrontal cortex pfc | #3274 |
expertise | #3276 |
memory processing | #3281 |
increased likelihood | #3282 |
longitudinal cohort | #3282 |
cognitive functioning | #3289 |
condition | #3291 |
glutamate receptor | #3296 |
replication | #3297 |
surveys | #3299 |
strict | #3304 |
contributed | #3305 |
synaptic function | #3306 |
clinical severity | #3306 |
genomics | #3309 |
restrictions | #3314 |
corrected | #3315 |
attribute | #3316 |
spearman | #3321 |
digit | #3322 |
neuroimaging data | #3323 |
differently | #3325 |
fewer | #3331 |
earlier studies | #3333 |
mrt | #3334 |
metropolitan | #3336 |
clock gene | #3336 |
ambiguity | #3336 |
417 | #3340 |
6 | #3343 |
slide | #3345 |
revealing | #3348 |
clinical | #3351 |
hoc analyses | #3352 |
healthy control | #3354 |
affect | #3357 |
national institute | #3359 |
functional studies | #3361 |
april | #3362 |
friend | #3366 |
motivational | #3367 |
retest | #3369 |
067 | #3370 |
frontal regions | #3371 |
glycolysis | #3371 |
battery | #3371 |
treatment strategies | #3373 |
cortex pfc | #3375 |
088 | #3376 |
marker | #3379 |
functional neuroimaging | #3382 |
initially | #3384 |
sex chromosomes | #3385 |
typically developing | #3386 |
impaired performance | #3386 |
stressful life events | #3387 |
monozygotic | #3389 |
multimorbidity | #3390 |
clock genes | #3390 |
health children | #3392 |
accounting | #3393 |
cnp | #3393 |
ifg | #3398 |
358 | #3402 |
baseline followup | #3404 |
traumatic brain | #3405 |
depression symptoms | #3405 |
desirability | #3406 |
oxidase | #3411 |
performing | #3413 |
pool | #3413 |
aucs | #3415 |
lack | #3419 |
health surveys | #3422 |
therapeutic response | #3423 |
longitudinal data | #3426 |
stepwise | #3431 |
03 | #3433 |
pediatric population | #3436 |
definition | #3439 |
experiencing | #3439 |
exert | #3441 |
fluency | #3446 |
showing | #3448 |
lca | #3448 |
children mothers | #3448 |
schoolaged children | #3449 |
lowered | #3450 |
psychotropic medication | #3455 |
supports | #3455 |
inception | #3457 |
schooling | #3461 |
estimating | #3463 |
differentiate | #3464 |
genomewide association study | #3466 |
cognitive behavioral | #3466 |
hallucinations | #3466 |
male sex | #3472 |
bilaterally | #3473 |
scan | #3475 |
methylation | #3477 |
remaining | #3477 |
behavioral response | #3478 |
irr | #3480 |
transmission | #3482 |
postmortem | #3482 |
slower | #3488 |
exposure pregnancy | #3489 |
lesser | #3489 |
convergent | #3489 |
applying | #3492 |
epidemiological study | #3492 |
short stature | #3497 |
social behaviors | #3497 |
alpha2 | #3497 |
aged polymorphism | #3497 |
083 | #3497 |
matched healthy | #3502 |
brain function | #3506 |
identifier | #3506 |
p002 | #3506 |
antidepressants | #3512 |
checklist | #3514 |
sans | #3518 |
specificity | #3519 |
104 | #3519 |
113 | #3520 |
antipsychotic | #3524 |
spouse | #3525 |
constitutes | #3527 |
basis | #3527 |
pediatricians | #3527 |
asperger syndrome | #3529 |
reflect | #3529 |
clinical phenotype | #3533 |
rett syndrome | #3535 |
preferentially | #3536 |
reliable | #3536 |
enrichment analysis | #3538 |
social behavior | #3539 |
school aged | #3540 |
mother child | #3541 |
fact | #3544 |
cognitive behavioral therapy | #3544 |
sleep wake | #3544 |
coming | #3545 |
rts | #3546 |
documentation | #3547 |
score | #3548 |
dmn | #3550 |
344 | #3557 |
ecgs | #3558 |
preventive interventions | #3558 |
neuronal function | #3558 |
prevalence estimates | #3563 |
suggestions | #3564 |
genetic analysis | #3567 |
psychiatrists | #3568 |
prevent | #3569 |
prospectively | #3570 |
developmental stages | #3573 |
psychosocial interventions | #3579 |
genotyping | #3580 |
reliability | #3583 |
mse | #3585 |
collaborative | #3585 |
mpfc | #3587 |
neurite outgrowth | #3587 |
crh | #3603 |
interrater reliability | #3604 |
cardio | #3606 |
major gene | #3606 |
consists | #3609 |
299 | #3613 |
screen | #3614 |
modalities | #3617 |
questions | #3618 |
methylation status | #3618 |
348 | #3620 |
races | #3621 |
pharmacogenetics | #3622 |
objectives | #3623 |
reviewed | #3624 |
article | #3625 |
214 | #3626 |
101 | #3628 |
neglect | #3630 |
185 | #3631 |
hypothalamo | #3634 |
prior | #3640 |
posttraumatic stress | #3640 |
seeking | #3641 |
wgs | #3648 |
cohesion | #3653 |
enrolment | #3654 |
facilitate | #3660 |
negative | #3661 |
downward | #3662 |
study association | #3663 |
increased prevalence | #3666 |
socioeconomic factors | #3668 |
weight | #3669 |
93 | #3670 |
administration oral | #3672 |
captured | #3675 |
360 | #3681 |
1st | #3682 |
genotype data | #3686 |
behavior problems | #3690 |
frontal lobes | #3691 |
marijuana | #3695 |
online survey | #3696 |
nacetylcysteine | #3700 |
disorders animals | #3703 |
oe | #3705 |
problem behavior | #3707 |
effort | #3711 |
brain cognition | #3719 |
manipulations | #3722 |
9 years | #3729 |
situations | #3730 |
pha | #3732 |
070 | #3733 |
ultimate | #3734 |
daily life | #3735 |
neurotransmission | #3735 |
fifty | #3736 |
hapmap | #3737 |
depressed mood | #3737 |
population | #3738 |
therapy cbt | #3744 |
international | #3744 |
relative | #3745 |
offer | #3746 |
reply | #3750 |
persisted | #3751 |
shortterm | #3753 |
epigenesis genetic | #3755 |
depression risk | #3756 |
proportional | #3757 |
333 | #3758 |
neurophysiological | #3758 |
interim analysis | #3760 |
comprehensive assessment | #3767 |
315 | #3777 |
addiction | #3780 |
transitions | #3781 |
recognition psychology | #3782 |
cocaine disorders | #3783 |
peers | #3787 |
promoter polymorphism | #3787 |
1012 | #3791 |
nonresponse | #3794 |
predictive validity | #3797 |
discriminate | #3800 |
forecast | #3802 |
monozygotic twins | #3803 |
statistical analyses | #3806 |
355 | #3809 |
ways | #3814 |
scientific | #3822 |
dimensions | #3824 |
030 | #3825 |
neurotransmitter | #3829 |
acetylcysteine | #3835 |
inclusion | #3837 |
male marijuana | #3844 |
exchanger | #3844 |
disease genes | #3850 |
developmental disorders | #3850 |
children aged | #3850 |
risk development | #3851 |
elevations | #3851 |
midlife | #3852 |
36 | #3854 |
rely | #3856 |
test | #3858 |
animal dopamine | #3859 |
superior temporal | #3862 |
strong | #3863 |
drug administration | #3866 |
prospective | #3872 |
explain | #3874 |
74 | #3876 |
208 | #3876 |
influences | #3876 |
p001 | #3879 |
ireland | #3882 |
mark | #3883 |
globus | #3886 |
child cohort | #3888 |
reevaluation | #3888 |
tesla | #3890 |
p0003 | #3895 |
neurology | #3898 |
plasma membrane | #3898 |
histories | #3901 |
obstetric | #3905 |
congruent | #3913 |
clinicians | #3915 |
ethnicities | #3922 |
monotherapy | #3923 |
variable | #3924 |
illnesses | #3925 |
robust | #3929 |
dbd | #3930 |
drug targets | #3931 |
suicidal behavior | #3932 |
antidepressant treatment | #3935 |
frontal gyrus | #3937 |
specific factors | #3937 |
preexisting | #3937 |
females males | #3944 |
2nd | #3945 |
directions | #3947 |
controversy | #3951 |
integrate | #3953 |
nicotine | #3956 |
normalization | #3959 |
support | #3960 |
systematic review metaanalysis | #3962 |
indicating | #3967 |
older children | #3969 |
trauma | #3970 |
disease control | #3971 |
untreated | #3976 |
alcohol | #3978 |
brain functional | #3980 |
forecasts | #3981 |
preliminary evidence | #4000 |
categorization | #4000 |
factorial | #4000 |
vulnerabilities | #4003 |
medial prefrontal | #4004 |
primary aim | #4005 |
initiating | #4012 |
kappa | #4013 |
cortex | #4018 |
eqtls | #4021 |
construct | #4023 |
fusiform gyrus | #4032 |
represent | #4036 |
clinical improvement | #4046 |
diabetes risk | #4047 |
common variants | #4047 |
discussion | #4051 |
modeled | #4051 |
mathematics | #4051 |
consequences | #4052 |
relevant | #4057 |
jointly | #4058 |
contextual factors | #4058 |
criminal | #4060 |
divergent | #4062 |
intellectual disability | #4063 |
causal role | #4064 |
cag | #4068 |
magnetic resonance | #4068 |
serotonin uptake | #4068 |
forecasting | #4071 |
statistics | #4072 |
118 | #4074 |
portion | #4075 |
child age | #4076 |
outcomes children | #4078 |
birth order | #4082 |
belgium | #4086 |
genetic loci | #4088 |
study efficacy | #4090 |
heroin | #4090 |
clinical characteristics | #4096 |
lobe | #4098 |
temporal lobe | #4098 |
maternal depression | #4100 |
genetic variations | #4100 |
limbic | #4102 |
age matched | #4103 |
psychologists | #4103 |
list | #4105 |
evidence base | #4107 |
062 | #4109 |
eicosapentaenoic | #4113 |
traumatic | #4115 |
vary | #4117 |
plausible | #4121 |
comprises | #4121 |
epigenesis | #4128 |
cortical areas | #4130 |
relationship | #4136 |
principal components | #4139 |
244 | #4140 |
german | #4145 |
dosing | #4145 |
span | #4146 |
neuronal migration | #4148 |
sectional | #4150 |
mj | #4156 |
regression | #4158 |
extensively | #4160 |
259 | #4161 |
124 | #4164 |
indicative | #4166 |
pathophysiology | #4167 |
fm | #4169 |
somatization | #4170 |
risk depression | #4174 |
bioinformatics | #4177 |
mapping | #4178 |
sedation | #4180 |
340 | #4182 |
dopamine d3 | #4184 |
109 | #4187 |
mri scans | #4188 |
preventive | #4190 |
military | #4191 |
lupus erythematosus | #4192 |
morphometry | #4193 |
structural connectivity | #4194 |
study differences | #4195 |
268 | #4196 |
describes | #4198 |
116 | #4199 |
transporter | #4204 |
growing | #4213 |
children age | #4215 |
helpful | #4216 |
route | #4216 |
based sample | #4218 |
suicidal thoughts | #4219 |
subgroups | #4219 |
functional magnetic | #4223 |
copy variations | #4224 |
determining | #4227 |
valproic | #4230 |
calcineurin | #4237 |
administration | #4239 |
tap | #4245 |
rat model | #4247 |
1987 | #4251 |
gpcr | #4253 |
predict | #4253 |
differential female humans | #4254 |
emerge | #4256 |
mortem | #4259 |
trajectory | #4263 |
representative | #4263 |
confers | #4264 |
posttreatment | #4268 |
antipsychotic medication | #4269 |
225 | #4270 |
follow‐up | #4273 |
early intervention | #4276 |
paediatric | #4280 |
principal component analysis | #4282 |
contributors | #4285 |
polymorphisms genes | #4292 |
select | #4293 |
deletion | #4296 |
pressor | #4302 |
outpatients | #4305 |
demographic variables | #4309 |
child development | #4314 |
potential targets | #4315 |
adequacy | #4315 |
highest risk | #4319 |
mutual | #4324 |
cardiovascular effects | #4326 |
patients diagnosed | #4327 |
buprenorphine | #4332 |
occasion | #4341 |
cingulate cortex | #4348 |
occurs | #4350 |
chart review | #4352 |
catechol | #4353 |
acute treatment | #4353 |
segregation | #4358 |
dropouts | #4361 |
searched | #4362 |
adjunct | #4363 |
166 | #4369 |
cambridge | #4370 |
aging brain | #4372 |
logistic regression analysis | #4373 |
exists | #4375 |
relation | #4375 |
intolerance | #4378 |
mediate | #4378 |
066 | #4382 |
psychological adolescent | #4383 |
clarity | #4383 |
docosahexaenoic | #4391 |
transcriptomic | #4391 |
solving | #4391 |
human | #4393 |
volumetric | #4395 |
privacy | #4396 |
low dose | #4399 |
exon | #4404 |
sexual dimorphism | #4409 |
corpus striatum | #4410 |
impulse | #4412 |
survive | #4413 |
diverse | #4413 |
membrane glycoproteins | #4416 |
polychlorinated biphenyls | #4418 |
ethnic differences | #4424 |
intranasal | #4426 |
opioids | #4429 |
terminology | #4434 |
concurrent | #4438 |
morbidities | #4444 |
197 | #4445 |
bias | #4447 |
human studies | #4449 |
striatal dopamine | #4449 |
62 | #4454 |
genotypes | #4454 |
192 | #4461 |
symposium | #4462 |
locomotor | #4464 |
serotonergic | #4465 |
outgrowth | #4467 |
dna methylation | #4470 |
219 | #4471 |
entered | #4473 |
emissioncomputed | #4476 |
smell | #4477 |
synapse | #4482 |
compilation | #4486 |
ethical | #4490 |
criterion validity | #4491 |
fourth | #4495 |
informal | #4500 |
superior temporal gyrus | #4501 |
parametric | #4508 |
313 | #4509 |
disorders cognitive | #4516 |
visits | #4516 |
valuation | #4516 |
alcohol abuse | #4517 |
investigate | #4521 |
notion | #4525 |
laterality | #4526 |
considerable | #4540 |
postnatal day | #4540 |
multiple | #4541 |
children families | #4542 |
incentive | #4546 |
transmit | #4548 |
pharmacology | #4552 |
employment | #4553 |
higher level | #4553 |
preschool children | #4564 |
birth | #4564 |
emr | #4565 |
component | #4572 |
22 | #4573 |
neuronal differentiation | #4587 |
psd | #4587 |
address | #4593 |
origin | #4595 |
initiated | #4599 |
006 | #4603 |
≤ | #4609 |
february | #4610 |
009 | #4612 |
indices | #4613 |
israel | #4617 |
attributed | #4630 |
genomic data | #4633 |
ssris | #4634 |
television | #4636 |
head injury | #4638 |
clinical risk | #4643 |
q1 | #4643 |
question | #4648 |
unmet | #4651 |
trouble | #4651 |
regression model | #4652 |
marriage | #4658 |
centers | #4660 |
deliveries | #4660 |
microsatellite | #4660 |
anterior cingulate cortex | #4661 |
243 | #4662 |
trajectories | #4662 |
children study | #4665 |
homogeneity | #4667 |
fg | #4668 |
mitigate | #4668 |
european | #4669 |
healthy individuals | #4670 |
psychometric properties | #4673 |
routes | #4676 |
disease onset | #4679 |
subsequently | #4680 |
pregnancy risk | #4682 |
264 | #4684 |
names | #4689 |
hunt | #4696 |
accurate diagnosis | #4699 |
concerns | #4705 |
5 | #4706 |
cardiorespiratory | #4707 |
imply | #4710 |
autosomal | #4711 |
hazards models | #4715 |
vector machine | #4715 |
estimate | #4716 |
smd | #4717 |
mbr | #4719 |
sed | #4719 |
appropriateness | #4720 |
positional | #4725 |
cinahl | #4729 |
fusiform | #4730 |
eqtl | #4731 |
participants included | #4732 |
biological factors | #4735 |
drug addiction | #4736 |
prototypes | #4745 |
val | #4747 |
unemployment | #4747 |
pons | #4753 |
cooperative | #4755 |
drug | #4757 |
taiwan | #4757 |
77 | #4760 |
conflict | #4760 |
tasks | #4762 |
heavily | #4763 |
portions | #4763 |
fumarate | #4773 |
231 | #4774 |
mother | #4782 |
subjects risk | #4784 |
noncarriers | #4791 |
samples | #4791 |
sharing | #4795 |
mp | #4798 |
publication administration | #4798 |
cleaning | #4804 |
coronary artery disease | #4814 |
fractional anisotropy | #4820 |
modafinil | #4825 |
cognitive tests | #4825 |
excluding | #4832 |
surge | #4835 |
visual perception | #4836 |
experts | #4837 |
223 | #4838 |
continuity | #4843 |
sparse | #4849 |
recognized | #4853 |
imaging female | #4858 |
41 | #4865 |
rg | #4873 |
specific | #4874 |
207 | #4875 |
wave | #4880 |
deterioration | #4880 |
cigarettes | #4881 |
subsamples | #4881 |
young age | #4881 |
fp | #4882 |
omega3 | #4882 |
prisma | #4885 |
facts | #4890 |
cascades | #4891 |
eliminated | #4894 |
antiepileptic drugs | #4910 |
operating | #4914 |
002 | #4915 |
preclinical studies | #4916 |
achievements | #4923 |
early adolescence | #4923 |
additive | #4924 |
scored | #4929 |
bdi | #4929 |
parietal lobe | #4930 |
outcome measures | #4932 |
034 | #4933 |
brain activity | #4937 |
inventory | #4941 |
relating | #4947 |
delays | #4949 |
hemispheric | #4949 |
pooled analysis | #4951 |
powerful | #4951 |
snap | #4957 |
rule | #4959 |
diffusion tensor imaging | #4962 |
acetylcholine receptor | #4965 |
srs | #4967 |
212 | #4969 |
altered expression | #4972 |
eye tracking | #4973 |
explosion | #4978 |
empirical data | #4979 |
continental | #4983 |
lower | #4994 |
170 | #4995 |
022 | #5001 |
treatment modalities | #5005 |
timing | #5008 |
esr1 | #5015 |
aged nerve | #5017 |
selective attention | #5021 |
caucasians | #5021 |
disagreement | #5024 |
aug | #5025 |
rarely | #5027 |
serotonin receptors | #5029 |
variation | #5030 |
adolescent health | #5031 |
specialty | #5036 |
task | #5038 |
discuss | #5039 |
probabilistic | #5039 |
distinguish | #5040 |
correct | #5040 |
auc | #5047 |
anxiety depression | #5047 |
cingulate gyrus | #5047 |
sga | #5050 |
early | #5051 |
convergent validity | #5051 |
marital | #5051 |
predictor | #5052 |
2003 | #5055 |
analgesics | #5056 |
obesity | #5064 |
bidirectional | #5067 |
gender identity | #5067 |
18 years | #5070 |
continuation | #5077 |
cadherins | #5079 |
decreasing | #5085 |
reductions | #5086 |
chinese children | #5092 |
placebo patients | #5095 |
aes | #5097 |
epilepsy | #5099 |
reached | #5101 |
09 | #5101 |
103 | #5104 |
screening | #5104 |
relative contributions | #5105 |
qtc | #5106 |
volume reduction | #5107 |
ancestral | #5112 |
time points | #5118 |
relevance | #5119 |
variables | #5127 |
substances | #5129 |
mediation | #5132 |
single nucleotide polymorphisms | #5132 |
maladaptive | #5133 |
ppv | #5134 |
individuals risk | #5136 |
mechanisms | #5142 |
readers | #5143 |
mental retardation | #5145 |
difference | #5146 |
inherent | #5146 |
involves | #5147 |
pharmacogenomics | #5147 |
carrying | #5158 |
enrichment | #5160 |
administered | #5162 |
homozygote | #5166 |
dropout | #5168 |
biological | #5170 |
diffusivity | #5177 |
picture | #5178 |
ventral | #5181 |
reuptake inhibitors | #5182 |
extent | #5183 |
dopamine d1 | #5187 |
adjustment | #5190 |
238 | #5193 |
disability | #5193 |
predictive | #5195 |
weighted | #5197 |
pleiotropy | #5205 |
characteristic | #5212 |
molecular biology | #5215 |
remains | #5215 |
term | #5218 |
conclude | #5223 |
dopaminergic neurons | #5224 |
167 | #5226 |
nonsmokers | #5231 |
dutch | #5233 |
256 | #5234 |
fail | #5237 |
smoking behavior | #5240 |
interaction | #5242 |
accurately | #5245 |
119 | #5246 |
critical period | #5248 |
tolerated | #5255 |
generated | #5260 |
boundaries | #5261 |
americans | #5263 |
exceeded | #5264 |
delineation | #5266 |
genotypic | #5269 |
daytime sleepiness | #5278 |
ws | #5278 |
cell surface receptors | #5280 |
brain injuries | #5283 |
001 | #5286 |
participated | #5287 |
variety | #5289 |
normality | #5290 |
written | #5291 |
billion | #5295 |
trend | #5295 |
eye movements | #5296 |
motor | #5298 |
thalamus | #5299 |
oligodendrocytes | #5299 |
learning | #5301 |
234 | #5302 |
emotion recognition | #5306 |
life events | #5308 |
072 | #5308 |
52 | #5309 |
healthy participants | #5310 |
environmental | #5312 |
observer | #5313 |
dense | #5316 |
hints | #5321 |
definite | #5322 |
treatment initiation | #5323 |
genomic imprinting | #5333 |
credibility | #5335 |
inferences | #5339 |
individual level | #5345 |
social interactions | #5345 |
predictive tests | #5345 |
classic | #5351 |
prenatal | #5353 |
word | #5354 |
estimated | #5359 |
cerebellum | #5363 |
nonresponders | #5368 |
nervosa | #5369 |
interplay | #5375 |
eventrelated potentials | #5376 |
penetrance | #5380 |
higher frequency | #5380 |
suicide attempts | #5382 |
lost | #5382 |
internet addiction | #5390 |
sweden | #5391 |
huntington disease | #5392 |
domains | #5396 |
potential confounders | #5402 |
label | #5403 |
37 | #5403 |
empirical | #5410 |
register | #5411 |
daily | #5413 |
0007 | #5419 |
average | #5424 |
tensor imaging | #5432 |
224 | #5436 |
pcp | #5449 |
172 | #5451 |
wiley | #5452 |
adjunctive therapy | #5454 |
modifiers | #5464 |
hour | #5467 |
york | #5468 |
risk individuals | #5468 |
× 10 | #5471 |
aim | #5474 |
settings | #5475 |
borderline | #5478 |
environmental effects | #5484 |
brains | #5486 |
copy | #5488 |
recall | #5491 |
confirms | #5494 |
locomotor activity | #5499 |
homozygotes | #5502 |
year | #5505 |
clinics | #5517 |
commission | #5518 |
termed | #5519 |
verbal fluency | #5525 |
promoter regions | #5525 |
fdr | #5534 |
320 | #5536 |
anxiety behavior | #5537 |
155 | #5547 |
modulate | #5547 |
closely | #5549 |
elevated | #5549 |
prevention | #5551 |
flanking | #5552 |
restraint | #5552 |
occur | #5553 |
154 | #5559 |
copy variation | #5562 |
health conditions | #5563 |
icd10 | #5564 |
frontal cortex | #5565 |
baseline treatment | #5565 |
15 | #5567 |
european ancestry | #5567 |
213 | #5574 |
predominance | #5578 |
significance | #5578 |
240 | #5579 |
mediators | #5579 |
spatial memory | #5581 |
subacute | #5584 |
175 | #5590 |
locus | #5592 |
epidemiological | #5593 |
scientists | #5596 |
narcolepsy | #5597 |
nrg1 | #5607 |
anhedonia | #5608 |
amygdala | #5623 |
percent | #5628 |
heavier | #5631 |
total | #5640 |
allocation | #5657 |
lower risk | #5663 |
perinatal | #5663 |
divided | #5666 |
exploring | #5670 |
probability | #5677 |
calculate | #5678 |
proportional hazards | #5684 |
40 years | #5686 |
1999 | #5686 |
gene variants | #5687 |
vbm | #5688 |
markov | #5688 |
published data | #5689 |
oculomotor | #5690 |
brain development | #5694 |
normal | #5696 |
databases | #5696 |
systems biology | #5703 |
primary outcome measure | #5713 |
cognitive functions | #5713 |
58 | #5723 |
signal detection | #5725 |
pleasure | #5727 |
thirty | #5728 |
focused | #5728 |
psychological surveys | #5735 |
020 | #5739 |
19 | #5745 |
definitions | #5746 |
cognitive tasks | #5751 |
missing data | #5755 |
divorce | #5758 |
approaches | #5761 |
nac | #5762 |
interactive | #5765 |
aged children | #5767 |
additional | #5773 |
deficient | #5778 |
oral | #5779 |
72 | #5780 |
rats inbred | #5786 |
susceptibility locus | #5788 |
extracted | #5792 |
206 | #5796 |
preferential | #5797 |
16 | #5799 |
139 | #5802 |
deaths | #5811 |
intracranial | #5814 |
nuclear | #5815 |
0002 | #5819 |
0005 | #5820 |
aaa | #5823 |
133 | #5826 |
98 | #5827 |
nerve net | #5827 |
ethnic groups | #5834 |
multidimensional | #5836 |
fell | #5841 |
dependency | #5846 |
cannabis | #5849 |
deletions | #5857 |
current understanding | #5860 |
signaling peptides | #5862 |
gene expression profiles | #5869 |
fetuses | #5872 |
membership | #5874 |
auditory | #5875 |
retrospective chart review | #5879 |
sexual behavior | #5880 |
synaptophysin | #5887 |
16 years | #5894 |
small | #5898 |
september | #5901 |
imputation | #5910 |
council | #5910 |
appendix | #5916 |
characterizing | #5917 |
broad | #5919 |
activity level | #5919 |
ethics | #5923 |
parietal | #5925 |
statement | #5928 |
region | #5928 |
linked | #5928 |
individuality | #5929 |
rights | #5930 |
prolactin | #5931 |
medical treatment | #5933 |
rapamycin | #5937 |
biphenyls | #5940 |
striatal | #5955 |
community | #5956 |
electroencephalography evoked | #5964 |
clearance | #5965 |
132 | #5966 |
cmax | #5969 |
091 | #5971 |
missed | #5974 |
explore | #5994 |
website | #6000 |
exclusively | #6001 |
threshold | #6003 |
rois | #6005 |
moderating role | #6005 |
matched | #6006 |
chromosomal | #6009 |
module | #6011 |
functional connectivity | #6013 |
newcastle | #6017 |
extreme | #6020 |
रिपोर्ट चलाएं | |
Prominent publications by Stephen V Faraone∗
IMPORTANCE: Attention-deficit/hyperactivity disorder (ADHD) is a heritable neurodevelopmental disorder. It has been linked to reductions in total brain volume and subcortical abnormalities. However, owing to heterogeneity within and between studies and limited sample sizes, findings on the neuroanatomical substrates of ADHD have shown considerable variability. Moreover, it remains unclear whether neuroanatomical alterations linked to ADHD are also present in the unaffected siblings of ...
के लिए जाना जाता है Unaffected Siblings | Putamen Volume | Participants Adhd | Hyperactivity Disorder | Total Brain |
Motor coordination problems in children and adolescents with ADHD rated by parents and teachers: effects of age and gender
[ PUBLICATION ]
Summary.Objective. ADHD is frequently accompanied by motor coordination problems. However, the co-occurrence of poor motor performance has received less attention in research than other coexisting problems in ADHD. The underlying mechanisms of this association remain unclear. Therefore, we investigated the prevalence of motor coordination problems in a large sample of children with ADHD, and the relationship between motor coordination problems and inattentive and hyperactive/impulsive ...
के लिए जाना जाता है Motor Coordination Problems | Children Adhd | Boys Girls | Hyperactivity Child Child | Parents Prevalence |
Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
[ PUBLICATION ]
We examined the status of the neural network mediating the default mode of brain function, which typically exhibits greater activation during rest than during task, in patients in the early phase of schizophrenia and in young first-degree relatives of persons with schizophrenia. During functional MRI, patients, relatives, and controls alternated between rest and performance of working memory (WM) tasks. As expected, controls exhibited task-related suppression of activation in the default ...
के लिए जाना जाता है Default Network | Patients Relatives | Rest Task | Wm Performance | Mpfc Dlpfc |
Patterns of Psychopathology and Dysfunction in High-Risk Children of Parents With Panic Disorder and Major Depression
[ PUBLICATION ]
OBJECTIVE: The purpose of the study was to evaluate 1) whether an underlying familial predisposition is shared by all anxiety disorders or whether specific risks are associated with specific disorders, and 2) whether panic disorder and major depression have a familial link.
METHOD: The study compared four groups of children: 1) offspring of parents with panic disorder and comorbid major depression (N=179), 2) offspring of parents with panic disorder without comorbid major depression ...
के लिए जाना जाता है Major Depression | Panic Disorder | Offspring Parents | Risk Children | Factors Social |
OBJECTIVE: Attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and obsessive-compulsive disorder (OCD) are common neurodevelopmental disorders that frequently co-occur. The authors sought to directly compare these disorders using structural brain imaging data from ENIGMA consortium data.
METHODS: Structural T1-weighted whole-brain MRI data from healthy control subjects (N=5,827) and from patients with ADHD (N=2,271), ASD (N=1,777), and OCD (N=2,323) from 151 ...
के लिए जाना जाता है Adhd Asd | Cortical Thickness | Children Adolescents | Brain Volume | Disorder Ocd |
BACKGROUND: Neuroimaging studies have shown structural alterations in several brain regions in children and adults with attention deficit hyperactivity disorder (ADHD). Through the formation of the international ENIGMA ADHD Working Group, we aimed to address weaknesses of previous imaging studies and meta-analyses, namely inadequate sample size and methodological heterogeneity. We aimed to investigate whether there are structural differences in children and adults with ADHD compared with ...
के लिए जाना जाता है Brain Volume | Adults Adhd | Attention Deficit | Hyperactivity Disorder | Subcortical Structures |
AIMS: To determine comorbidity patterns in treatment-seeking substance use disorder (SUD) patients with and without adult attention deficit hyperactivity disorder (ADHD), with an emphasis on subgroups defined by ADHD subtype, taking into account differences related to gender and primary substance of abuse.
DESIGN: Data were obtained from the cross-sectional International ADHD in Substance use disorder Prevalence (IASP) study.
SETTING: Forty-seven centres of SUD treatment in 10 ...
के लिए जाना जाता है Disorder Patients | Psychiatric Comorbidity | Attention Deficit | Seeking Substance | Presence Adhd |
CONTEXT: Controversy exists about the appropriate criteria for a diagnosis of adult attention-deficit/hyperactivity disorder (ADHD).
OBJECTIVE: To examine the structure and symptoms most predictive of DSM-IV adult ADHD.
DESIGN: The data are from clinical interviews in enriched subsamples of the National Comorbidity Survey Replication (n = 131) and a survey of a large managed health care plan (n = 214). The physician-administered Adult ADHD Clinical Diagnostic Scale (ACDS) was used to ...
के लिए जाना जाता है Adult Adhd | Hyperactivity Disorder | Illness Surveys | Clinical Diagnostic | Symptoms Childhood |
The Massachusetts General Hospital studies of gender influences on attention-deficit/hyperactivity disorder in youth and relatives
[ PUBLICATION ]
With the single exception of SUDs, no statistically significant gender-by ADHD interactions were identified in the multiple, outcomes evaluated. These results suggest that with the exception of SUDs, ADHD expresses itself similarly in boys and girls relative to comparison subjects of the same gender, indicating that ADHD-associated impairments are correlates of ADHD in both genders. Gender differences, such as the higher prevalence of symptoms of inattention and lower rates of ...
के लिए जाना जाता है Girls Adhd | Hyperactivity Disorder | Gender Differences | Higher Prevalence | Symptoms Inattention |
OBJECTIVE: To complete an exploratory uncontrolled study of the effects of lisdexamfetamine dimesylate (LDX) on growth of children treated for attention-deficit/hyperactivity disorder (ADHD).
METHOD: Height, weight, and body mass index (BMI) from 281 children ages 6 to 13 years from longitudinal assessments up to 15 months were compared to norms from the Centers for Disease Control.
RESULTS: At study entry, children were taller and heavier than average. Growth delays were largest for ...
के लिए जाना जाता है Lisdexamfetamine Dimesylate | Height Weight | Growth Children | Ldx Bmi | Centers Disease Control |
Psychopathology in Adolescent Offspring of Parents With Panic Disorder, Major Depression, or Both: A 10-Year Follow-Up
[ PUBLICATION ]
OBJECTIVE: The authors examined the specificity and course of psychiatric disorders from early childhood through adolescence in offspring of parents with confirmed panic disorder and major depressive disorder.
METHOD: The authors examined rates of psychiatric disorders at 10-year-follow-up (mean age, 14 years) in four groups: offspring of referred parents with panic and depression (N=137), offspring of referred parents with panic without depression (N=26), offspring of referred parents ...
के लिए जाना जाता है Panic Disorder | Offspring Parents | Parental Depression | Disruptive Behavior | Year Follow |
BACKGROUND: The goal of this study was to investigate the occurrence, severity and clinical correlates of emotional lability (EL) in children with attention deficit/hyperactivity disorder (ADHD), and to examine factors contributing to EL and familiality of EL in youth with ADHD.
METHODS: One thousand, one hundred and eighty-six children with ADHD combined type and 1827 siblings (aged 6-18 years) were assessed for symptoms of EL, ADHD, associated psychopathology and comorbid psychiatric ...
के लिए जाना जाता है Symptoms Adhd | Emotional Lability | Hyperactivity Disorder | Attention Deficit | Odd Disruptive Behavior |
A Controlled Study of Behavioral Inhibition in Children of Parents With Panic Disorder and Depression
[ PUBLICATION ]
OBJECTIVE: "Behavioral inhibition to the unfamiliar" has been proposed as a precursor to anxiety disorders. Children with behavioral inhibition are cautious, quiet, introverted, and shy in unfamiliar situations. Several lines of evidence suggest that behavioral inhibition is an index of anxiety proneness. The authors sought to replicate prior findings and examine the specificity of the association between behavioral inhibition and anxiety.
METHOD: Laboratory-based behavioral observations ...
के लिए जाना जाता है Behavioral Inhibition | Major Depression | Children Parents | Panic Disorder | Controlled Study |
Traumatic Brain Injury and Schizophrenia in Members of Schizophrenia and Bipolar Disorder Pedigrees
[ PUBLICATION ]
OBJECTIVE: Schizophrenia following a traumatic brain injury could be a phenocopy of genetic schizophrenia or the consequence of a gene-environment interaction. Alternatively, traumatic brain injury and schizophrenia could be spuriously associated if those who are predisposed to develop schizophrenia have greater amounts of trauma for other reasons. The authors investigated the relationship between traumatic brain injury and psychiatric diagnoses in a large group of subjects from families ...
के लिए जाना जाता है Traumatic Brain Injury | Bipolar Disorder | Subjects Schizophrenia | Mental Illness | Genetic Vulnerability |
के लिए प्रमुख लोग Hyperactivity Disorder
Stephen V Faraone∗:विशेषज्ञ प्रभाव
जिसके लिए अवधारणाएंStephen V Faraone∗प्रत्यक्ष प्रभाव है:Hyperactivity disorder, Bipolar disorder, Attention deficit, Deficit hyperactivity, Disorder adhd, Anxiety disorders, Disorder hyperactivity, Children adhd.
Stephen V Faraone∗:कोल इम्पैक्ट
अन्य लेखकों के काम से संबंधित अवधारणाएं जिनके लिएfor which Stephen V Faraone∗ प्रभाव है:Bipolar disorder, Attention deficit, Children adhd, Executive function, Mental health, Schizophrenia patients.
Tools
क्या यह आपकी प्रोफ़ाइल है? अपनी प्रोफ़ाइल का दावा करें यूआरएल कॉपी करें अपनी प्रोफ़ाइल के लिए लिंक एम्बेड करें |